WO1998022501A2 - Secreted proteins and polynucleotides encoding them - Google Patents

Secreted proteins and polynucleotides encoding them Download PDF

Info

Publication number
WO1998022501A2
WO1998022501A2 PCT/US1997/021123 US9721123W WO9822501A2 WO 1998022501 A2 WO1998022501 A2 WO 1998022501A2 US 9721123 W US9721123 W US 9721123W WO 9822501 A2 WO9822501 A2 WO 9822501A2
Authority
WO
WIPO (PCT)
Prior art keywords
polynucleotide
protein
seq
amino acid
sequence
Prior art date
Application number
PCT/US1997/021123
Other languages
French (fr)
Other versions
WO1998022501A3 (en
Inventor
Kenneth Jacobs
John M. Mccoy
Edward R. Lavallie
Lisa A. Racie
David Merberg
Maurice Treacy
Vikki Spaulding
Michael J. Agostino
Original Assignee
Genetics Institute, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Institute, Inc. filed Critical Genetics Institute, Inc.
Priority to JP52383798A priority Critical patent/JP2001505053A/en
Priority to EP97946948A priority patent/EP0941242A2/en
Priority to AU52024/98A priority patent/AU5202498A/en
Priority to CA002272050A priority patent/CA2272050A1/en
Publication of WO1998022501A2 publication Critical patent/WO1998022501A2/en
Publication of WO1998022501A3 publication Critical patent/WO1998022501A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention provides novel polynucleotides and proteins encoded by such polynucleotides, along with therapeutic, diagnostic and research utilities for these polynucleotides and proteins.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:2 from nucleotide 390 to nucleotide 563; the nucleotide sequence of the full-length protein coding sequence of clone BD441_1 deposited under accession number ATCC
  • the polynucleotide encodes the full-length or mature protein encoded by the cDNA insert of clone BD441_1 deposited under accession number ATCC 98264.
  • Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:2, SEQ ID NO:l or SEQ ID NO:4 .
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h).
  • polynucleotide comprises the nucleotide sequence of SEQ ID NO: 1
  • nucleotide sequence from nucleotide 583 to nucleotide 756; the nucleotide sequence of the full-length protein coding sequence of clone BD441_2 deposited under accession number ATCC
  • the polynucleotide encodes the full-length or mature protein encoded by the cDNA insert of clone BD441_2 deposited under accession number ATCC 98264.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:8 from nucleotide 426 to nucleotide 581; the nucleotide sequence of SEQ ID NO:8 from nucleotide 495 to nucleotide 581; the nucleotide sequence of SEQ ID NO:8 from nucleotide 354 to nucleotide 503; the nucleotide sequence of the full-length protein coding sequence of clone BG102_3 deposited under accession number ATCC 98264; or the nucleotide sequence of the mature protein coding sequence of clone BG102_3 deposited under accession number ATCC 98264.
  • the polynucleotide encodes the full-length or mature protein encoded by the cDNA insert of clone BG102_3 deposited under accession number ATCC 98264.
  • the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:9 from amino acid 1 to amino acid 26.
  • Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:8.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • protein comprises the amino acid sequence of SEQ ID NO:9 or the amino acid sequence of SEQ ID NO:9 from amino acid 1 to amino acid 26.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
  • (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and (1) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:10 from nucleotide 112 to nucleotide 978; the nucleotide sequence of SEQ ID NO:10 from nucleotide 436 to nucleotide 1048; the nucleotide sequence of the full-length protein coding sequence of clone BK158_1 deposited under accession number ATCC 98264; or the nucleotide sequence of the mature protein coding sequence of clone BK158_1 deposited under accession number ATCC 98264.
  • the polynucleotide encodes the full-length or mature protein encoded by the cDNA insert of clone BK158_1 deposited under accession number ATCC 98264.
  • Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO: 1
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO:ll;
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:12 from nucleotide 16 to nucleotide 492; the nucleotide sequence of the full-length protein coding sequence of clone BP163_1 deposited under accession number ATCC 98264; or the nucleotide sequence of the mature protein coding sequence of clone BP163_1 deposited under accession number ATCC 98264.
  • the polynucleotide encodes the full-length or mature protein encoded by the cDNA insert of clone BP163_1 deposited under accession number ATCC 98264.
  • Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:12 from nucleotide 16 to nucleotide 492; the nucleotide sequence of the full-length protein coding sequence of clone BP163_1 deposited under accession number ATCC 98264; or the nucleotide sequence of the
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO: 13;
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
  • polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h).
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO: 16 from nucleotide 72 to nucleotide 569; the nucleotide sequence of the full-length protein coding sequence of clone BZ16_3 deposited under accession number ATCC 98264; or the nucleotide sequence of the mature protein coding sequence of clone BZ16_3 deposited under accession number ATCC 98264.
  • the polynucleotide encodes the full-length or mature protein encoded by the cDNA insert of clone BZ16_3 deposited under accession number ATCC 98264.
  • the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO: 17 from amino acid 1 to amino acid 124.
  • Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO: 17;
  • protein comprises the amino acid sequence of SEQ ID NO:17 or the amino acid sequence of SEQ ID NO:17 from amino acid 1 to amino acid 124.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:18 from nucleotide 405 to nucleotide 662; the nucleotide sequence of SEQ ID NO:18 from nucleotide 519 to nucleotide 662; the nucleotide sequence of SEQ ID NO:18 from nucleotide 1 to nucleotide 584; the nucleotide sequence of the full-length protein coding sequence of clone CC182_1 deposited under accession number ATCC 98264; or the nucleotide sequence of the mature protein coding sequence of clone CC182_1 deposited under accession number ATCC 98264.
  • the polynucleotide encodes the full-length or mature protein encoded by the cDNA insert of clone CC182_1 deposited under accession number ATCC 98264.
  • the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO: 19 from amino acid 1 to amino acid 60.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • protein comprises the amino acid sequence of SEQ ID NO:19 or the amino acid sequence of SEQ ID NO:19 from amino acid 1 to amino acid 60.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and (1) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:20 from nucleotide 311 to nucleotide 409; the nucleotide sequence of SEQ ID NO:20 from nucleotide 24 to nucleotide 414; the nucleotide sequence of the full-length protein coding sequence of clone CG109_1 deposited under accession number ATCC 98264; or the nucleotide sequence of the mature protein coding sequence of clone CG109_1 deposited under accession number ATCC 98264.
  • the polynucleotide encodes the full-length or mature protein encoded by the cDNA insert of clone CG109_1 deposited under accession number ATCC 98264.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:23 from nucleotide 471 to nucleotide 611; the nucleotide sequence of the full-length protein coding sequence of clone CJ397_1 deposited under accession number ATCC 98264; or the nucleotide sequence of the mature protein coding sequence of clone CJ397_1 deposited under accession number ATCC 98264.
  • the polynucleotide encodes the full-length or mature protein encoded by the cDNA insert of clone CJ397_1 deposited under accession number ATCC 98264.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • the polynucleotide is operably linked to an expression control sequence.
  • the invention also provides a host cell, including bacterial, yeast, insect and mammalian cells, transformed with such polynucleotide compositions. Processes are also provided for producing a protein, which comprise: (a) growing a culture of the host cell transformed with such polynucleotide compositions in a suitable culture medium; and (b) purifying the protein from the culture.
  • the protein produced according to such methods is also provided by the present invention. Preferred embodiments include those in which the protein produced by such process is a mature form of the protein.
  • Protein compositions of the present invention may further comprise a pharmaceutically acceptable carrier.
  • Compositions comprising an antibody which specifically reacts with such protein are also provided by the present invention.
  • Methods are also provided for preventing, treating or ameliorating a medical condition which comprises administering to a mammalian subject a therapeutically effective amount of a composition comprising a protein of the present invention and a pharmaceutically acceptable carrier.
  • Figures 1 A and IB are schematic representations of the pED6 and pNOTs vectors, respectively, used for deposit of clones disclosed herein.
  • nucleotide and amino acid sequences are reported below for each clone and protein disclosed in the present application.
  • the nucleotide sequence of each clone can readily be determined by sequencing of the deposited clone in accordance with known methods. The predicted amino acid sequence (both full-length and mature) can then be determined from such nucleotide sequence.
  • the amino acid sequence of the protein encoded by a particular clone can also be determined by expression of the clone in a suitable host cell, collecting the protein and determining its sequence. For each disclosed protein applicants have identified what they have determined to be the reading frame best identifiable with sequence information available at the time of filing.
  • a "secreted” protein is one which, when expressed in ' a suitable host cell, is transported across or through a membrane, including transport as a result of signal sequences in its amino acid sequence.
  • "Secreted” proteins include without limitation proteins secreted wholly (e.g., soluble proteins) or partially (e.g. , receptors) from the cell in which they are expressed.
  • “Secreted” proteins also include without limitation proteins which are transported across the membrane of the endoplasmic reticulum.
  • BD441_1 A polynucleotide of the present invention has been identified as clone "BD441_1".
  • BD441_1 was isolated from a human fetal kidney cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein.
  • BD441_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "BD441_1 protein").
  • nucleotide sequence of the 5' portion of BD441_1 as presently determined is reported in SEQ ID NO:l.
  • An additional internal nucleotide sequence from BD441_1 as presently determined is reported in SEQ ID NO:2. What applicants believe is the proper reading frame and the predicted amino acid sequence encoded by such internal sequence is reported in SEQ ID NO:3.
  • Additional nucleotide sequence from the 3' portion of BD441_1, including the polyA tail, is reported in SEQ ID NO:4.
  • the EcoRI/Notl restriction fragment obtainable from the deposit containing clone BD441_1 should be approximately 2400 bp.
  • the predicted amino acid sequence disclosed herein for BD441_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol.
  • the predicted BD441_1 protein demonstrated at least some similarity to sequences identified as X61615 (leukemia inhibitory factor receptor [Homo sapiens]). Based upon sequence similarity, BD441_1 proteins and each similar protein or peptide may share at least some activity.
  • BD441_2 A polynucleotide of the present invention has been identified as clone "BD441_2".
  • BD441_2 was isolated from a human fetal kidney cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein.
  • BD441_2 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "BD441_2 protein").
  • nucleotide sequence of the 5' portion of BD441_2 as presently determined is reported in SEQ ID NO:5. What applicants presently believe is the proper reading frame for the coding region is indicated in SEQ ID NO:6.
  • the predicted amino acid sequence of the BD441_2 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:6.
  • Additional nucleotide sequence from the 3' portion of BD441_2, including the polyA tail, is reported in SEQ ID NO:7.
  • the EcoRI/Notl restriction fragment obtainable from the deposit containing clone BD441_2 should be approximately 1200 bp.
  • the predicted amino acid sequence disclosed herein for BD441_2 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol.
  • the predicted BD441_2 protein demonstrated at least some similarity to sequences identified as X61615 (leukemia inhibitory factor receptor [Homo sapiens]). Based upon sequence similarity, BD441_2 proteins and each similar protein or peptide may share at least some activity.
  • BG102_3 A polynucleotide of the present invention has been identified as clone "BG102_3".
  • BG102_3 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein.
  • BG102_3 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "BG102_3 protein").
  • nucleotide sequence of BG102_3 as presently determined is reported in SEQ ID NO:8. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the BG102_3 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:9. Amino acids 11 to 23 are a predicted leader /signal sequence, with the predicted mature amino acid sequence beginning at amino acid 24, or are a transmembrane domain.
  • the EcoRI/Notl restriction fragment obtainable from the deposit containing clone BG102_3 should be approximately 1100 bp.
  • BG102_3 demonstrated at least some similarity with sequences identified as AC002078 (Human BAC clone RG111H14 from 7q22, complete sequence),
  • BG102_3 DNA sequence from cosmid L129H7, Huntington's Disease Region, chromosome 4pl6.3 contains CpG island), Z75747 (Human DNA sequence from cosmid U96H1, between markers DXS366 and DXS87 on chromosome X *), and Z80899 (Human DNA sequence from cosmid F1121 on chromosome 6).
  • the predicted amino acid sequence disclosed herein for BG102_3 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol.
  • the predicted BG102_3 protein demonstrated at least some similarity to sequences identified as M13100 (unknown protein [Rattus norvegicus]) and U15647 (reverse transcriptase [Mus musculus]). Based upon sequence similarity, BG102_3 proteins and each similar protein or peptide may share at least some activity.
  • the nucleotide sequence of BG102_3 indicates that it may contain an LI repetitive element.
  • BK158_1 A polynucleotide of the present invention has been identified as clone "BK158_1".
  • BK158_1 was isolated from a human adult muscle cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein.
  • BK158_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "BK158_1 protein").
  • the EcoRI/Notl restriction fragment obtainable from the deposit containing clone BK158_1 should be approximately 1150 bp.
  • the nucleotide sequence disclosed herein for BK158_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols.
  • BK158_1 demonstrated at least some similarity with sequences identified as N39195 (yv26e08.sl Homo sapiens cDNA clone 243878 3') and N45263 (yv26e08.rl Homo sapiens cDNA clone 243878 5'). Based upon sequence similarity, BK158_1 proteins and each similar protein or peptide may share at least some activity.
  • BP163_1 A polynucleotide of the present invention has been identified as clone "BP163_1".
  • BP163_1 was isolated from a human fetal kidney cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein.
  • BP163_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "BP163_1 protein").
  • nucleotide sequence of the 5' portion of BP163_1 as presently determined is reported in SEQ ID NO:12. What applicants presently believe is the proper reading frame for the coding region is indicated in SEQ ID NO:13.
  • the predicted amino acid sequence of the BP163_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:13.
  • Additional nucleotide sequence from the 3' portion of BP163_1, including the polyA tail, is reported in SEQ ID NO:14.
  • the EcoRI/Notl restriction fragment obtainable from the deposit containing clone BP163_1 should be approximately 1240 bp.
  • BP163_1 The nucleotide sequence disclosed herein for BP163_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols.
  • BP163_1 demonstrated at least some similarity with sequences identified as AA187086 (zp58h06.rl Stratagene endothelial cell 937223 Homo sapiens cDNA clone 6244435' similar to TR G285943 G285943 ORF, COMPLETE CDS), AA301506 (EST14475 Testis tumor Homo sapiens cDNA 5' end similar to hypothetical protein (GB D14659)), D14659 (Human mRNA for KIAA0103 gene, complete cds), and W57328
  • BP163_1 The predicted amino acid sequence disclosed herein for BP163_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol.
  • the predicted BP163_1 protein demonstrated at least some similarity to sequences identified as D14659 (KIAA0103 [Homo sapiens]). Based upon sequence similarity, BP163_1 proteins and each similar protein or peptide may share at least some activity.
  • BZ16_3 was isolated from a human fetal kidney cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein.
  • BZ16_3 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "BZ16_3 protein").
  • the partial nucleotide sequence of BZ16_3, including its 3' end and any identified polyA tail, as presently determined is reported in SEQ ID NO:16. What applicants presently believe is the proper reading frame for the coding region is indicated in SEQ ID NO: 17.
  • the predicted amino acid sequence of the BZ16_3 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:17. Additional nucleotide sequence from the 5' portion of BZ16_3 is reported in SEQ ID NO:15.
  • the EcoRI /Noil restriction fragment obtainable from the deposit containing clone BZ16_3 should be approximately 2120 bp.
  • the nucleotide sequence disclosed herein for BZ16_3 was searched against the
  • BZ16_3 demonstrated at least some similarity with sequences identified as F06886 (H. sapiens partial cDNA sequence; clone c-lnf02), F06870 (H.
  • sapiens partial cDNA sequence clone c-lncll
  • N53511 yz26b08.
  • sl Homo sapiens cDNA clone 284151 3' T65313 (yc79gl2.
  • sl Homo sapiens cDNA clone 221323' U00084 (Haemophilus influenzae), W44815 (zc21d01.sl Soares senescent fibroblasts NbHSF Homo sapiens cDNA clone 322945 3'), and Z49128 (Caenorhabditis elegans cosmid M03C11).
  • the predicted amino acid sequence disclosed herein for BZ16_3 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol.
  • the predicted BZ16_3 protein demonstrated at least some similarity to sequences identified as D26185 (cell division protein [Bacillus subtilis]), L46096 (HEAHI1465_1 cell division protein [Haemophilus influenzae]), and Z49128 (CEM03C11_5 M03C11.5 [Caenorhabditis elegans]).
  • the BZ16_3 protein demonstrated at least some similarity to ATP-dependent proteases such as ftsH. Based upon sequence similarity, BZ16_3 proteins and each similar protein or peptide may share at least some activity.
  • CC182_1 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein.
  • CC182_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "CC182_1 protein").
  • nucleotide sequence of CC182_1 as presently determined is reported in SEQ ID NO:18. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the CC182_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:19.
  • Amino acids 26 to 38 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 39, or are a transmembrane domain.
  • the EcoRI /Notl restriction fragment obtainable from the deposit containing clone CC182_1 should be approximately 1600 bp.
  • the nucleotide sequence disclosed herein for CC182_1 was searched against the
  • CC182_1 demonstrated at least some similarity with sequences identified as H61159 (yu37f08.sl Homo sapiens cDNA clone 236007 3' similar to contains LI repetitive element), L09709 (Human lysosomal-associated membrane glycoprotein-2 (LAMP2) gene, 5' end of CDS and flanking region), W44797 (zb98el0.sl Soares parathyroid tumor NbHPA Homo sapiens cDNA clone 320874 3' similar to contains Alu repetitive element), and X62167 (H.sapiens mRNA for P2 protein of peripheral myelin). Based upon sequence similarity, CC182_1 proteins and each similar protein or peptide may share at least some activity. The nucleotide sequence of CC182_1 indicates that it may contain an LI repetitive element and a MER42C repetitive element.
  • CG109_1 A polynucleotide of the present invention has been identified as clone "CG109_1".
  • CG109_1 was isolated from a human adult testes cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein.
  • CG109_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "CG109_1 protein").
  • CG109_1 should be approximately 600 bp.
  • nucleotide sequence disclosed herein for CG109_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. No hits were found in the database.
  • CJ397_1 A polynucleotide of the present invention has been identified as clone "CJ397_1".
  • CJ397_1 was isolated from a human fetal brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein.
  • CJ397_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "CJ397_1 protein").
  • nucleotide sequence of the 5' portion of CJ397_1 as presently determined is reported in SEQ ID NO:22.
  • An additional internal nucleotide sequence from CJ397_1 as presently determined is reported in SEQ ID NO:23. What applicants believe is the proper reading frame and the predicted amino acid sequence encoded by such internal sequence is reported in SEQ ID NO:24.
  • Additional nucleotide sequence from the 3' portion of CJ397_1, including the polyA tail, is reported in SEQ ID NO:25.
  • CJ397_1 should be approximately 1900 bp.
  • CJ397_1 The nucleotide sequence disclosed herein for CJ397_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols.
  • CJ397_1 demonstrated at least some similarity with sequences identified as H18685 (yn52b08.sl Homo sapiens cDNA clone 172023 3'), H46001 (yol3f06.sl Homo sapiens cDNA clone 1778273'), and T77612 (yc91f06.rl Homo sapiens cDNA clone 232985'). Based upon sequence similarity, CJ397_1 proteins and each similar protein or peptide may share at least some activity.
  • Clones BD441_1, BD441_2, BG102_3, BK158_1, BP163_1, BZ16_3, CC182_1, CG109_1 and CJ397_1 were deposited on November 20, 1996 with the American Type Culture Collection as an original deposit under the Budapest Treaty and were given the accession number ATCC 98264, from which each clone comprising a particular polynucleotide is obtainable. All restrictions on the availability to the public of the deposited material will be irrevocably removed upon the granting of the patent, except for the requirements specified in 37 C.F.R. ⁇ 1.808(b).
  • Each clone has been transfected into separate bacterial cells (E. coli) in this composite deposit. Each clone can be removed from the vector in which it was deposited by performing an EcoRI/Notl digestion (5' site, EcoRI; 3' site, Notl) to produce the appropriate fragment for such clone. Each clone was deposited in either the pED6 or pNOTs vector depicted in Fig. 1.
  • the pED6dpc2 vector (“pED6" was derived from pED ⁇ dpcl by insertion of a new polylinker to facilitate cDNA cloning (Kaufman et al, 1991, Nucleic Acids Res.
  • the pNOTs vector was derived from pMT2 (Kaufman et al, 1989, Mol. Cell. Biol. 9: 946-958) by deletion of the DHFR sequences, insertion of a new polylinker, and insertion of the M13 origin of replication in the Clal site.
  • the deposited clone can become "flipped" (i.e., in the reverse orientation) in the deposited isolate.
  • the cDNA insert can still be isolated by digestion with EcoRI and Notl. However, Notl will then produce the 5' site and EcoRI will produce the 3' site for placement of the cDNA in proper orientation for expression in a suitable vector.
  • the cDNA may also be expressed from the vectors in which they were deposited.
  • Bacterial cells containing a particular clone can be obtained from the composite deposit as follows:
  • oligonucleotide probe or probes should be designed to the sequence that is known for that particular clone. This sequence can be derived from the sequences provided herein, or from a combination of those sequences. The sequence of the oligonucleotide probe that was used to isolate each full-length clone is identified below, and should be most reliable in isolating the clone of interest.
  • the oligonucleotide should preferably be labeled with g- 32 P ATP (specific activity 6000 Ci/mmole) and T4 polynucleotide kinase using commonly employed techniques for labeling oligonucleotides. Other labeling techniques can also be used. Unincorporated label should preferably be removed by gel filtration chromatography or other established methods. The amount of radioactivity incorporated into the probe should be quantitated by measurement in a scintillation counter. Preferably, specific activity of the resulting probe should be approximately 4e+6 dpm/pmole.
  • the bacterial culture containing the pool of full-length clones should preferably be thawed and 100 ⁇ l of the stock used to inoculate a sterile culture flask containing 25 ml of sterile L-broth containing ampicillin at 100 ⁇ g/ml.
  • the culture should preferably be grown to saturation at 37°C, and the saturated culture should preferably be diluted in fresh L-broth.
  • Aliquots of these dilutions should preferably be plated to determine the dilution and volume which will yield approximately 5000 distinct and well-separated colonies on solid bacteriological media containing L-broth containing ampicillin at 100 ⁇ g/ml and agar at 1.5% in a 150 mm petri dish when grown overnight at 37°C. Other known methods of obtaining distinct, well-separated colonies can also be employed.
  • Standard colony hybridization procedures should then be used to transfer the colonies to nitrocellulose filters and lyse, denature and bake them.
  • the filter is then preferably incubated at 65°C for 1 hour with gentle agitation in
  • 6X SSC (20X stock is 175.3 g NaCl/liter, 88.2 g Na citrate /liter, adjusted to pH 7.0 with NaOH) containing 0.5% SDS, 100 ⁇ g/ml of yeast RNA, and 10 mM EDTA (approximately 10 mL per 150 mm filter).
  • the probe is then added to the hybridization mix at a concentration greater than or equal to le+6 dpm/mL.
  • the filter is then preferably incubated at 65°C with gentle agitation overnight.
  • the filter is then preferably washed in 500 mL of 2X SSC/0.5% SDS at room temperature without agitation, preferably followed by 500 mL of 2X SSC/0.1% SDS at room temperature with gentle shaking for 15 minutes. A third wash with 0.1X SSC/0.5% SDS at 65°C for 30 minutes to 1 hour is optional.
  • the filter is then preferably dried and subjected to autoradiography for sufficient time to visualize the positives on the X-ray film. Other known hybridization methods can also be employed.
  • Fragments of the proteins of the present invention which are capable of exhibiting biological activity are also encompassed by the present invention. Fragments of the protein may be in linear form or they may be cyclized using known methods, for example, as described in H.U. Saragovi, et al, Bio /Technology 10, 773-778 (1992) and in R.S. McDowell, et al, J. Amer. Chem. Soc. 114, 9245-9253 (1992), both of which are incorporated herein by reference.
  • fragments may be fused to carrier molecules such as immunoglobulins for many purposes, including increasing the valency of protein binding sites.
  • fragments of the protein may be fused through "linker" sequences to the Fc portion of an immunoglobulin.
  • linker For a bivalent form of the protein, such a fusion could be to the Fc portion of an IgG molecule.
  • Other immunoglobulin isotypes may also be used to generate such fusions.
  • a protein - IgM fusion would generate a decavalent form of the protein of the invention.
  • the present invention also provides both full-length and mature forms of the disclosed proteins.
  • the full-length form of the such proteins is identified in the sequence listing by translation of the nucleotide sequence of each disclosed clone.
  • the mature form of such protein may be obtained by expression of the disclosed full-length polynucleotide (preferably those deposited with ATCC) in a suitable mammalian cell or other host cell.
  • the sequence of the mature form of the protein may also be determinable from the amino acid sequence of the full-length form.
  • the present invention also provides genes corresponding to the cDNA sequences disclosed herein.
  • Corresponding genes are the regions of the genome that are transcribed to produce the mRNAs from which the cDNA sequences are derived and any contiguous regions of the genome necessary for the regulated expression of such genes, including but not limited to coding sequences, 5' and 3' untranslated regions, alternatively spliced exons, introns, promoters, enhancers, and silencer or suppressor elements.
  • the corresponding genes can be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include the preparation of probes or primers from the disclosed sequence information for identification and /or amplification of genes in appropriate genomic libraries or other sources of genomic materials.
  • the present invention also provides for soluble forms of such protein.
  • the intracellular and transmembrane domains of the protein are deleted such that the protein is fully secreted from the cell in which it is expressed.
  • the intracellular and transmembrane domains of proteins of the invention can be identified in accordance with known techniques for determination of such domains from sequence information.
  • Proteins and protein fragments of the present invention include proteins with amino acid sequence lengths that are at least 25%(more preferably at least 50%, and most preferably at least 75%) of the length of a disclosed protein and have at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% or 95% identity) with that disclosed protein, where sequence identity is determined by comparing the amino acid sequences of the proteins when aligned so as to maximize overlap and identity while minimizing sequence gaps.
  • proteins and protein fragments that contain a segment preferably comprising 8 or more (more preferably 20 or more, most preferably 30 or more) contiguous aniino acids that shares at least 75% sequence identity (more preferably, at least 85% identity; most preferably at least 95% identity) with any such segment of any of the disclosed proteins.
  • Species homologs of the disclosed polynucleotides and proteins are also provided by the present invention.
  • a "species homologue" is a protein or polynucleotide with a different species of origin from that of a given protein or polynucleotide, but with significant sequence similarity to the given protein or polynucleotide, as determined by those of skill in the art.
  • Species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source from the desired species.
  • the invention also encompasses allelic variants of the disclosed polynucleotides or proteins; that is, naturally-occurring alternative forms of the isolated polynucleotide which also encode proteins which are identical, homologous, or related to that encoded by the polynucleotides .
  • the invention also includes polynucleotides with sequences complementary to those of the polynucleotides disclosed herein.
  • the present invention also includes polynucleotides capable of hybridizing under reduced stringency conditions, more preferably stringent conditions, and most preferably highly stringent conditions, to polynucleotides described herein.
  • stringency conditions are shown in the table below: highly stringent conditions are those that are at least as stringent as, for example, conditions A-F; stringent conditions are at least as stringent as, for example, conditions G-L; and reduced stringency conditions are at least as stringent as, for example, conditions M-R.
  • the hybrid length is that anticipated for the hybridized reg ⁇ on(s) of the hybridizing polynucleohdes When hybridizing a polynucleotide to a target polynucleotide of unknown sequence, the hybrid length is assumed to be that of the hybridizing polynucleotide When polynucleotides of known sequence are hybridized, the hybrid length can be determined by aligning the sequences of the polynucleohdes and idenhfying the region or regions of optimal sequence complementarity
  • SSPE 0 15M NaCl, lOmM NaH 2 P0 4 , and 1 25mM EDTA, pH 74
  • SSC 0 15M NaCl and 15mM sodium citrate
  • T m melting temperature
  • each such hybridizing polynucleotide has a length that is at least 25%(more preferably at least 50%, and most preferably at least 75%) of the length of the polynucleotide of the present invention to which it hybridizes, and has at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% or 95% identity) with the polynucleotide of the present invention to which it hybridizes, where sequence identity is determined by comparing the sequences of the hybridizing polynucleotides when aligned so as to maximize overlap and identity while minimizing sequence gaps.
  • the isolated polynucleotide of the invention may be operably linked to an expression control sequence such as the pMT2 or pED expression vectors disclosed in Kaufman et al, Nucleic Acids Res. 19, 4485-4490 (1991), in order to produce the protein recombinantly.
  • an expression control sequence such as the pMT2 or pED expression vectors disclosed in Kaufman et al, Nucleic Acids Res. 19, 4485-4490 (1991)
  • Many suitable expression control sequences are known in the art. General methods of expressing recombinant proteins are also known and are exemplified in R. Kaufman, Methods in Enzymology 185, 537-566 (1990).
  • operably linked means that the isolated polynucleotide of the invention and an expression control sequence are situated within a vector or cell in such a way that the protein is expressed by a host cell which has been transformed (transfected) with the ligated polynucleotide /expression control sequence.
  • Mammalian host cells include, for example, monkey COS cells, Chinese Hamster
  • Ovary (CHO) cells human kidney 293 cells, human epidermal A431 cells, human Colo205 cells, 3T3 cells, CV-1 cells, other transformed primate cell lines, normal diploid cells, cell strains derived from in vitro culture of primary tissue, primary explants, HeLa cells, mouse L cells, BHK, HL-60, U937, HaK or Jurkat cells.
  • yeast in lower eukaryotes such as yeast or in prokaryotes such as bacteria.
  • yeast strains include Saccharomyces cerevisiae, Schizosaccharomyces pombe, Kluyveromyces strains, Candida, or any yeast strain capable of expressing heterologous proteins.
  • bacterial strains include Escherichia coli, Bacillus subtilis, Salmonella y ⁇ himurium, or any bacterial strain capable of expressing heterologous proteins. If the protein is made in yeast or bacteria, it may be necessary to modify the protein produced therein, for example by phosphorylation or glycosylation of the appropriate sites, in order to obtain the functional protein. Such covalent attachments may be accomplished using known chemical or enzymatic methods.
  • the protein may also be produced by operably linking the isolated polynucleotide of the invention to suitable control sequences in one or more insect expression vectors, and employing an insect expression system.
  • suitable control sequences in one or more insect expression vectors, and employing an insect expression system.
  • Materials and methods for baculovirus /insect cell expression systems are commercially available in kit form from, e.g., Invitrogen, San Diego, California, U.S.A. (the MaxBac® kit), and such methods are well known in the art, as described in Summers and Smith, Texas Agricultural Experiment Station Bulletin No. 1555 (1987), incorporated herein by reference.
  • an insect cell capable of expressing a polynucleotide of the present invention is "transformed.”
  • the protein of the invention may be prepared by culturing transformed host cells under culture conditions suitable to express the recombinant protein.
  • the resulting expressed protein may then be purified from such culture (i.e., from culture medium or cell extracts) using known purification processes, such as gel filtration and ion exchange chromatography.
  • the purification of the protein may also include an affinity column containing agents which will bind to the protein; one or more column steps over such affinity resins as concanavalin A-agarose, heparin-toyopearl® or Cibacrom blue 3GA Sepharose®; one or more steps involving hydrophobic interaction chromatography using such resins as phenyl ether, butyl ether, or propyl ether; or immunoaffinity chromatography.
  • the protein of the invention may also be expressed in a form which will facilitate purification. For example, it may be expressed as a fusion protein, such as those of maltose binding protein (MBP), glutathione-S-transferase (GST) or thioredoxin (TRX).
  • Kits for expression and purification of such fusion proteins are commercially available from New England BioLab (Beverly, MA), Pharmacia (Piscataway, NJ) and InVitrogen, respectively.
  • the protein can also be tagged with an epitope and subsequently purified by using a specific antibody directed to such epitope.
  • One such epitope (“Flag") is commercially available from Kodak (New Haven, CT).
  • RP- HPLC reverse-phase high performance liquid chromatography
  • hydrophobic RP-HPLC media e.g., silica gel having pendant methyl or other aliphatic groups
  • Some or all of the foregoing purification steps, in various combinations, can also be employed to provide a substantially homogeneous isolated recombinant protein.
  • the protein thus purified is substantially free of other mammalian proteins and is defined in accordance with the present invention as an "isolated protein.”
  • the protein of the invention may also be expressed as a product of transgenic animals, e.g., as a component of the milk of transgenic cows, goats, pigs, or sheep which are characterized by somatic or germ cells containing a nucleotide sequence encoding the protein.
  • the protein may also be produced by known conventional chemical synthesis.
  • the synthetically-constructed protein sequences by virtue of sharing primary, secondary or tertiary structural and /or conformational characteristics with proteins may possess biological properties in common therewith, including protein activity. Thus, they may be employed as biologically active or immunological substitutes for natural, purified proteins in screening of therapeutic compounds and in immunological processes for the development of antibodies.
  • the proteins provided herein also include proteins characterized by amino acid sequences similar to those of purified proteins but into which modification are naturally provided or deliberately engineered.
  • modifications in the peptide or DNA sequences can be made by those skilled in the art using known techniques.
  • Modifications of interest in the protein sequences may include the alteration, substitution, replacement, insertion or deletion of a selected amino acid residue in the coding sequence.
  • one or more of the cysteine residues may be deleted or replaced with another amino acid to alter the conformation of the molecule.
  • Techniques for such alteration, substitution, replacement, insertion or deletion are well known to those skilled in the art (see, e.g., U.S. Patent No.4,518,584).
  • such alteration, substitution, replacement, insertion or deletion retains the desired activity of the protein.
  • polynucleotides and proteins of the present invention are expected to exhibit one or more of the uses or biological activities (including those associated with assays cited herein) identified below.
  • Uses or activities described for proteins of the present invention may be provided by administration or use of such proteins or by administration or use of polynucleotides encoding such proteins (such as, for example, in gene therapies or vectors suitable for introduction of DNA).
  • the polynucleotides provided by the present invention can be used by the research community for various purposes.
  • the polynucleotides can be used to express recombinant protein for analysis, characterization or therapeutic use; as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in disease states); as molecular weight markers on Southern gels; as chromosome markers or tags (when labeled) to identify chromosomes or to map related gene positions; to compare with endogenous DNA sequences in patients to identify potential genetic disorders; as probes to hybridize and thus discover novel, related DNA sequences; as a source of information to derive PCR primers for genetic finge rinting; as a probe to "subtract-out" known sequences in the process of discovering other novel polynucleotides; for selecting and making oligomers for attachment to a "gene chip” or other support, including for examination of expression patterns; to raise anti-protein
  • the polynucleotide encodes a protein which binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction)
  • the polynucleotide can also be used in interaction trap assays (such as, for example, that described in Gyuris et al., Cell 75:791-803 (1993)) to identify polynucleotides encoding the other protein with which binding occurs or to identify inhibitors of the binding interaction.
  • the proteins provided by the present invention can similarly be used in assay to determine biological activity, including in a panel of multiple proteins for high- throughput screening; to raise antibodies or to elicit another immune response; as a reagent (including the labeled reagent) in assays designed to quantitatively determine levels of the protein (or its receptor) in biological fluids; as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in a disease state); and, of course, to isolate correlative receptors or ligands.
  • the protein binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction)
  • the protein can be used to identify the other protein with which binding occurs or to identify inhibitors of the binding interaction. Proteins involved in these binding interactions can also be used to screen for peptide or small molecule inhibitors or agonists of the binding interaction.
  • Polynucleotides and proteins of the present invention can also be used as nutritional sources or supplements. Such uses include without limitation use as a protein or amino acid supplement, use as a carbon source, use as a nitrogen source and use as a source of carbohydrate.
  • the protein or polynucleotide of the invention can be added to the feed of a particular organism or can be administered as a separate solid or liquid preparation, such as in the form of powder, pills, solutions, suspensions or capsules.
  • the protein or polynucleotide of the invention can be added to the medium in or on which the microorganism is cultured.
  • a protein of the present invention may exhibit cytokine, cell proliferation (either inducing or inhibiting) or cell differentiation (either inducing or inhibiting) activity or may induce production of other cytokines in certain cell populations.
  • cytokine cytokine
  • cell proliferation either inducing or inhibiting
  • cell differentiation either inducing or inhibiting
  • the activity of a protein of the present invention is evidenced by any one of a number of routine factor dependent cell proliferation assays for cell lines including, without limitation, 32D, DA2, DA1G, T10, B9, B9/11, BaF3, MC9/G, M+ (preB M+), 2E8, RB5, DAI, 123, T1165, HT2, CTLL2, TF-1, Mo7e and CMK.
  • the activity of a protein of the invention may, among other means, be measured by the following methods:
  • Assays for T-cell or thymocyte proliferation include without limitation those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley- Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai et al., J. Immunol. 137:3494-3500, 1986; Bertagnolli et al., J. Immunol.
  • Assays for cytokine production and /or proliferation of spleen cells, lymph node cells or thymocytes include, without limitation, those described in: Polyclonal T cell stimulation, Kruisbeek, A.M. and Shevach, E.M. In Current Protocols in Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 3.12.1-3.12.14, John Wiley and Sons, Toronto. 1994; and Measurement of mouse and human Interferon ⁇ , Schreiber, R.D. In Current Protocols in Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 6.8.1-6.8.8, John Wiley and Sons, Toronto. 1994.
  • Assays for proliferation and differentiation of hematopoietic and lymphopoietic cells include, without limitation, those described in: Measurement of Human and Murine Interleukin 2 and Interleukin 4, Bottomly, K., Davis, L.S. and Lipsky, P.E. In Current Protocols in Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 6.3.1-6.3.12, John Wiley and Sons, Toronto. 1991; deVries et al., J. Exp. Med. 173:1205-1211, 1991; Moreau et al., Nature 336:690-692, 1988; Greenberger et al, Proc. Natl. Acad. Sci. U.S.A. 80:2931-2938, 1983;
  • a protein of the present invention may also exhibit immune stimulating or immune suppressing activity, including without limitation the activities for which assays are described herein.
  • a protein may be useful in the treatment of various immune deficiencies and disorders (including severe combined immunodeficiency (SOD)), e.g., in regulating (up or down) growth and proliferation of T and /or B lymphocytes, as well as effecting the cytolytic activity of NK cells and other cell populations.
  • SOD severe combined immunodeficiency
  • These immune deficiencies may be genetic or be caused by viral (e.g., HIV) as well as bacterial or fungal infections, or may result from autoimmune disorders.
  • infectious diseases causes by viral, bacterial, fungal or other infection may be treatable using a protein of the present invention, including infections by HIV, hepatitis viruses, herpesviruses, mycobacteria, Leishmania spp., malaria spp. and various fungal infections such as candidiasis.
  • a protein of the present invention may also be useful where a boost to the immune system generally may be desirable, i.e., in the treatment of cancer.
  • Autoimmune disorders which may be treated using a protein of the present invention include, for example, connective tissue disease, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes mellitis, myasthenia gravis, graft- versus-host disease and autoimmune inflammatory eye disease.
  • a protein of the present invention may also to be useful in the treatment of allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems.
  • Other conditions, in which immune suppression is desired may also be treatable using a protein of the present invention.
  • Down regulation may be in the form of inhibiting or blocking an immune response already in progress or may involve preventing the induction of an immune response.
  • the functions of activated T cells may be inhibited by suppressing T cell responses or by inducing specific tolerance in T cells, or both.
  • Immunosuppression of T cell responses is generally an active, non-antigen-specific, process which requires continuous exposure of the T cells to the suppressive agent. Tolerance, which involves inducing non-responsiveness or anergy in T cells, is distinguishable from immunosuppression in that it is generally antigen-specific and persists after exposure to the tolerizing agent has ceased.
  • tolerance can be demonstrated by the lack of a T cell response upon reexposure to specific antigen in the absence of the tolerizing agent.
  • Down regulating or preventing one or more antigen functions including without limitation B lymphocyte antigen functions (such as , for example, B7)), e.g., preventing high level lymphokine synthesis by activated T cells, will be useful in situations of tissue, skin and organ transplantation and in graft-versus-host disease (GVHD).
  • B lymphocyte antigen functions such as , for example, B7
  • GVHD graft-versus-host disease
  • blockage of T cell function should result in reduced tissue destruction in tissue transplantation.
  • rejection of the transplant is initiated through its recognition as foreign by T cells, followed by an immune reaction that destroys the transplant.
  • a molecule which inhibits or blocks interaction of a B7 lymphocyte antigen with its natural ligand(s) on immune cells such as a soluble, monomeric form of a peptide having B7-2 activity alone or in conjunction with a monomeric form of a peptide having an activity of another B lymphocyte antigen (e.g., B7-
  • Blocking B lymphocyte antigen function in this matter prevents cytokine synthesis by immune cells, such as T cells, and thus acts as an immunosuppressant. Moreover, the lack of costimulation may also be sufficient to anergize the T cells, thereby inducing tolerance in a subject. Induction of long-term tolerance by B lymphocyte antigen-blocking reagents may avoid the necessity of repeated administration of these blocking reagents. To achieve sufficient immunosuppression or tolerance in a subject, it may also be necessary to block the function of a combination of
  • the efficacy of particular blocking reagents in preventing organ transplant rejection or GVHD can be assessed using animal models that are predictive of efficacy in humans.
  • appropriate systems which can be used include allogeneic cardiac grafts in rats and xenogeneic pancreatic islet cell grafts in mice, both of which have been used to examine the immunosuppressive effects of CTLA4Ig fusion proteins in vivo as described in Lenschow et al, Science 257:789-792 (1992) and Turka et al, Proc. Natl. Acad.
  • Blocking antigen function may also be therapeutically useful for treating autoimmune diseases.
  • Many autoimmune disorders are the result of inappropriate activation of T cells that are reactive against self tissue and which promote the production of cytokines and autoantibodies involved in the pathology of the diseases. Preventing the activation of autoreactive T cells may reduce or eliminate disease symptoms.
  • reagents which block costimulation of T cells by disrupting receptor:ligand interactions of B lymphocyte antigens can be used to inhibit T cell activation and prevent production of autoantibodies or T cell-derived cytokines which may be involved in the disease process. Additionally, blocking reagents may induce antigen-specific tolerance of autoreactive T cells which could lead to long-term relief from the disease.
  • the efficacy of blocking reagents in preventing or alleviating autoimmune disorders can be determined using a number of well-characterized animal models of human autoimmune diseases.
  • Examples include murine experimental autoimmune encephalitis, systemic lupus erythmatosis in MK /lpr/lpr mice or NZB hybrid mice, murine autoimmune collagen arthritis, diabetes mellitus in NOD mice and BB rats, and murine experimental myasthenia gravis (see Paul ed., Fundamental Immunology, Raven Press, New York, 1989, pp. 840-856).
  • Upregulation of an antigen function preferably a B lymphocyte antigen function
  • Upregulation of immune responses may be in the form of enhancing an existing immune response or eliciting an initial immune response.
  • enhancing an immune response through stimulating B lymphocyte antigen function may be useful in cases of viral infection.
  • systemic viral diseases such as influenza, the common cold, and encephalitis might be alleviated by the administration of stimulatory forms of B lymphocyte antigens systemically.
  • anti-viral immune responses may be enhanced in an infected patient by removing T cells from the patient, costimulating the T cells in vitro with viral antigen- pulsed APCs either expressing a peptide of the present invention or together with a stimulatory form of a soluble peptide of the present invention and reintroducing the in vitro activated T cells into the patient.
  • Another method of enhancing anti-viral immune responses would be to isolate infected cells from a patient, transfect them with a nucleic acid encoding a protein of the present invention as described herein such that the cells express all or a portion of the protein on their surface, and reintroduce the transfected cells into the patient.
  • the infected cells would now be capable of delivering a costimulatory signal to, and thereby activate, T cells in vivo.
  • up regulation or enhancement of antigen function may be useful in the induction of tumor immunity.
  • Tumor cells e.g., sarcoma, melanoma, lymphoma, leukemia, neuroblastoma, carcinoma
  • a nucleic acid encoding at least one peptide of the present invention can be administered to a subject to overcome tumor-specific tolerance in the subject. If desired, the tumor cell can be transfected to express a combination of peptides.
  • tumor cells obtained from a patient can be transfected ex vivo with an expression vector directing the expression of a peptide having B7-2-like activity alone, or in conjunction with a peptide having B7-l-like activity and/or B7-3-like activity.
  • the transfected tumor cells are returned to the patient to result in expression of the peptides on the surface of the transfected cell.
  • gene therapy techniques can be used to target a tumor cell for transfection in vivo.
  • tumor cells which lack MHC class I or MHC class II molecules, or which fail to reexpress sufficient amounts of MHC class I or MHC class II molecules, can be transfected with nucleic acid encoding all or a portion of (e.g., a cytoplasmic-domain truncated portion) of an MHC class I ⁇ chain protein and ⁇ 2 microglobulin protein or an MHC class II a chain protein and an MHC class II ⁇ chain protein to thereby express MHC class I or MHC class II proteins on the cell surface.
  • nucleic acid encoding all or a portion of (e.g., a cytoplasmic-domain truncated portion) of an MHC class I ⁇ chain protein and ⁇ 2 microglobulin protein or an MHC class II a chain protein and an MHC class II ⁇ chain protein to thereby express MHC class I or MHC class II proteins on the cell surface.
  • a gene encoding an antisense construct which blocks expression of an MHC class II associated protein, such as the invariant chain can also be cotransfected with a DNA encoding a peptide having the activity of a B lymphocyte antigen to promote presentation of tumor associated antigens and induce tumor specific immunity.
  • a T cell mediated immune response in a human subject may be sufficient to overcome tumor-specific tolerance in the subject.
  • the activity of a protein of the invention may, among other means, be measured by the following methods:
  • Suitable assays for thymocyte or splenocyte cytotoxicity include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1- 3.19; Chapter 7, Immunologic studies in Humans); Herrmann et al., Proc. Natl. Acad. Sci. USA 78:2488-2492, 1981; Herrmann et al., J. Immunol. 128:1968-1974, 1982; Handa et al., J. Immunol.
  • T-cell-dependent immunoglobulin responses and isotype switching (which will identify, among others, proteins that modulate T-cell dependent antibody responses and that affect Thl/Th2 profiles) include, without limitation, those described in: Maliszewski, J. Immunol. 144:3028-3033, 1990; and Assays for B cell function: In vitro antibody production, Mond, J.J. and Brunswick, M. In Current Protocols in Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 3.8.1-3.8.16, John Wiley and Sons, Toronto. 1994.
  • MLR Mixed lymphocyte reaction
  • Dendritic cell-dependent assays (which will identify, among others, proteins expressed by dendritic cells that activate naive T-cells) include, without limitation, those described in: Guery et al., J. Immunol. 134:536-544, 1995; Inaba et al., Journal of Experimental Medicine 173:549-559, 1991; Macatonia et al., Journal of Immunology 154:5071-5079, 1995; Porgador et al, Journal of Experimental Medicine 182:255-260, 1995; Nair et al, Journal of Virology 67:4062-4069, 1993; Huang et al., Science 264:961-965, 1994; Macatonia et al., Journal of Experimental Medicine 169:1255-1264, 1989; Bhardwaj et al., Journal of Clinical Investigation 94:797-807, 1994; and Inaba et al., Journal of Experimental Medicine 172:631-640, 1990.
  • lymphocyte survival /apoptosis (which will identify, among others, proteins that prevent apoptosis after superantigen induction and proteins that regulate lymphocyte homeostasis) include, without limitation, those described in: Darzynkiewicz et al., Cytometry 13:795-808, 1992; Gorczyca et al., Leukemia 7:659-670, 1993; Gorczyca et al., Cancer Research 53:1945-1951, 1993; Itoh et al, Cell 66:233-243, 1991; Zacharchuk, Journal of Immunology 145:4037-4045, 1990; Zamai et al, Cytometry 14:891-897, 1993; Gorczyca et al., International Journal of Oncology 1:639-648, 1992.
  • a protein of the present invention may be useful in regulation of hematopoiesis and, consequently, in the treatment of myeloid or lymphoid cell deficiencies. Even marginal biological activity in support of colony forming cells or of factor-dependent cell lines indicates involvement in regulating hematopoiesis, e.g.
  • erythroid progenitor cells in supporting the growth and proliferation of erythroid progenitor cells alone or in combination with other cytokines, thereby indicating utility, for example, in treating various anemias or for use in conjunction with irradiation /chemotherapy to stimulate the production of erythroid precursors and /or erythroid cells; in supporting the growth and proliferation of myeloid cells such as granulocytes and monocytes/macrophages (i.e., traditional CSF activity) useful, for example, in conjunction with chemotherapy to prevent or treat consequent myelo-suppression; in supporting the growth and proliferation of megakaryocytes and consequently of platelets thereby allowing prevention or treatment of various platelet disorders such as thrombocytopenia, and generally for use in place of or complimentary to platelet transfusions; and/or in supporting the growth and proliferation of hematopoietic stem cells which are capable of maturing to any and all of the above- mentioned hematopoietic cells and therefore find therapeutic utility in various stem
  • the activity of a protein of the invention may, among other means, be measured by the following methods: Suitable assays for proliferation and differentiation of various hematopoietic lines are cited above.
  • Assays for embryonic stem cell differentiation include, without limitation, those described in: Johansson et al. Cellular Biology 15:141-151, 1995; Keller et al., Molecular and Cellular Biology 13:473-486, 1993; McClanahan et al., Blood 81:2903-2915, 1993.
  • Assays for stem cell survival and differentiation include, without limitation, those described in: Methylcellulose colony forming assays, Freshney, M.G. In Culture of Hematopoietic Cells. R.I. Freshney, et al. eds. Vol pp. 265-268, Wiley-Liss, Inc., New York,
  • a protein of the present invention also may have utility in compositions used for bone, cartilage, tendon, ligament and /or nerve tissue growth or regeneration, as well as for wound healing and tissue repair and replacement, and in the treatment of burns, incisions and ulcers.
  • a protein of the present invention which induces cartilage and /or bone growth in circumstances where bone is not normally formed, has application in the healing of bone fractures and cartilage damage or defects in humans and other animals.
  • Such a preparation employing a protein of the invention may have prophylactic use in closed as well as open fracture reduction and also in the improved fixation of artificial joints. De novo bone formation induced by an osteogenic agent contributes to the repair of congenital, trauma induced, or oncologic resection induced craniof acial defects, and also is useful in cosmetic plastic surgery.
  • a protein of this invention may also be used in the treatment of periodontal disease, and in other tooth repair processes. Such agents may provide an environment to attract bone-forming cells, stimulate growth of bone-forming cells or induce differentiation of progenitors of bone-forming cells.
  • a protein of the invention may also be useful in the treatment of osteoporosis or osteoarthritis, such as through stimulation of bone and /or cartilage repair or by blocking inflammation or processes of tissue destruction (collagenase activity, osteoclast activity, etc.) mediated by inflammatory processes.
  • Another category of tissue regeneration activity that may be attributable to the protein of the present invention is tendon /ligament formation.
  • a protein of the present invention which induces tendon/ligament-like tissue or other tissue formation in circumstances where such tissue is not normally formed, has application in the healing of tendon or ligament tears, deformities and other tendon or ligament defects in humans and other animals.
  • Such a preparation employing a tendon/ligament-like tissue inducing protein may have prophylactic use in preventing damage to tendon or ligament tissue, as well as use in the improved fixation of tendon or ligament to bone or other tissues, and in repairing defects to tendon or ligament tissue.
  • compositions of the present invention contributes to the repair of congenital, trauma induced, or other tendon or ligament defects of other origin, and is also useful in cosmetic plastic surgery for attachment or repair of tendons or ligaments.
  • the compositions of the present invention may provide an environment to attract tendon- or ligament-forming cells, stimulate growth of tendon- or ligament-forming cells, induce differentiation of progenitors of tendon- or ligament-forming cells, or induce growth of tendon /ligament cells or progenitors ex vivo for return in vivo to effect tissue repair.
  • the compositions of the invention may also be useful in the treatment of tendinitis, carpal tunnel syndrome and other tendon or ligament defects.
  • the compositions may also include an appropriate matrix and /or sequestering agent as a carrier as is well known in the art.
  • the protein of the present invention may also be useful for proliferation of neural cells and for regeneration of nerve and brain tissue, i.e. for the treatment of central and peripheral nervous system diseases and neuropathies, as well as mechanical and traumatic disorders, which involve degeneration, death or trauma to neural cells or nerve tissue. More specifically, a protein may be used in the treatment of diseases of the peripheral nervous system, such as peripheral nerve injuries, peripheral neuropathy and localized neuropathies, and central nervous system diseases, such as Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome. Further conditions which may be treated in accordance with the present invention include mechanical and traumatic disorders, such as spinal cord disorders, head trauma and cerebrovascular diseases such as stroke. Peripheral neuropathies resulting from chemotherapy or other medical therapies may also be treatable using a protein of the invention.
  • Proteins of the invention may also be useful to promote better or faster closure of non-healing wounds, including without limitation pressure ulcers, ulcers associated with vascular insufficiency, surgical and traumatic wounds, and the like.
  • a protein of the present invention may also exhibit activity for generation or regeneration of other tissues, such as organs (including, for example, pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac) and vascular (including vascular endothelium) tissue, or for promoting the growth of cells comprising such tissues. Part of the desired effects may be by inhibition or modulation of fibrotic scarring to allow normal tissue to regenerate.
  • a protein of the invention may also exhibit angiogenic activity.
  • a protein of the present invention may also be useful for gut protection or regeneration and treatment of lung or liver fibrosis, reperfusion injury in various tissues, and conditions resulting from systemic cytokine damage.
  • a protein of the present invention may also be useful for promoting or inhibiting differentiation of tissues described above from precursor tissues or cells; or for inhibiting the growth of tissues described above.
  • the activity of a protein of the invention may, among other means, be measured by the following methods:
  • Assays for tissue generation activity include, without limitation, those described in: International Patent Publication No. WO95/ 16035 (bone, cartilage, tendon); International Patent Publication No. WO95/05846 (nerve, neuronal); International Patent Publication No. WO91/07491 (skin, endothelium ).
  • Assays for wound healing activity include, without limitation, those described in: Winter, Epidermal Wound Healing, pps. 71-112 (Maibach, HI and Rovee, DT, eds.), Year Book Medical Publishers, Inc., Chicago, as modified by Eaglstein and Mertz, J. Invest. Dermatol 71:382-84 (1978).
  • a protein of the present invention may also exhibit activin- or inhibin-related activities. Inhibins are characterized by their ability to inhibit the release of follicle stimulating hormone (FSH), while activins and are characterized by their ability to stimulate the release of follicle stimulating hormone (FSH). Thus, a protein of the present invention, alone or in heterodimers with a member of the inhibin family, may be useful as a contraceptive based on the ability of inhibins to decrease fertility in female mammals and decrease spermatogenesis in male mammals. Administration of sufficient amounts of other inhibins can induce infertility in these mammals.
  • FSH follicle stimulating hormone
  • the protein of the invention may be useful as a fertility inducing therapeutic, based upon the ability of activin molecules in stimulating FSH release from cells of the anterior pituitary. See, for example, United States Patent 4,798,885.
  • a protein of the invention may also be useful for advancement of the onset of fertility in sexually immature mammals, so as to increase the lifetime reproductive performance of domestic animals such as cows, sheep and pigs.
  • the activity of a protein of the invention may, among other means, be measured by the following methods: Assays for activin/inhibin activity include, without limitation, those described in: Vale et al., Endocrinology 91:562-572, 1972; Ling et al., Nature 321:779-782, 1986; Vale et al., Nature 321:776-779, 1986; Mason et al., Nature 318:659-663, 1985; Forage et al., Proc. Natl. Acad. Sci. USA 83:3091-3095, 1986.
  • a protein of the present invention may have chemotactic or chemokinetic activity (e.g., act as a chemokine) for mammalian cells, including, for example, monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and /or endothelial cells.
  • Chemotactic and chemokinetic proteins can be used to mobilize or attract a desired cell population to a desired site of action.
  • Chemotactic or chemokinetic proteins provide particular advantages in treatment of wounds and other trauma to tissues, as well as in treatment of localized infections. For example, attraction of lymphocytes, monocytes or neutrophils to tumors or sites of infection may result in improved immune responses against the tumor or infecting agent.
  • a protein or peptide has chemotactic activity for a particular cell population if it can stimulate, directly or indirectly, the directed orientation or movement of such cell population.
  • the protein or peptide has the ability to directly stimulate directed movement of cells. Whether a particular protein has chemotactic activity for a population of cells can be readily determined by employing such protein or peptide in any known assay for cell chemotaxis.
  • the activity of a protein of the invention may, among other means, be measured by the following methods:
  • Assays for chemotactic activity consist of assays that measure the ability of a protein to induce the migration of cells across a membrane as well as the ability of a protein to induce the adhesion of one cell population to another cell population.
  • Suitable assays for movement and adhesion include, without limitation, those described in: Current Protocols in Immunology, Ed by J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W.Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 6.12, Measurement of alpha and beta Chemokines 6.12.1-6.12.28; Taub et al. J. Clin. Invest.
  • a protein of the invention may also exhibit hemostatic or thrombolytic activity. As a result, such a protein is expected to be useful in treatment of various coagulation disorders (including hereditary disorders, such as hemophilias) or to enhance coagulation and other hemostatic events in treating wounds resulting from trauma, surgery or other causes.
  • a protein of the invention may also be useful for dissolving or inhibiting formation of thromboses and for treatment and prevention of conditions resulting therefrom (such as, for example, infarction of cardiac and central nervous system vessels (e.g., stroke).
  • the activity of a protein of the invention may, among other means, be measured by the following methods:
  • Assay for hemostatic and thrombolytic activity include, without limitation, those described in: Linet et al., J. Clin. Pharmacol. 26:131-140, 1986; Burdick et al., Thrombosis Res.45:413-419, 1987; Humphrey et al., Fibrinolysis 5:71-79 (1991); Schaub, Prostaglandins 35:467-474, 1988.
  • a protein of the present invention may also demonstrate activity as receptors, receptor ligands or inhibitors or agonists of receptor /ligand interactions.
  • receptors and ligands include, without limitation, cytokine receptors and their ligands, receptor kinases and their ligands, receptor phosphatases and their ligands, receptors involved in cell-cell interactions and their ligands (including without limitation, cellular adhesion molecules (such as selectins, integrins and their ligands) and receptor/ligand pairs involved in antigen presentation, antigen recognition and development of cellular and humoral immune responses).
  • Receptors and ligands are also useful for screening of potential peptide or small molecule inhibitors of the relevant receptor/ligand interaction.
  • a protein of the present invention (including, without limitation, fragments of receptors and ligands) may themselves be useful as inhibitors of receptor/ligand interactions.
  • the activity of a protein of the invention may, among other means, be measured by the following methods:
  • Suitable assays for receptor-ligand activity include without limitation those described in:Current Protocols in Immunology, Ed by J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W.Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 7.28, Measurement of Cellular Adhesion under static conditions 7.28.1-7.28.22), Takai et al, Proc. Natl. Acad. Sci. USA 84:6864-6868, 1987; Bierer et al., J. Exp. Med. 168:1145-1156, 1988; Rosenstein et al., J. Exp. Med. 169:149-160 1989; Stoltenborg et al., J. Immunol. Methods 175:59-68, 1994; Stitt et al, Cell 80:661-670, 1995.
  • Proteins of the present invention may also exhibit anti-inflammatory activity.
  • the anti-inflammatory activity may be achieved by providing a stimulus to cells involved in the inflammatory response, by inhibiting or promoting cell-cell interactions (such as, for example, cell adhesion), by inhibiting or promoting chemotaxis of cells involved in the inflammatory process, inhibiting or promoting cell extravasation, or by stimulating or suppressing production of other factors which more directly inhibit or promote an inflammatory response.
  • Proteins exhibiting such activities can be used to treat inflammatory conditions including chronic or acute conditions), including without limitation inflammation associated with infection (such as septic shock, sepsis or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine-induced lung injury, inflammatory bowel disease, Crohn's disease or resulting from over production of cytokines such as TNF or IL-1. Proteins of the invention may also be useful to treat anaphylaxis and hypersensitivity to an antigenic substance or material.
  • infection such as septic shock, sepsis or systemic inflammatory response syndrome (SIRS)
  • ischemia-reperfusion injury such as endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine-induced lung injury, inflammatory bowel disease, Crohn's disease or resulting
  • Cadherins are calcium-dependent adhesion molecules that appear to play major roles during development, particularly in defining specific cell types. Loss or alteration of normal cadherin expression can lead to changes in cell adhesion properties linked to tumor growth and metastasis. Cadherin malfunction is also implicated in other human diseases, such as pemphigus vulgaris and pemphigus foliaceus (auto-immune blistering skin diseases), Crohn's disease, and some developmental abnormalities.
  • the cadherin superfamily includes well over forty members, each with a distinct pattern of expression. All members of the superfamily have in common conserved extracellular repeats (cadherin domains), but structural differences are found in other parts of the molecule.
  • the cadherin domains bind calcium to form their tertiary structure and thus calcium is required to mediate their adhesion. Only a few amino acids in the first cadherin domain provide the basis for homophilic adhesion; modification of this recognition site can change the specificity of a cadherin so that instead of recognizing only itself, the mutant molecule can now also bind to a different cadherin. In addition, some cadherins engage in heterophilic adhesion with other cadherins. E-cadherin, one member of the cadherin superfamily, is expressed in epithelial cell types. Pathologically, if E-cadherin expression is lost in a tumor, the malignant cells become invasive and the cancer metastasizes.
  • Transfection of cancer cell lines with polynucleotides expressing E-cadherin has reversed cancer-associated changes by returning altered cell shapes to normal, restoring cells' adhesiveness to each other and to their substrate, decreasing the cell growth rate, and drastically reducing anchorage- independent cell growth.
  • reintroducing E-cadherin expression reverts carcinomas to a less advanced stage. It is likely that other cadherins have the same invasion suppressor role in carcinomas derived from other tissue types. Therefore, proteins of the present invention with cadherin activity, and polynucleotides of the present invention encoding such proteins, can be used to treat cancer. Introducing such proteins or polynucleotides into cancer cells can reduce or eliminate the cancerous changes observed in these cells by providing normal cadherin expression.
  • Cancer cells have also been shown to express cadherins of a different tissue type than their origin, thus allowing these cells to invade and metastasize in a different tissue in the body.
  • Proteins of the present invention with cadherin activity, and polynucleotides of the present invention encoding such proteins, can be substituted in these cells for the inappropriately expressed cadherins, restoring normal cell adhesive properties and reducing or eliminating the tendency of the cells to metastasize.
  • proteins of the present invention with cadherin activity can be used to generate antibodies recognizing and binding to cadherins.
  • Such antibodies can be used to block the adhesion of inappropriately expressed tumor-cell cadherins, preventing the cells from forming a tumor elsewhere.
  • Such an anti-cadherin antibody can also be used as a marker for the grade, pathological type, and prognosis of a cancer, i.e. the more progressed the cancer, the less cadherin expression there will be, and this decrease in cadherin expression can be detected by the use of a cadherin-binding antibody.
  • Fragments of proteins of the present invention with cadherin activity can also be used to block cadherin function by binding to cadherins and preventing them from binding in ways that produce undesirable effects. Additionally, fragments of proteins of the present invention with cadherin activity, preferably truncated soluble cadherin fragments which have been found to be stable in the circulation of cancer patients, and polynucleotides encoding such protein fragments, can be used to disturb proper cell-cell adhesion.
  • Assays for cadherin adhesive and invasive suppressor activity include, without limitation, those described in: Hortsch et al. J Biol Chem 270 (32): 18809-18817, 1995; Miyaki et al. Oncogene 11: 2547-2552, 1995; Ozawa et al. Cell 63: 1033-1038, 1990.
  • a protein of the invention may exhibit other anti- tumor activities.
  • a protein may inhibit tumor growth directly or indirectly (such as, for example, via ADCC).
  • a protein may exhibit its tumor inhibitory activity by acting on tumor tissue or tumor precursor tissue, by inhibiting formation of tissues necessary to support tumor growth (such as, for example, by inhibiting angiogenesis), by causing production of other factors, agents or cell types which inhibit tumor growth, or by suppressing, eliminating or inhibiting factors, agents or cell types which promote tumor growth.
  • a protein of the invention may also exhibit one or more of the following additional activities or effects: inhibiting the growth, infection or function of, or killing, infectious agents, including, without limitation, bacteria, viruses, fungi and other parasites; effecting (suppressing or enhancing) bodily characteristics, including, without limitation, height, weight, hair color, eye color, skin, fat to lean ratio or other tissue pigmentation, or organ or body part size or shape (such as, for example, breast augmentation or diminution, change in bone form or shape); effecting biorhythms or caricadic cycles or rhythms; effecting the fertility of male or female subjects; effecting the metabolism, catabolism, anabolism, processing, utilization, storage or elimination of dietary fat, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional factors or component(s); effecting behavioral characteristics, including, without limitation, appetite, libido, stress, cognition (including cognitive disorders), depression (including depressive disorders) and violent behaviors; providing analgesic effects or other pain reducing effects; promoting differentiation and
  • a protein of the present invention may be used in a pharmaceutical composition when combined with a pharmaceutically acceptable carrier.
  • a pharmaceutically acceptable carrier may also contain (in addition to protein and a carrier) diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials well known in the art.
  • pharmaceutically acceptable means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredient(s). The characteristics of the carrier will depend on the route of administration.
  • the pharmaceutical composition of the invention may also contain cytokines, lymphokines, or other hematopoietic factors such as M-CSF, GM-CSF, TNF, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IFN, TNFO, TNFl, TNF2, G-CSF, Meg-CSF, thrombopoietin, stem cell factor, and erythropoietin.
  • the pharmaceutical composition may further contain other agents which either enhance the activity of the protein or compliment its activity or use in treatment.
  • protein of the present invention may be included in formulations of the particular cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent to minimize side effects of the cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent.
  • a protein of the present invention may be active in multimers (e.g., heterodimers or homodimers) or complexes with itself or other proteins.
  • compositions of the invention may comprise a protein of the invention in such multimeric or complexed form.
  • the pharmaceutical composition of the invention may be in the form of a complex of the protein(s) of present invention along with protein or peptide antigens.
  • the protein and/or peptide antigen will deliver a stimulatory signal to both B and T lymphocytes.
  • B lymphocytes will respond to antigen through their surface immunoglobulin receptor.
  • T lymphocytes will respond to antigen through the T cell receptor (TCR) following presentation of the antigen by MHC proteins.
  • TCR T cell receptor
  • MHC and structurally related proteins including those encoded by class I and class II MHC genes on host cells will serve to present the peptide antigen(s) to T lymphocytes.
  • the antigen components could also be supplied as purified MHC-peptide complexes alone or with co-stimulatory molecules that can directly signal T cells.
  • antibodies able to bind surface immunolgobulin and other molecules on B cells as well as antibodies able to bind the TCR and other molecules on T cells can be combined with the pharmaceutical composition of the invention.
  • the pharmaceutical composition of the invention may be in the form of a liposome in which protein of the present invention is combined, in addition to other pharmaceutically acceptable carriers, with amphipathic agents such as lipids which exist in aggregated form as micelles, insoluble monolayers, liquid crystals, or lamellar layers in aqueous solution.
  • Suitable lipids for liposomal formulation include, without limitation, monoglycerides, diglycerides, sulfatides, lysolecithin, phospholipids, saponin, bile acids, and the like. Preparation of such liposomal formulations is within the level of skill in the art, as disclosed, for example, in U.S. Patent No. 4,235,871; U.S. Patent No. 4,501,728; U.S. Patent No. 4,837,028; and U.S. Patent No. 4,737,323, all of which are incorporated herein by reference.
  • the term "therapeutically effective amount” means the total amount of each active component of the pharmaceutical composition or method that is sufficient to show a meaningful patient benefit, i.e., treatment, healing, prevention or amelioration of the relevant medical condition, or an increase in rate of treatment, healing, prevention or amelioration of such conditions.
  • a meaningful patient benefit i.e., treatment, healing, prevention or amelioration of the relevant medical condition, or an increase in rate of treatment, healing, prevention or amelioration of such conditions.
  • the term refers to that ingredient alone.
  • the term refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially or simultaneously.
  • a therapeutically effective amount of protein of the present invention is administered to a mammal having a condition to be treated.
  • Protein of the present invention may be administered in accordance with the method of the invention either alone or in combination with other therapies such as treatments employing cytokines, lymphokines or other hematopoietic factors.
  • protein of the present invention may be administered either simultaneously with the cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors, or sequentially. If administered sequentially, the attending physician will decide on the appropriate sequence of administering protein of the present invention in combination with cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors.
  • Administration of protein of the present invention used in the pharmaceutical composition or to practice the method of the present invention can be carried out in a variety of conventional ways, such as oral ingestion, inhalation, topical application or cutaneous, subcutaneous, intraperitoneal, parenteral or intravenous injection. Intravenous administration to the patient is preferred.
  • protein of the present invention When a therapeutically effective amount of protein of the present invention is administered orally, protein of the present invention will be in the form of a tablet, capsule, powder, solution or elixir.
  • the pharmaceutical composition of the invention may additionally contain a solid carrier such as a gelatin or an adjuvant.
  • the tablet, capsule, and powder contain from about 5 to 95% protein of the present invention, and preferably from about 25 to 90% protein of the present invention.
  • a liquid carrier such as water, petroleum, oils of animal or plant origin such as peanut oil, mineral oil, soybean oil, or sesame oil, or synthetic oils may be added.
  • the liquid form of the pharmaceutical composition may further contain physiological saline solution, dextrose or other saccharide solution, or glycols such as ethylene glycol, propylene glycol or polyethylene glycol.
  • the pharmaceutical composition contains from about 0.5 to 90% by weight of protein of the present invention, and preferably from about 1 to 50% protein of the present invention.
  • protein of the present invention will be in the form of a pyrogen-free, parenterally acceptable aqueous solution.
  • the preparation of such parenterally acceptable protein solutions having due regard to pH, isotonicity, stability, and the like, is within the skill in the art.
  • a preferred pharmaceutical composition for intravenous, cutaneous, or subcutaneous injection should contain, in addition to protein of the present invention, an isotonic vehicle such as Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, Lactated Ringer's Injection, or other vehicle as known in the art.
  • the pharmaceutical composition of the present invention may also contain stabilizers, preservatives, buffers, antioxidants, or other additives known to those of skill in the art.
  • the amount of protein of the present invention in the pharmaceutical composition of the present invention will depend upon the nature and severity of the condition being treated, and on the nature of prior treatments which the patient has undergone.
  • the attending physician will decide the amount of protein of the present invention with which to treat each individual patient. Initially, the attending physician will administer low doses of protein of the present invention and observe the patient's response. Larger doses of protein of the present invention may be administered until the optimal therapeutic effect is obtained for the patient, and at that point the dosage is not increased further. It is contemplated that the various pharmaceutical compositions used to practice the method of the present invention should contain about 0.01 ⁇ g to about 100 mg (preferably about O.lng to about 10 mg, more preferably about 0.1 ⁇ g to about 1 mg) of protein of the present invention per kg body weight.
  • the duration of intravenous therapy using the pharmaceutical composition of the present invention will vary, depending on the severity of the disease being treated and the condition and potential idiosyncratic response of each individual patient. It is contemplated that the duration of each application of the protein of the present invention will be in the range of 12 to 24 hours of continuous intravenous administration. Ultimately the attending physician will decide on the appropriate duration of intravenous therapy using the pharmaceutical composition of the present invention.
  • Protein of the invention may also be used to immunize animals to obtain polyclonal and monoclonal antibodies which specifically react with the protein. Such antibodies may be obtained using either the entire protein or fragments thereof as an immunogen.
  • the peptide immunogens additionally may contain a cysteine residue at the carboxyl terminus, and are conjugated to a hapten such as keyhole limpet hemocyanin
  • Monoclonal antibodies binding to the protein of the invention may be useful diagnostic agents for the immunodetection of the protein.
  • Neutralizing monoclonal antibodies binding to the protein may also be useful therapeutics for both conditions associated with the protein and also in the treatment of some forms of cancer where abnormal expression of the protein is involved.
  • neutralizing monoclonal antibodies against the protein may be useful in detecting and preventing the metastatic spread of the cancerous cells, which may be mediated by the protein.
  • the therapeutic method includes administering the composition topically, systematically, or locally as an implant or device.
  • the therapeutic composition for use in this invention is, of course, in a pyrogen-free, physiologically acceptable form.
  • the composition may desirably be encapsulated or injected in a viscous form for delivery to the site of bone, cartilage or tissue damage.
  • Topical administration may be suitable for wound healing and tissue repair.
  • Therapeutically useful agents other than a protein of the invention which may also optionally be included in the composition as described above, may alternatively or additionally, be administered simultaneously or sequentially with the composition in the methods of the invention.
  • the composition would include a matrix capable of delivering the protein-containing composition to the site of bone and /or cartilage damage, providing a structure for the developing bone and cartilage and optimally capable of being resorbed into the body.
  • matrices may be formed of materials presently in use for other implanted medical applications.
  • compositions may be biodegradable and chemically defined calcium sulfate, tricalciumphosphate, hydroxyapatite, polylactic acid, polyglycolic acid and polyanhydrides.
  • potential materials are biodegradable and biologically well- defined, such as bone or dermal collagen.
  • Further matrices are comprised of pure proteins or extracellular matrix components.
  • Other potential matrices are nonbiodegradable and chemically defined, such as sintered hydroxapatite, bioglass, aluminates, or other ceramics.
  • Matrices may be comprised of combinations of any of the above mentioned types of material, such as polylactic acid and hydroxyapatite or collagen and tricalciumphosphate.
  • the bioceramics may be altered in composition, such as in calcium- aluminate-phosphate and processing to alter pore size, particle size, particle shape, and biodegradability.
  • a 50:50 (mole weight) copolymer of lactic acid and glycolic acid in the form of porous particles having diameters ranging from 150 to 800 microns.
  • a sequestering agent such as carboxymethyl cellulose or autologous blood clot, to prevent the protein compositions from disassociating from the matrix.
  • a preferred family of sequestering agents is cellulosic materials such as alkylcelluloses (including hydroxyalkylcelluloses), including methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropyl- methylcellulose, and carboxymethylcellulose, the most preferred being cationic salts of carboxymethylcellulose (CMC).
  • CMC carboxymethylcellulose
  • Other preferred sequestering agents include hyaluronic acid, sodium alginate, poly(ethylene glycol), polyoxyethylene oxide, carboxyvinyl polymer and poly(vinyl alcohol).
  • the amount of sequestering agent useful herein is 0.5-20 wt%, preferably 1-10 wt% based on total formulation weight, which represents the amount necessary to prevent desorbtion of the protein from the polymer matrix and to provide appropriate handling of the composition, yet not so much that the progenitor cells are prevented from infiltrating the matrix, thereby providing the protein the opportunity to assist the osteogenic activity of the progenitor cells.
  • proteins of the invention may be combined with other agents beneficial to the treatment of the bone and/or cartilage defect, wound, or tissue in question. These agents include various growth factors such as epidermal growth factor (EGF), platelet derived growth factor (PDGF), transforming growth factors (TGF- ⁇ and TGF- ⁇ ), and insulin-like growth factor (IGF).
  • EGF epidermal growth factor
  • PDGF platelet derived growth factor
  • TGF- ⁇ and TGF- ⁇ transforming growth factors
  • IGF insulin-like growth factor
  • the therapeutic compositions are also presently valuable for veterinary applications. Particularly domestic animals and thoroughbred horses, in addition to humans, are desired patients for such treatment with proteins of the present invention.
  • the dosage regimen of a protein-containing pharmaceutical composition to be used in tissue regeneration will be determined by the attending physician considering various factors which modify the action of the proteins, e.g., amount of tissue weight desired to be formed, the site of damage, the condition of the damaged tissue, the size of a wound, type of damaged tissue (e.g., bone), the patient's age, sex, and diet, the severity of any infection, time of administration and other clinical factors.
  • the dosage may vary with the type of matrix used in the reconstitution and with inclusion of other proteins in the pharmaceutical composition.
  • IGF I insulin like growth factor I
  • the addition of other known growth factors, such as IGF I may also effect the dosage.
  • Progress can be monitored by periodic assessment of tissue/bone growth and /or repair, for example, X-rays, histomorphometric determinations and tetracycline labeling.
  • Polynucleotides of the present invention can also be used for gene therapy. Such polynucleotides can be introduced either in vivo or ex vivo into cells for expression in a mammalian subject. Polynucleotides of the invention may also be administered by other known methods for introduction of nucleic acid into a cell or organism (including, without limitation, in the form of viral vectors or naked DNA).
  • Cells may also be cultured ex vivo in the presence of proteins of the present invention in order to proliferate or to produce a desired effect on or activity in such cells. Treated cells can then be introduced in vivo for therapeutic purposes.
  • ACTTCGCANC CCATCCCGGC TGGACGCGAC CGGGGAGTGC AGCAGCCCGT TCCCCTCCTC 60
  • AAATCTCCAA CCATTGTTGT GCATTTATTT CTATTTCTTT AGTTCTGTTG ATTTTTGTTT 1260
  • TTCAAACTTT TCCAGGAATA
  • TGCCAATTTA CAAGTGAGTG AGCCCCAAAT CCGAGAGGGC 900
  • AAGACCAAAG ATGAACTCTG A ATGCAAAA TAACTTCTAT TAGAATAATG GTGCTCTGAA 1020
  • Ser Lys Asp lie Val Met Pro Thr Tyr Asp Leu Thr Asp Ser Val Leu 50 55 60 Glu Thr Met Gly Arg Val Ser Leu Asp Met Met Ser Val Gin Ala Asn 65 70 75 80
  • Gin Asp Ser lie Tyr Tyr Glu His Phe Tyr Asn Glu Leu Gin Pro Trp 180 185 190
  • Lys His Tyr lie Pro Val Lys Ser Asn Leu Ser Asp Leu Leu Glu Lys 195 200 205
  • Glu Pro Gin lie Arg Glu Gly Met Lys Arg Val Glu Pro Gin Thr Glu 260 265 270
  • AGTTTTCATA CAGTCTCGGG GTTTTAAAAC TTTGAAATCA AGGACACNAC GTCTCCAGTC 300 TACCTCCGAG AGA 313
  • CAATCATGCC ACGGGGGCCA ACACTTGGAC ATGTGTCCCT GTTACCTGAG AATGACAGAT 300
  • MOLECULE TYPE other nucleic acid
  • /desc "oligonucleotide"

Abstract

Novel polynucleotides and the proteins encoded thereby are disclosed.

Description

SECRETED PROTEINS AND POLYNUCLEOTIDES ENCODING THEM
This application is a continuation-in-part of the following applications: Ser. No. 08/752,912, filed November 20, 1996; and Ser. No. 08/800,826, filed February 14, 1997; all of which are incorporated by reference herein.
FIELD OF THE INVENTION
The present invention provides novel polynucleotides and proteins encoded by such polynucleotides, along with therapeutic, diagnostic and research utilities for these polynucleotides and proteins.
BACKGROUND OF THE INVENTION
Technology aimed at the discovery of protein factors (including e.g., cytokines, such as lymphokines, interferons, CSFs and interleukins) has matured rapidly over the past decade. The now routine hybridization cloning and expression cloning techniques clone novel polynucleotides "directly" in the sense that they rely on information directly related to the discovered protein (i.e., partial DNA/amino acid sequence of the protein in the case of hybridization cloning; activity of the protein in the case of expression cloning). More recent "indirect" cloning techniques such as signal sequence cloning, which isolates DNA sequences based on the presence of a now well-recognized secretory leader sequence motif, as well as various PCR-based or low stringency hybridization cloning techniques, have advanced the state of the art by making available large numbers of DNA/amino acid sequences for proteins that are known to have biological activity by virtue of their secreted nature in the case of leader sequence cloning, or by virtue of the cell or tissue source in the case of PCR-based techniques. It is to these proteins and the polynucleotides encoding them that the present invention is directed. SUMMARY OF THE INVENTION In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:2;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:2 from nucleotide 390 to nucleotide 563;
(c) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone BD441_1 deposited under accession number ATCC 98264;
(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BD441_1 deposited under accession number ATCC 98264;
(e) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone BD441_1 deposited under accession number ATCC 98264;
(f) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone BD441_1 deposited under accession number ATCC 98264;
(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:3; (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:3 having biological activity;
(i) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(f) above;
(j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ; and
(k) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h).
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:2 from nucleotide 390 to nucleotide 563; the nucleotide sequence of the full-length protein coding sequence of clone BD441_1 deposited under accession number ATCC
98264; or the nucleotide sequence of the mature protein coding sequence of clone BD441_1 deposited under accession number ATCC 98264. In other preferred embodiments, the polynucleotide encodes the full-length or mature protein encoded by the cDNA insert of clone BD441_1 deposited under accession number ATCC 98264. Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:2, SEQ ID NO:l or SEQ ID NO:4 .
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:3;
(b) fragments of the amino acid sequence of SEQ ID NO:3; and
(c) the amino acid sequence encoded by the cDNA insert of clone BD441_1 deposited under accession number ATCC 98264; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:3.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5 from nucleotide 583 to nucleotide 756;
(c) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone BD441_2 deposited under accession number ATCC 98264;
(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BD441_2 deposited under accession number ATCC 98264;
(e) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone BD441_2 deposited under accession number ATCC 98264;
(f) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone BD441_2 deposited under accession number ATCC 98264;
(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:6; (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity;
(i) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(f) above; (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ; and
(k) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h). Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
NO:5 from nucleotide 583 to nucleotide 756; the nucleotide sequence of the full-length protein coding sequence of clone BD441_2 deposited under accession number ATCC
98264; or the nucleotide sequence of the mature protein coding sequence of clone BD441_2 deposited under accession number ATCC 98264. In other preferred embodiments, the polynucleotide encodes the full-length or mature protein encoded by the cDNA insert of clone BD441_2 deposited under accession number ATCC 98264.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:5 or SEQ ID NO:7.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:6;
(b) fragments of the amino acid sequence of SEQ ID NO:6; and
(c) the amino acid sequence encoded by the cDNA insert of clone BD441_2 deposited under accession number ATCC 98264; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:6.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:8;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:8 from nucleotide 426 to nucleotide 581;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:8 from nucleotide 495 to nucleotide 581;
(d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:8 from nucleotide 354 to nucleotide 503; (e) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone BG102_3 deposited under accession number ATCC 98264;
(f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BG102_3 deposited under accession number ATCC 98264;
(g) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone BG102_3 deposited under accession number ATCC 98264;
(h) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone BG102_3 deposited under accession number ATCC 98264;
(i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:9;
(j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:9 having biological activity; (k) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(h) above;
(1) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ; and
(m) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(j).
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:8 from nucleotide 426 to nucleotide 581; the nucleotide sequence of SEQ ID NO:8 from nucleotide 495 to nucleotide 581; the nucleotide sequence of SEQ ID NO:8 from nucleotide 354 to nucleotide 503; the nucleotide sequence of the full-length protein coding sequence of clone BG102_3 deposited under accession number ATCC 98264; or the nucleotide sequence of the mature protein coding sequence of clone BG102_3 deposited under accession number ATCC 98264. In other preferred embodiments, the polynucleotide encodes the full-length or mature protein encoded by the cDNA insert of clone BG102_3 deposited under accession number ATCC 98264. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:9 from amino acid 1 to amino acid 26. Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:8. In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:9; (b) the amino acid sequence of SEQ ID NO:9 from amino acid 1 to amino acid 26;
(c) fragments of the amino acid sequence of SEQ ID NO:9; and
(d) the amino acid sequence encoded by the cDNA insert of clone BG102_3 deposited under accession number ATCC 98264; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:9 or the amino acid sequence of SEQ ID NO:9 from amino acid 1 to amino acid 26.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:10;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:10 from nucleotide 112 to nucleotide 978;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:10 from nucleotide 436 to nucleotide 1048;
(d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone BK158_1 deposited under accession number ATCC 98264;
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BK158_1 deposited under accession number ATCC 98264;
(f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone BK158_1 deposited under accession number ATCC 98264;
(g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone BK158_1 deposited under accession number ATCC 98264;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:ll;
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:ll having biological activity; (j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and (1) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:10 from nucleotide 112 to nucleotide 978; the nucleotide sequence of SEQ ID NO:10 from nucleotide 436 to nucleotide 1048; the nucleotide sequence of the full-length protein coding sequence of clone BK158_1 deposited under accession number ATCC 98264; or the nucleotide sequence of the mature protein coding sequence of clone BK158_1 deposited under accession number ATCC 98264. In other preferred embodiments, the polynucleotide encodes the full-length or mature protein encoded by the cDNA insert of clone BK158_1 deposited under accession number ATCC 98264. Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID NO:10.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO:ll;
(b) fragments of the amino acid sequence of SEQ ID NO:ll; and
(c) the amino acid sequence encoded by the cDNA insert of clone BK158_1 deposited under accession number ATCC 98264; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO: 11.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:12; (b) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:12 from nucleotide 16 to nucleotide 492;
(c) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone BP163_1 deposited under accession number ATCC 98264; (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BP163_1 deposited under accession number ATCC 98264;
(e) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone BP163_1 deposited under accession number ATCC 98264;
(f) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone BP163_1 deposited under accession number ATCC 98264;
(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:13; (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 13 having biological activity;
(i) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(f) above;
(j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ; and
(k) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h).
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:12 from nucleotide 16 to nucleotide 492; the nucleotide sequence of the full-length protein coding sequence of clone BP163_1 deposited under accession number ATCC 98264; or the nucleotide sequence of the mature protein coding sequence of clone BP163_1 deposited under accession number ATCC 98264. In other preferred embodiments, the polynucleotide encodes the full-length or mature protein encoded by the cDNA insert of clone BP163_1 deposited under accession number ATCC 98264. Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID NO:12 or SEQ ID NO:14.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO: 13;
(b) fragments of the amino acid sequence of SEQ ID NO:13; and
(c) the amino acid sequence encoded by the cDNA insert of clone BP163_1 deposited under accession number ATCC 98264; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:13.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:16;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:16 from nucleotide 72 to nucleotide 569;
(c) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone BZ16_3 deposited under accession number ATCC 98264;
(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BZ16_3 deposited under accession number ATCC 98264;
(e) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone BZ16_3 deposited under accession number
ATCC 98264;
(f) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone BZ16_3 deposited under accession number ATCC 98264;
(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:17;
(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:17 having biological activity;
(i) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(f) above; (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ; and
(k) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h). Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO: 16 from nucleotide 72 to nucleotide 569; the nucleotide sequence of the full-length protein coding sequence of clone BZ16_3 deposited under accession number ATCC 98264; or the nucleotide sequence of the mature protein coding sequence of clone BZ16_3 deposited under accession number ATCC 98264. In other preferred embodiments, the polynucleotide encodes the full-length or mature protein encoded by the cDNA insert of clone BZ16_3 deposited under accession number ATCC 98264. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO: 17 from amino acid 1 to amino acid 124. Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID NO:16 or SEQ ID NO:15.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO: 17;
(b) the amino acid sequence of SEQ ID NO: 17 from amino acid 1 to amino acid 124;
(c) fragments of the amino acid sequence of SEQ ID NO:17; and
(d) the amino acid sequence encoded by the cDNA insert of clone BZ16_3 deposited under accession number ATCC 98264; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:17 or the amino acid sequence of SEQ ID NO:17 from amino acid 1 to amino acid 124.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:18;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 18 from nucleotide 405 to nucleotide 662; (c) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:18 from nucleotide 519 to nucleotide 662;
(d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 18 from nucleotide 1 to nucleotide 584;
(e) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone CC182_1 deposited under accession number ATCC 98264;
(f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CC182_1 deposited under accession number ATCC 98264; (g) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone CC182_1 deposited under accession number ATCC 98264;
(h) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone CC182_1 deposited under accession number ATCC 98264;
(i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:19;
(j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 19 having biological activity; (k) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(h) above;
(1) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ; and
(m) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(j).
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:18 from nucleotide 405 to nucleotide 662; the nucleotide sequence of SEQ ID NO:18 from nucleotide 519 to nucleotide 662; the nucleotide sequence of SEQ ID NO:18 from nucleotide 1 to nucleotide 584; the nucleotide sequence of the full-length protein coding sequence of clone CC182_1 deposited under accession number ATCC 98264; or the nucleotide sequence of the mature protein coding sequence of clone CC182_1 deposited under accession number ATCC 98264. In other preferred embodiments, the polynucleotide encodes the full-length or mature protein encoded by the cDNA insert of clone CC182_1 deposited under accession number ATCC 98264. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO: 19 from amino acid 1 to amino acid 60.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:18. In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO: 19; (b) the amino acid sequence of SEQ ID NO: 19 from amino acid 1 to amino acid 60;
(c) fragments of the amino acid sequence of SEQ ID NO:19; and
(d) the amino acid sequence encoded by the cDNA insert of clone CC182_1 deposited under accession number ATCC 98264; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:19 or the amino acid sequence of SEQ ID NO:19 from amino acid 1 to amino acid 60.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:20;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:20 from nucleotide 311 to nucleotide 409; (c) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:20 from nucleotide 24 to nucleotide 414;
(d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone CG109_1 deposited under accession number ATCC 98264; (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CG109_1 deposited under accession number ATCC 98264;
(f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone CG109_1 deposited under accession number
ATCC 98264; (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone CG109_1 deposited under accession number ATCC 98264;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:21;
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:21 having biological activity;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and (1) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:20 from nucleotide 311 to nucleotide 409; the nucleotide sequence of SEQ ID NO:20 from nucleotide 24 to nucleotide 414; the nucleotide sequence of the full-length protein coding sequence of clone CG109_1 deposited under accession number ATCC 98264; or the nucleotide sequence of the mature protein coding sequence of clone CG109_1 deposited under accession number ATCC 98264. In other preferred embodiments, the polynucleotide encodes the full-length or mature protein encoded by the cDNA insert of clone CG109_1 deposited under accession number ATCC 98264.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:20.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:21;
(b) fragments of the amino acid sequence of SEQ ID NO:21; and
(c) the amino acid sequence encoded by the cDNA insert of clone CG109_1 deposited under accession number ATCC 98264; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:21.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:23;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:23 from nucleotide 471 to nucleotide 611;
(c) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone CJ397_1 deposited under accession number ATCC 98264;
(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CJ397_1 deposited under accession number ATCC 98264; (e) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone CJ397_1 deposited under accession number ATCC 98264;
(f) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone CJ397_1 deposited under accession number ATCC 98264;
(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:24;
(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:24 having biological activity; (i) a polynucleotide which is an allelic variant of a polynucleotide of ,
(a)-(f) above;
(j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ; and
(k) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h).
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:23 from nucleotide 471 to nucleotide 611; the nucleotide sequence of the full-length protein coding sequence of clone CJ397_1 deposited under accession number ATCC 98264; or the nucleotide sequence of the mature protein coding sequence of clone CJ397_1 deposited under accession number ATCC 98264. In other preferred embodiments, the polynucleotide encodes the full-length or mature protein encoded by the cDNA insert of clone CJ397_1 deposited under accession number ATCC 98264.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:23, SEQ ID NO:22 or SEQ ID NO:25 . In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:24;
(b) fragments of the amino acid sequence of SEQ ID NO:24; and (c) the amino acid sequence encoded by the cDNA insert of clone
CJ397_1 deposited under accession number ATCC 98264; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:24. In certain preferred embodiments, the polynucleotide is operably linked to an expression control sequence. The invention also provides a host cell, including bacterial, yeast, insect and mammalian cells, transformed with such polynucleotide compositions. Processes are also provided for producing a protein, which comprise: (a) growing a culture of the host cell transformed with such polynucleotide compositions in a suitable culture medium; and (b) purifying the protein from the culture. The protein produced according to such methods is also provided by the present invention. Preferred embodiments include those in which the protein produced by such process is a mature form of the protein.
Protein compositions of the present invention may further comprise a pharmaceutically acceptable carrier. Compositions comprising an antibody which specifically reacts with such protein are also provided by the present invention.
Methods are also provided for preventing, treating or ameliorating a medical condition which comprises administering to a mammalian subject a therapeutically effective amount of a composition comprising a protein of the present invention and a pharmaceutically acceptable carrier.
BRIEF DESCRIPTION OF THE DRAWINGS Figures 1 A and IB are schematic representations of the pED6 and pNOTs vectors, respectively, used for deposit of clones disclosed herein.
DETAILED DESCRIPTION ISOLATED PROTEINS AND POLYNUCLEOTIDES Nucleotide and amino acid sequences, as presently determined, are reported below for each clone and protein disclosed in the present application. The nucleotide sequence of each clone can readily be determined by sequencing of the deposited clone in accordance with known methods. The predicted amino acid sequence (both full-length and mature) can then be determined from such nucleotide sequence. The amino acid sequence of the protein encoded by a particular clone can also be determined by expression of the clone in a suitable host cell, collecting the protein and determining its sequence. For each disclosed protein applicants have identified what they have determined to be the reading frame best identifiable with sequence information available at the time of filing. As used herein a "secreted" protein is one which, when expressed in' a suitable host cell, is transported across or through a membrane, including transport as a result of signal sequences in its amino acid sequence. "Secreted" proteins include without limitation proteins secreted wholly (e.g., soluble proteins) or partially (e.g. , receptors) from the cell in which they are expressed. "Secreted" proteins also include without limitation proteins which are transported across the membrane of the endoplasmic reticulum.
Clone "BD441 1"
A polynucleotide of the present invention has been identified as clone "BD441_1". BD441_1 was isolated from a human fetal kidney cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. BD441_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "BD441_1 protein").
The nucleotide sequence of the 5' portion of BD441_1 as presently determined is reported in SEQ ID NO:l. An additional internal nucleotide sequence from BD441_1 as presently determined is reported in SEQ ID NO:2. What applicants believe is the proper reading frame and the predicted amino acid sequence encoded by such internal sequence is reported in SEQ ID NO:3. Additional nucleotide sequence from the 3' portion of BD441_1, including the polyA tail, is reported in SEQ ID NO:4.
The EcoRI/Notl restriction fragment obtainable from the deposit containing clone BD441_1 should be approximately 2400 bp.
The predicted amino acid sequence disclosed herein for BD441_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted BD441_1 protein demonstrated at least some similarity to sequences identified as X61615 (leukemia inhibitory factor receptor [Homo sapiens]). Based upon sequence similarity, BD441_1 proteins and each similar protein or peptide may share at least some activity.
Clone "BD441 2"
A polynucleotide of the present invention has been identified as clone "BD441_2". BD441_2 was isolated from a human fetal kidney cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. BD441_2 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "BD441_2 protein"). The nucleotide sequence of the 5' portion of BD441_2 as presently determined is reported in SEQ ID NO:5. What applicants presently believe is the proper reading frame for the coding region is indicated in SEQ ID NO:6. The predicted amino acid sequence of the BD441_2 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:6. Additional nucleotide sequence from the 3' portion of BD441_2, including the polyA tail, is reported in SEQ ID NO:7.
The EcoRI/Notl restriction fragment obtainable from the deposit containing clone BD441_2 should be approximately 1200 bp.
The predicted amino acid sequence disclosed herein for BD441_2 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted BD441_2 protein demonstrated at least some similarity to sequences identified as X61615 (leukemia inhibitory factor receptor [Homo sapiens]). Based upon sequence similarity, BD441_2 proteins and each similar protein or peptide may share at least some activity.
Clone "BG102 3"
A polynucleotide of the present invention has been identified as clone "BG102_3". BG102_3 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. BG102_3 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "BG102_3 protein").
The nucleotide sequence of BG102_3 as presently determined is reported in SEQ ID NO:8. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the BG102_3 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:9. Amino acids 11 to 23 are a predicted leader /signal sequence, with the predicted mature amino acid sequence beginning at amino acid 24, or are a transmembrane domain. The EcoRI/Notl restriction fragment obtainable from the deposit containing clone BG102_3 should be approximately 1100 bp.
The nucleotide sequence disclosed herein for BG102_3 was searched against the
GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. BG102_3 demonstrated at least some similarity with sequences identified as AC002078 (Human BAC clone RG111H14 from 7q22, complete sequence),
L11910 (Human retinoblastoma susceptibility gene exons 1-27, complete cds), U62317
(Chromosome 22ql3 BAC Clone CIT987SK-384D8 complete sequence), Z54147 (Human
DNA sequence from cosmid L129H7, Huntington's Disease Region, chromosome 4pl6.3 contains CpG island), Z75747 (Human DNA sequence from cosmid U96H1, between markers DXS366 and DXS87 on chromosome X *), and Z80899 (Human DNA sequence from cosmid F1121 on chromosome 6). The predicted amino acid sequence disclosed herein for BG102_3 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted BG102_3 protein demonstrated at least some similarity to sequences identified as M13100 (unknown protein [Rattus norvegicus]) and U15647 (reverse transcriptase [Mus musculus]). Based upon sequence similarity, BG102_3 proteins and each similar protein or peptide may share at least some activity. The nucleotide sequence of BG102_3 indicates that it may contain an LI repetitive element.
Clone "BK158 1"
A polynucleotide of the present invention has been identified as clone "BK158_1". BK158_1 was isolated from a human adult muscle cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. BK158_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "BK158_1 protein").
The nucleotide sequence of BK158_1 as presently determined is reported in SEQ ID NO:10. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the BK158_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:ll.
The EcoRI/Notl restriction fragment obtainable from the deposit containing clone BK158_1 should be approximately 1150 bp. The nucleotide sequence disclosed herein for BK158_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. BK158_1 demonstrated at least some similarity with sequences identified as N39195 (yv26e08.sl Homo sapiens cDNA clone 243878 3') and N45263 (yv26e08.rl Homo sapiens cDNA clone 243878 5'). Based upon sequence similarity, BK158_1 proteins and each similar protein or peptide may share at least some activity.
Clone "BP163 1"
A polynucleotide of the present invention has been identified as clone "BP163_1". BP163_1 was isolated from a human fetal kidney cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. BP163_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "BP163_1 protein").
The nucleotide sequence of the 5' portion of BP163_1 as presently determined is reported in SEQ ID NO:12. What applicants presently believe is the proper reading frame for the coding region is indicated in SEQ ID NO:13. The predicted amino acid sequence of the BP163_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:13. Additional nucleotide sequence from the 3' portion of BP163_1, including the polyA tail, is reported in SEQ ID NO:14.
The EcoRI/Notl restriction fragment obtainable from the deposit containing clone BP163_1 should be approximately 1240 bp.
The nucleotide sequence disclosed herein for BP163_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. BP163_1 demonstrated at least some similarity with sequences identified as AA187086 (zp58h06.rl Stratagene endothelial cell 937223 Homo sapiens cDNA clone 6244435' similar to TR G285943 G285943 ORF, COMPLETE CDS), AA301506 (EST14475 Testis tumor Homo sapiens cDNA 5' end similar to hypothetical protein (GB D14659)), D14659 (Human mRNA for KIAA0103 gene, complete cds), and W57328
(ma26dl0.rl Life Tech mouse brain Mus musculus cDNA clone). The predicted amino acid sequence disclosed herein for BP163_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted BP163_1 protein demonstrated at least some similarity to sequences identified as D14659 (KIAA0103 [Homo sapiens]). Based upon sequence similarity, BP163_1 proteins and each similar protein or peptide may share at least some activity.
Clone "BZ16 3" A polynucleotide of the present invention has been identified as clone "BZ16_3 "■
BZ16_3 was isolated from a human fetal kidney cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. BZ16_3 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "BZ16_3 protein").
The partial nucleotide sequence of BZ16_3, including its 3' end and any identified polyA tail, as presently determined is reported in SEQ ID NO:16. What applicants presently believe is the proper reading frame for the coding region is indicated in SEQ ID NO: 17. The predicted amino acid sequence of the BZ16_3 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:17. Additional nucleotide sequence from the 5' portion of BZ16_3 is reported in SEQ ID NO:15.
The EcoRI /Noil restriction fragment obtainable from the deposit containing clone BZ16_3 should be approximately 2120 bp. The nucleotide sequence disclosed herein for BZ16_3 was searched against the
GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. BZ16_3 demonstrated at least some similarity with sequences identified as F06886 (H. sapiens partial cDNA sequence; clone c-lnf02), F06870 (H. sapiens partial cDNA sequence; clone c-lncll), N53511 (yz26b08.sl Homo sapiens cDNA clone 284151 3'), T65313 (yc79gl2.sl Homo sapiens cDNA clone 221323'), U00084 (Haemophilus influenzae), W44815 (zc21d01.sl Soares senescent fibroblasts NbHSF Homo sapiens cDNA clone 322945 3'), and Z49128 (Caenorhabditis elegans cosmid M03C11). The predicted amino acid sequence disclosed herein for BZ16_3 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted BZ16_3 protein demonstrated at least some similarity to sequences identified as D26185 (cell division protein [Bacillus subtilis]), L46096 (HEAHI1465_1 cell division protein [Haemophilus influenzae]), and Z49128 (CEM03C11_5 M03C11.5 [Caenorhabditis elegans]). The BZ16_3 protein demonstrated at least some similarity to ATP-dependent proteases such as ftsH. Based upon sequence similarity, BZ16_3 proteins and each similar protein or peptide may share at least some activity.
Clone "CC182 1" A polynucleotide of the present invention has been identified as clone "CC182_1".
CC182_1 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. CC182_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "CC182_1 protein").
The nucleotide sequence of CC182_1 as presently determined is reported in SEQ ID NO:18. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the CC182_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:19. Amino acids 26 to 38 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 39, or are a transmembrane domain.
The EcoRI /Notl restriction fragment obtainable from the deposit containing clone CC182_1 should be approximately 1600 bp. The nucleotide sequence disclosed herein for CC182_1 was searched against the
GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. CC182_1 demonstrated at least some similarity with sequences identified as H61159 (yu37f08.sl Homo sapiens cDNA clone 236007 3' similar to contains LI repetitive element), L09709 (Human lysosomal-associated membrane glycoprotein-2 (LAMP2) gene, 5' end of CDS and flanking region), W44797 (zb98el0.sl Soares parathyroid tumor NbHPA Homo sapiens cDNA clone 320874 3' similar to contains Alu repetitive element), and X62167 (H.sapiens mRNA for P2 protein of peripheral myelin). Based upon sequence similarity, CC182_1 proteins and each similar protein or peptide may share at least some activity. The nucleotide sequence of CC182_1 indicates that it may contain an LI repetitive element and a MER42C repetitive element.
Clone "CG109 1"
A polynucleotide of the present invention has been identified as clone "CG109_1". CG109_1 was isolated from a human adult testes cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. CG109_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "CG109_1 protein").
The nucleotide sequence of CG109_1 as presently determined is reported in SEQ ID NO:20. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the CG109_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:21. The EcoRI/Notl restriction fragment obtainable from the deposit containing clone
CG109_1 should be approximately 600 bp.
The nucleotide sequence disclosed herein for CG109_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. No hits were found in the database.
Clone "CT397 1"
A polynucleotide of the present invention has been identified as clone "CJ397_1". CJ397_1 was isolated from a human fetal brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. CJ397_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "CJ397_1 protein").
The nucleotide sequence of the 5' portion of CJ397_1 as presently determined is reported in SEQ ID NO:22. An additional internal nucleotide sequence from CJ397_1 as presently determined is reported in SEQ ID NO:23. What applicants believe is the proper reading frame and the predicted amino acid sequence encoded by such internal sequence is reported in SEQ ID NO:24. Additional nucleotide sequence from the 3' portion of CJ397_1, including the polyA tail, is reported in SEQ ID NO:25. The EcoRI/Notl restriction fragment obtainable from the deposit containing clone
CJ397_1 should be approximately 1900 bp.
The nucleotide sequence disclosed herein for CJ397_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. CJ397_1 demonstrated at least some similarity with sequences identified as H18685 (yn52b08.sl Homo sapiens cDNA clone 172023 3'), H46001 (yol3f06.sl Homo sapiens cDNA clone 1778273'), and T77612 (yc91f06.rl Homo sapiens cDNA clone 232985'). Based upon sequence similarity, CJ397_1 proteins and each similar protein or peptide may share at least some activity.
Deposit of Clones
Clones BD441_1, BD441_2, BG102_3, BK158_1, BP163_1, BZ16_3, CC182_1, CG109_1 and CJ397_1 were deposited on November 20, 1996 with the American Type Culture Collection as an original deposit under the Budapest Treaty and were given the accession number ATCC 98264, from which each clone comprising a particular polynucleotide is obtainable. All restrictions on the availability to the public of the deposited material will be irrevocably removed upon the granting of the patent, except for the requirements specified in 37 C.F.R. § 1.808(b).
Each clone has been transfected into separate bacterial cells (E. coli) in this composite deposit. Each clone can be removed from the vector in which it was deposited by performing an EcoRI/Notl digestion (5' site, EcoRI; 3' site, Notl) to produce the appropriate fragment for such clone. Each clone was deposited in either the pED6 or pNOTs vector depicted in Fig. 1. The pED6dpc2 vector ("pED6") was derived from pEDόdpcl by insertion of a new polylinker to facilitate cDNA cloning (Kaufman et al, 1991, Nucleic Acids Res. 19: 4485-4490); the pNOTs vector was derived from pMT2 (Kaufman et al, 1989, Mol. Cell. Biol. 9: 946-958) by deletion of the DHFR sequences, insertion of a new polylinker, and insertion of the M13 origin of replication in the Clal site. In some instances, the deposited clone can become "flipped" (i.e., in the reverse orientation) in the deposited isolate. In such instances, the cDNA insert can still be isolated by digestion with EcoRI and Notl. However, Notl will then produce the 5' site and EcoRI will produce the 3' site for placement of the cDNA in proper orientation for expression in a suitable vector. The cDNA may also be expressed from the vectors in which they were deposited.
Bacterial cells containing a particular clone can be obtained from the composite deposit as follows:
An oligonucleotide probe or probes should be designed to the sequence that is known for that particular clone. This sequence can be derived from the sequences provided herein, or from a combination of those sequences. The sequence of the oligonucleotide probe that was used to isolate each full-length clone is identified below, and should be most reliable in isolating the clone of interest.
Clone Probe Sequence BD441_1 SEQ ID NO:26
BD441_2 SEQ ID NO:27
BG102_3 SEQ ID NO:28
BK158_1 SEQ ID NO:29
BP163_1 SEQ ID NO:30 BZ16_3 SEQ ID NO:31
CC182_1 SEQ ID NO:32
CG109_1 SEQ ID NO:33
CJ397_1 SEQ ID NO:34
In the sequences listed above which include an N at position 2, that position is occupied in preferred probes/primers by a biotinylated phosphoaramidite residue rather than a nucleotide (such as , for example, that produced by use of biotin phosphoramidite (1- dimethoxytrityloxy-2-(N-biotinyl-4-aminobutyl)-propyl-3-O-(2-cyanoethyl)-(N,N- diisopropyl)-phosphoramadite) (Glen Research, cat. no. 10-1953)). The design of the oligonucleotide probe should preferably follow these parameters:
(a) It should be designed to an area of the sequence which has the fewest ambiguous bases ("N's"), if any;
(b) It should be designed to have a Tm of approx. 80 ° C (assuming 2° for each A or T and 4 degrees for each G or C).
The oligonucleotide should preferably be labeled with g-32P ATP (specific activity 6000 Ci/mmole) and T4 polynucleotide kinase using commonly employed techniques for labeling oligonucleotides. Other labeling techniques can also be used. Unincorporated label should preferably be removed by gel filtration chromatography or other established methods. The amount of radioactivity incorporated into the probe should be quantitated by measurement in a scintillation counter. Preferably, specific activity of the resulting probe should be approximately 4e+6 dpm/pmole.
The bacterial culture containing the pool of full-length clones should preferably be thawed and 100 μl of the stock used to inoculate a sterile culture flask containing 25 ml of sterile L-broth containing ampicillin at 100 μg/ml. The culture should preferably be grown to saturation at 37°C, and the saturated culture should preferably be diluted in fresh L-broth. Aliquots of these dilutions should preferably be plated to determine the dilution and volume which will yield approximately 5000 distinct and well-separated colonies on solid bacteriological media containing L-broth containing ampicillin at 100 μg/ml and agar at 1.5% in a 150 mm petri dish when grown overnight at 37°C. Other known methods of obtaining distinct, well-separated colonies can also be employed.
Standard colony hybridization procedures should then be used to transfer the colonies to nitrocellulose filters and lyse, denature and bake them. The filter is then preferably incubated at 65°C for 1 hour with gentle agitation in
6X SSC (20X stock is 175.3 g NaCl/liter, 88.2 g Na citrate /liter, adjusted to pH 7.0 with NaOH) containing 0.5% SDS, 100 μg/ml of yeast RNA, and 10 mM EDTA (approximately 10 mL per 150 mm filter). Preferably, the probe is then added to the hybridization mix at a concentration greater than or equal to le+6 dpm/mL. The filter is then preferably incubated at 65°C with gentle agitation overnight. The filter is then preferably washed in 500 mL of 2X SSC/0.5% SDS at room temperature without agitation, preferably followed by 500 mL of 2X SSC/0.1% SDS at room temperature with gentle shaking for 15 minutes. A third wash with 0.1X SSC/0.5% SDS at 65°C for 30 minutes to 1 hour is optional. The filter is then preferably dried and subjected to autoradiography for sufficient time to visualize the positives on the X-ray film. Other known hybridization methods can also be employed.
The positive colonies are picked, grown in culture, and plasmid DNA isolated using standard procedures. The clones can then be verified by restriction analysis, hybridization analysis, or DNA sequencing. Fragments of the proteins of the present invention which are capable of exhibiting biological activity are also encompassed by the present invention. Fragments of the protein may be in linear form or they may be cyclized using known methods, for example, as described in H.U. Saragovi, et al, Bio /Technology 10, 773-778 (1992) and in R.S. McDowell, et al, J. Amer. Chem. Soc. 114, 9245-9253 (1992), both of which are incorporated herein by reference. Such fragments may be fused to carrier molecules such as immunoglobulins for many purposes, including increasing the valency of protein binding sites. For example, fragments of the protein may be fused through "linker" sequences to the Fc portion of an immunoglobulin. For a bivalent form of the protein, such a fusion could be to the Fc portion of an IgG molecule. Other immunoglobulin isotypes may also be used to generate such fusions. For example, a protein - IgM fusion would generate a decavalent form of the protein of the invention.
The present invention also provides both full-length and mature forms of the disclosed proteins. The full-length form of the such proteins is identified in the sequence listing by translation of the nucleotide sequence of each disclosed clone. The mature form of such protein may be obtained by expression of the disclosed full-length polynucleotide (preferably those deposited with ATCC) in a suitable mammalian cell or other host cell. The sequence of the mature form of the protein may also be determinable from the amino acid sequence of the full-length form. The present invention also provides genes corresponding to the cDNA sequences disclosed herein. "Corresponding genes" are the regions of the genome that are transcribed to produce the mRNAs from which the cDNA sequences are derived and any contiguous regions of the genome necessary for the regulated expression of such genes, including but not limited to coding sequences, 5' and 3' untranslated regions, alternatively spliced exons, introns, promoters, enhancers, and silencer or suppressor elements. The corresponding genes can be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include the preparation of probes or primers from the disclosed sequence information for identification and /or amplification of genes in appropriate genomic libraries or other sources of genomic materials.
Where the protein of the present invention is membrane-bound (e.g., is a receptor), the present invention also provides for soluble forms of such protein. In such forms part or all of the intracellular and transmembrane domains of the protein are deleted such that the protein is fully secreted from the cell in which it is expressed. The intracellular and transmembrane domains of proteins of the invention can be identified in accordance with known techniques for determination of such domains from sequence information.
Proteins and protein fragments of the present invention include proteins with amino acid sequence lengths that are at least 25%(more preferably at least 50%, and most preferably at least 75%) of the length of a disclosed protein and have at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% or 95% identity) with that disclosed protein, where sequence identity is determined by comparing the amino acid sequences of the proteins when aligned so as to maximize overlap and identity while minimizing sequence gaps. Also included in the present invention are proteins and protein fragments that contain a segment preferably comprising 8 or more (more preferably 20 or more, most preferably 30 or more) contiguous aniino acids that shares at least 75% sequence identity (more preferably, at least 85% identity; most preferably at least 95% identity) with any such segment of any of the disclosed proteins. Species homologs of the disclosed polynucleotides and proteins are also provided by the present invention. As used herein, a "species homologue" is a protein or polynucleotide with a different species of origin from that of a given protein or polynucleotide, but with significant sequence similarity to the given protein or polynucleotide, as determined by those of skill in the art. Species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source from the desired species.
The invention also encompasses allelic variants of the disclosed polynucleotides or proteins; that is, naturally-occurring alternative forms of the isolated polynucleotide which also encode proteins which are identical, homologous, or related to that encoded by the polynucleotides . The invention also includes polynucleotides with sequences complementary to those of the polynucleotides disclosed herein.
The present invention also includes polynucleotides capable of hybridizing under reduced stringency conditions, more preferably stringent conditions, and most preferably highly stringent conditions, to polynucleotides described herein. Examples of stringency conditions are shown in the table below: highly stringent conditions are those that are at least as stringent as, for example, conditions A-F; stringent conditions are at least as stringent as, for example, conditions G-L; and reduced stringency conditions are at least as stringent as, for example, conditions M-R.
Figure imgf000030_0001
* The hybrid length is that anticipated for the hybridized regιon(s) of the hybridizing polynucleohdes When hybridizing a polynucleotide to a target polynucleotide of unknown sequence, the hybrid length is assumed to be that of the hybridizing polynucleotide When polynucleotides of known sequence are hybridized, the hybrid length can be determined by aligning the sequences of the polynucleohdes and idenhfying the region or regions of optimal sequence complementarity
+ SSPE (lxSSPE is 0 15M NaCl, lOmM NaH2P04, and 1 25mM EDTA, pH 74) can be substituted for SSC (lxSSC is 0 15M NaCl and 15mM sodium citrate) in the hybridization and wash buffers, washes are performed for 15 minutes after hybridization is complete
*TB - TR The hybndizahon temperature for hybrids anhcipated to be less than 50 base pairs in length should be 5-10°C less than the melting temperature (Tm) of the hybrid, where Tm is determined according to the following equations For hybrids less than 18 base pairs m length, Tm(°C) = 2(# of A + T bases) + 4(# of G + C bases) For hybrids between 18 and 49 base pairs m length, Tm(°C) = 81 5 + 166(log10[Na+]) + 041(%G+C) - (600/N), where N is the number of bases in the hybrid, and [Na+] is the concentration of sodium ions m the hybridization buffer ([Na+] for lxSSC = 0 165 M) Additional examples of stringency conditions for polynucleotide hybridization are provided in Sambrook, J., E.F. Fritsch, and T. Maniatis, 1989, Molecular Cloning: A
Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, chapters 9 and 11, and Current Protocols in Molecular Biology, 1995, F.M. Ausubel et al., eds., John Wiley & Sons, Inc., sections 2.10 and 6.3-6.4, incorporated herein by reference.
Preferably, each such hybridizing polynucleotide has a length that is at least 25%(more preferably at least 50%, and most preferably at least 75%) of the length of the polynucleotide of the present invention to which it hybridizes, and has at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% or 95% identity) with the polynucleotide of the present invention to which it hybridizes, where sequence identity is determined by comparing the sequences of the hybridizing polynucleotides when aligned so as to maximize overlap and identity while minimizing sequence gaps.
The isolated polynucleotide of the invention may be operably linked to an expression control sequence such as the pMT2 or pED expression vectors disclosed in Kaufman et al, Nucleic Acids Res. 19, 4485-4490 (1991), in order to produce the protein recombinantly. Many suitable expression control sequences are known in the art. General methods of expressing recombinant proteins are also known and are exemplified in R. Kaufman, Methods in Enzymology 185, 537-566 (1990). As defined herein "operably linked" means that the isolated polynucleotide of the invention and an expression control sequence are situated within a vector or cell in such a way that the protein is expressed by a host cell which has been transformed (transfected) with the ligated polynucleotide /expression control sequence.
A number of types of cells may act as suitable host cells for expression of the protein. Mammalian host cells include, for example, monkey COS cells, Chinese Hamster
Ovary (CHO) cells, human kidney 293 cells, human epidermal A431 cells, human Colo205 cells, 3T3 cells, CV-1 cells, other transformed primate cell lines, normal diploid cells, cell strains derived from in vitro culture of primary tissue, primary explants, HeLa cells, mouse L cells, BHK, HL-60, U937, HaK or Jurkat cells. Alternatively, it may be possible to produce the protein in lower eukaryotes such as yeast or in prokaryotes such as bacteria. Potentially suitable yeast strains include Saccharomyces cerevisiae, Schizosaccharomyces pombe, Kluyveromyces strains, Candida, or any yeast strain capable of expressing heterologous proteins. Potentially suitable bacterial strains include Escherichia coli, Bacillus subtilis, Salmonella yυhimurium, or any bacterial strain capable of expressing heterologous proteins. If the protein is made in yeast or bacteria, it may be necessary to modify the protein produced therein, for example by phosphorylation or glycosylation of the appropriate sites, in order to obtain the functional protein. Such covalent attachments may be accomplished using known chemical or enzymatic methods.
The protein may also be produced by operably linking the isolated polynucleotide of the invention to suitable control sequences in one or more insect expression vectors, and employing an insect expression system. Materials and methods for baculovirus /insect cell expression systems are commercially available in kit form from, e.g., Invitrogen, San Diego, California, U.S.A. (the MaxBac® kit), and such methods are well known in the art, as described in Summers and Smith, Texas Agricultural Experiment Station Bulletin No. 1555 (1987), incorporated herein by reference. As used herein, an insect cell capable of expressing a polynucleotide of the present invention is "transformed." The protein of the invention may be prepared by culturing transformed host cells under culture conditions suitable to express the recombinant protein. The resulting expressed protein may then be purified from such culture (i.e., from culture medium or cell extracts) using known purification processes, such as gel filtration and ion exchange chromatography. The purification of the protein may also include an affinity column containing agents which will bind to the protein; one or more column steps over such affinity resins as concanavalin A-agarose, heparin-toyopearl® or Cibacrom blue 3GA Sepharose®; one or more steps involving hydrophobic interaction chromatography using such resins as phenyl ether, butyl ether, or propyl ether; or immunoaffinity chromatography. Alternatively, the protein of the invention may also be expressed in a form which will facilitate purification. For example, it may be expressed as a fusion protein, such as those of maltose binding protein (MBP), glutathione-S-transferase (GST) or thioredoxin (TRX). Kits for expression and purification of such fusion proteins are commercially available from New England BioLab (Beverly, MA), Pharmacia (Piscataway, NJ) and InVitrogen, respectively. The protein can also be tagged with an epitope and subsequently purified by using a specific antibody directed to such epitope. One such epitope ("Flag") is commercially available from Kodak (New Haven, CT).
Finally, one or more reverse-phase high performance liquid chromatography (RP- HPLC) steps employing hydrophobic RP-HPLC media, e.g., silica gel having pendant methyl or other aliphatic groups, can be employed to further purify the protein. Some or all of the foregoing purification steps, in various combinations, can also be employed to provide a substantially homogeneous isolated recombinant protein. The protein thus purified is substantially free of other mammalian proteins and is defined in accordance with the present invention as an "isolated protein."
The protein of the invention may also be expressed as a product of transgenic animals, e.g., as a component of the milk of transgenic cows, goats, pigs, or sheep which are characterized by somatic or germ cells containing a nucleotide sequence encoding the protein. The protein may also be produced by known conventional chemical synthesis.
Methods for constructing the proteins of the present invention by synthetic means are known to those skilled in the art. The synthetically-constructed protein sequences, by virtue of sharing primary, secondary or tertiary structural and /or conformational characteristics with proteins may possess biological properties in common therewith, including protein activity. Thus, they may be employed as biologically active or immunological substitutes for natural, purified proteins in screening of therapeutic compounds and in immunological processes for the development of antibodies.
The proteins provided herein also include proteins characterized by amino acid sequences similar to those of purified proteins but into which modification are naturally provided or deliberately engineered. For example, modifications in the peptide or DNA sequences can be made by those skilled in the art using known techniques. Modifications of interest in the protein sequences may include the alteration, substitution, replacement, insertion or deletion of a selected amino acid residue in the coding sequence. For example, one or more of the cysteine residues may be deleted or replaced with another amino acid to alter the conformation of the molecule. Techniques for such alteration, substitution, replacement, insertion or deletion are well known to those skilled in the art (see, e.g., U.S. Patent No.4,518,584). Preferably, such alteration, substitution, replacement, insertion or deletion retains the desired activity of the protein.
Other fragments and derivatives of the sequences of proteins which would be expected to retain protein activity in whole or in part and may thus be useful for screening or other immunological methodologies may also be easily made by those skilled in the art given the disclosures herein. Such modifications are believed to be encompassed by the present invention. USES AND BIOLOGICAL ACTIVITY
The polynucleotides and proteins of the present invention are expected to exhibit one or more of the uses or biological activities (including those associated with assays cited herein) identified below. Uses or activities described for proteins of the present invention may be provided by administration or use of such proteins or by administration or use of polynucleotides encoding such proteins (such as, for example, in gene therapies or vectors suitable for introduction of DNA).
Research Uses and Utilities The polynucleotides provided by the present invention can be used by the research community for various purposes. The polynucleotides can be used to express recombinant protein for analysis, characterization or therapeutic use; as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in disease states); as molecular weight markers on Southern gels; as chromosome markers or tags (when labeled) to identify chromosomes or to map related gene positions; to compare with endogenous DNA sequences in patients to identify potential genetic disorders; as probes to hybridize and thus discover novel, related DNA sequences; as a source of information to derive PCR primers for genetic finge rinting; as a probe to "subtract-out" known sequences in the process of discovering other novel polynucleotides; for selecting and making oligomers for attachment to a "gene chip" or other support, including for examination of expression patterns; to raise anti-protein antibodies using DNA immunization techniques; and as an antigen to raise anti-DNA antibodies or elicit another immune response. Where the polynucleotide encodes a protein which binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction), the polynucleotide can also be used in interaction trap assays (such as, for example, that described in Gyuris et al., Cell 75:791-803 (1993)) to identify polynucleotides encoding the other protein with which binding occurs or to identify inhibitors of the binding interaction. The proteins provided by the present invention can similarly be used in assay to determine biological activity, including in a panel of multiple proteins for high- throughput screening; to raise antibodies or to elicit another immune response; as a reagent (including the labeled reagent) in assays designed to quantitatively determine levels of the protein (or its receptor) in biological fluids; as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in a disease state); and, of course, to isolate correlative receptors or ligands. Where the protein binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction), the protein can be used to identify the other protein with which binding occurs or to identify inhibitors of the binding interaction. Proteins involved in these binding interactions can also be used to screen for peptide or small molecule inhibitors or agonists of the binding interaction.
Any or all of these research utilities are capable of being developed into reagent grade or kit format for commercialization as research products.
Methods for performing the uses listed above are well known to those skilled in the art. References disclosing such methods include without limitation "Molecular Cloning: A Laboratory Manual", 2d ed., Cold Spring Harbor Laboratory Press, Sambrook, J., E.F. Fritsch and T. Maniatis eds., 1989, and "Methods in Enzymology: Guide to Molecular Cloning Techniques", Academic Press, Berger, S.L. and A.R. Kimmel eds., 1987.
Nutritional Uses
Polynucleotides and proteins of the present invention can also be used as nutritional sources or supplements. Such uses include without limitation use as a protein or amino acid supplement, use as a carbon source, use as a nitrogen source and use as a source of carbohydrate. In such cases the protein or polynucleotide of the invention can be added to the feed of a particular organism or can be administered as a separate solid or liquid preparation, such as in the form of powder, pills, solutions, suspensions or capsules. In the case of microorganisms, the protein or polynucleotide of the invention can be added to the medium in or on which the microorganism is cultured.
Cytokine and Cell Proliferation /Differentiation Activity
A protein of the present invention may exhibit cytokine, cell proliferation (either inducing or inhibiting) or cell differentiation (either inducing or inhibiting) activity or may induce production of other cytokines in certain cell populations. Many protein factors discovered to date, including all known cytokines, have exhibited activity in one or more factor dependent cell proliferation assays, and hence the assays serve as a convenient confirmation of cytokine activity. The activity of a protein of the present invention is evidenced by any one of a number of routine factor dependent cell proliferation assays for cell lines including, without limitation, 32D, DA2, DA1G, T10, B9, B9/11, BaF3, MC9/G, M+ (preB M+), 2E8, RB5, DAI, 123, T1165, HT2, CTLL2, TF-1, Mo7e and CMK.
The activity of a protein of the invention may, among other means, be measured by the following methods:
Assays for T-cell or thymocyte proliferation include without limitation those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley- Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai et al., J. Immunol. 137:3494-3500, 1986; Bertagnolli et al., J. Immunol. 145:1706-1712, 1990; Bertagnolli et al., Cellular Immunology 133:327-341, 1991; Bertagnolli, et al., J. Immunol. 149:3778-3783, 1992; Bowman et al., J. Immunol. 152: 1756-1761, 1994.
Assays for cytokine production and /or proliferation of spleen cells, lymph node cells or thymocytes include, without limitation, those described in: Polyclonal T cell stimulation, Kruisbeek, A.M. and Shevach, E.M. In Current Protocols in Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 3.12.1-3.12.14, John Wiley and Sons, Toronto. 1994; and Measurement of mouse and human Interferon γ, Schreiber, R.D. In Current Protocols in Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 6.8.1-6.8.8, John Wiley and Sons, Toronto. 1994. Assays for proliferation and differentiation of hematopoietic and lymphopoietic cells include, without limitation, those described in: Measurement of Human and Murine Interleukin 2 and Interleukin 4, Bottomly, K., Davis, L.S. and Lipsky, P.E. In Current Protocols in Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 6.3.1-6.3.12, John Wiley and Sons, Toronto. 1991; deVries et al., J. Exp. Med. 173:1205-1211, 1991; Moreau et al., Nature 336:690-692, 1988; Greenberger et al, Proc. Natl. Acad. Sci. U.S.A. 80:2931-2938, 1983;
Measurement of mouse and human interleukin 6 - Nordan, R. In Current Protocols in Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 6.6.1-6.6.5, John Wiley and Sons, Toronto. 1991; Smith et al, Proc. Natl. Acad. Sci. U.S.A. 83:1857-1861, 1986; Measurement of human Interleukin 11 - Bennett, F., Giannotti, J., Clark, S.C. and Turner, K. J. In Current Protocols in Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 6.15.1 John Wiley and Sons, Toronto. 1991;
Measurement of mouse and human Interleukin 9 - Ciarletta, A., Giannotti, J., Clark, S.C. and Turner, K.J. In Current Protocols in Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 6.13.1, John Wiley and Sons, Toronto. 1991. Assays for T-cell clone responses to antigens (which will identify, among others, proteins that affect APC-T cell interactions as well as direct T-cell effects by measuring proliferation and cytokine production) include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Inter science (Chapter 3, In Vitro assays for Mouse Lymphocyte Function; Chapter 6, Cytokines and their cellular receptors; Chapter 7, Immunologic studies in Humans); Weinberger et al., Proc. Natl. Acad. Sci. USA 77:6091-6095, 1980; Weinberger et al., Eur. J. Immun. 11:405-411, 1981; Takai et al, J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988.
Immune Stimulating or Suppressing Activity
A protein of the present invention may also exhibit immune stimulating or immune suppressing activity, including without limitation the activities for which assays are described herein. A protein may be useful in the treatment of various immune deficiencies and disorders (including severe combined immunodeficiency (SOD)), e.g., in regulating (up or down) growth and proliferation of T and /or B lymphocytes, as well as effecting the cytolytic activity of NK cells and other cell populations. These immune deficiencies may be genetic or be caused by viral (e.g., HIV) as well as bacterial or fungal infections, or may result from autoimmune disorders. More specifically, infectious diseases causes by viral, bacterial, fungal or other infection may be treatable using a protein of the present invention, including infections by HIV, hepatitis viruses, herpesviruses, mycobacteria, Leishmania spp., malaria spp. and various fungal infections such as candidiasis. Of course, in this regard, a protein of the present invention may also be useful where a boost to the immune system generally may be desirable, i.e., in the treatment of cancer.
Autoimmune disorders which may be treated using a protein of the present invention include, for example, connective tissue disease, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes mellitis, myasthenia gravis, graft- versus-host disease and autoimmune inflammatory eye disease. Such a protein of the present invention may also to be useful in the treatment of allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems. Other conditions, in which immune suppression is desired (including, for example, organ transplantation), may also be treatable using a protein of the present invention.
Using the proteins of the invention it may also be possible to immune responses, in a number of ways. Down regulation may be in the form of inhibiting or blocking an immune response already in progress or may involve preventing the induction of an immune response. The functions of activated T cells may be inhibited by suppressing T cell responses or by inducing specific tolerance in T cells, or both. Immunosuppression of T cell responses is generally an active, non-antigen-specific, process which requires continuous exposure of the T cells to the suppressive agent. Tolerance, which involves inducing non-responsiveness or anergy in T cells, is distinguishable from immunosuppression in that it is generally antigen-specific and persists after exposure to the tolerizing agent has ceased. Operationally, tolerance can be demonstrated by the lack of a T cell response upon reexposure to specific antigen in the absence of the tolerizing agent. Down regulating or preventing one or more antigen functions (including without limitation B lymphocyte antigen functions (such as , for example, B7)), e.g., preventing high level lymphokine synthesis by activated T cells, will be useful in situations of tissue, skin and organ transplantation and in graft-versus-host disease (GVHD). For example, blockage of T cell function should result in reduced tissue destruction in tissue transplantation. Typically, in tissue transplants, rejection of the transplant is initiated through its recognition as foreign by T cells, followed by an immune reaction that destroys the transplant. The administration of a molecule which inhibits or blocks interaction of a B7 lymphocyte antigen with its natural ligand(s) on immune cells (such as a soluble, monomeric form of a peptide having B7-2 activity alone or in conjunction with a monomeric form of a peptide having an activity of another B lymphocyte antigen (e.g., B7-
1, B7-3) or blocking antibody), prior to transplantation can lead to the binding of the molecule to the natural ligand (s) on the immune cells without transmitting the corresponding costimulatory signal. Blocking B lymphocyte antigen function in this matter prevents cytokine synthesis by immune cells, such as T cells, and thus acts as an immunosuppressant. Moreover, the lack of costimulation may also be sufficient to anergize the T cells, thereby inducing tolerance in a subject. Induction of long-term tolerance by B lymphocyte antigen-blocking reagents may avoid the necessity of repeated administration of these blocking reagents. To achieve sufficient immunosuppression or tolerance in a subject, it may also be necessary to block the function of a combination of
B lymphocyte antigens.
The efficacy of particular blocking reagents in preventing organ transplant rejection or GVHD can be assessed using animal models that are predictive of efficacy in humans. Examples of appropriate systems which can be used include allogeneic cardiac grafts in rats and xenogeneic pancreatic islet cell grafts in mice, both of which have been used to examine the immunosuppressive effects of CTLA4Ig fusion proteins in vivo as described in Lenschow et al, Science 257:789-792 (1992) and Turka et al, Proc. Natl. Acad.
Sci USA, 89:11102-11105 (1992). In addition, murine models of GVHD (see Paul ed., Fundamental Immunology, Raven Press, New York, 1989, pp. 846-847) can be used to determine the effect of blocking B lymphocyte antigen function in vivo on the development of that disease.
Blocking antigen function may also be therapeutically useful for treating autoimmune diseases. Many autoimmune disorders are the result of inappropriate activation of T cells that are reactive against self tissue and which promote the production of cytokines and autoantibodies involved in the pathology of the diseases. Preventing the activation of autoreactive T cells may reduce or eliminate disease symptoms.
Administration of reagents which block costimulation of T cells by disrupting receptor:ligand interactions of B lymphocyte antigens can be used to inhibit T cell activation and prevent production of autoantibodies or T cell-derived cytokines which may be involved in the disease process. Additionally, blocking reagents may induce antigen-specific tolerance of autoreactive T cells which could lead to long-term relief from the disease. The efficacy of blocking reagents in preventing or alleviating autoimmune disorders can be determined using a number of well-characterized animal models of human autoimmune diseases. Examples include murine experimental autoimmune encephalitis, systemic lupus erythmatosis in MK /lpr/lpr mice or NZB hybrid mice, murine autoimmune collagen arthritis, diabetes mellitus in NOD mice and BB rats, and murine experimental myasthenia gravis (see Paul ed., Fundamental Immunology, Raven Press, New York, 1989, pp. 840-856). Upregulation of an antigen function (preferably a B lymphocyte antigen function), as a means of up regulating immune responses, may also be useful in therapy. Upregulation of immune responses may be in the form of enhancing an existing immune response or eliciting an initial immune response. For example, enhancing an immune response through stimulating B lymphocyte antigen function may be useful in cases of viral infection. In addition, systemic viral diseases such as influenza, the common cold, and encephalitis might be alleviated by the administration of stimulatory forms of B lymphocyte antigens systemically.
Alternatively, anti-viral immune responses may be enhanced in an infected patient by removing T cells from the patient, costimulating the T cells in vitro with viral antigen- pulsed APCs either expressing a peptide of the present invention or together with a stimulatory form of a soluble peptide of the present invention and reintroducing the in vitro activated T cells into the patient. Another method of enhancing anti-viral immune responses would be to isolate infected cells from a patient, transfect them with a nucleic acid encoding a protein of the present invention as described herein such that the cells express all or a portion of the protein on their surface, and reintroduce the transfected cells into the patient. The infected cells would now be capable of delivering a costimulatory signal to, and thereby activate, T cells in vivo.
In another application, up regulation or enhancement of antigen function (preferably B lymphocyte antigen function) may be useful in the induction of tumor immunity. Tumor cells (e.g., sarcoma, melanoma, lymphoma, leukemia, neuroblastoma, carcinoma) transfected with a nucleic acid encoding at least one peptide of the present invention can be administered to a subject to overcome tumor-specific tolerance in the subject. If desired, the tumor cell can be transfected to express a combination of peptides. For example, tumor cells obtained from a patient can be transfected ex vivo with an expression vector directing the expression of a peptide having B7-2-like activity alone, or in conjunction with a peptide having B7-l-like activity and/or B7-3-like activity. The transfected tumor cells are returned to the patient to result in expression of the peptides on the surface of the transfected cell. Alternatively, gene therapy techniques can be used to target a tumor cell for transfection in vivo.
The presence of the peptide of the present invention having the activity of a B lymphocyte antigen(s) on the surface of the tumor cell provides the necessary costimulation signal to T cells to induce a T cell mediated immune response against the transfected tumor cells. In addition, tumor cells which lack MHC class I or MHC class II molecules, or which fail to reexpress sufficient amounts of MHC class I or MHC class II molecules, can be transfected with nucleic acid encoding all or a portion of (e.g., a cytoplasmic-domain truncated portion) of an MHC class I α chain protein and β2 microglobulin protein or an MHC class II a chain protein and an MHC class II β chain protein to thereby express MHC class I or MHC class II proteins on the cell surface. Expression of the appropriate class I or class II MHC in conjunction with a peptide having the activity of a B lymphocyte antigen (e.g., B7-1, B7-2, B7-3) induces a T cell mediated immune response against the transfected tumor cell. Optionally, a gene encoding an antisense construct which blocks expression of an MHC class II associated protein, such as the invariant chain, can also be cotransfected with a DNA encoding a peptide having the activity of a B lymphocyte antigen to promote presentation of tumor associated antigens and induce tumor specific immunity. Thus, the induction of a T cell mediated immune response in a human subject may be sufficient to overcome tumor-specific tolerance in the subject. The activity of a protein of the invention may, among other means, be measured by the following methods:
Suitable assays for thymocyte or splenocyte cytotoxicity include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1- 3.19; Chapter 7, Immunologic studies in Humans); Herrmann et al., Proc. Natl. Acad. Sci. USA 78:2488-2492, 1981; Herrmann et al., J. Immunol. 128:1968-1974, 1982; Handa et al., J. Immunol. 135:1564-1572, 1985; Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al, J. Immunol. 140:508-512, 1988; Herrmann et al., Proc. Natl. Acad. Sci. USA 78:2488-2492, 1981; Herrmann et al., J. Immunol. 128:1968-1974, 1982; Handa et al., J. Immunol.
135:1564-1572, 1985; Takai et al., J. Immunol. 137:3494-3500, 1986; Bowmanet al., J.
Virology 61:1992-1998; Takai et al, J. Immunol. 140:508-512, 1988; Bertagnolli et al.,
Cellular Immunology 133:327-341, 1991; Brown et al, J. Immunol. 153:3079-3092, 1994.
Assays for T-cell-dependent immunoglobulin responses and isotype switching (which will identify, among others, proteins that modulate T-cell dependent antibody responses and that affect Thl/Th2 profiles) include, without limitation, those described in: Maliszewski, J. Immunol. 144:3028-3033, 1990; and Assays for B cell function: In vitro antibody production, Mond, J.J. and Brunswick, M. In Current Protocols in Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 3.8.1-3.8.16, John Wiley and Sons, Toronto. 1994. Mixed lymphocyte reaction (MLR) assays (which will identify, among others, proteins that generate predominantly Thl and CTL responses) include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Pubkshing Associates and Wiley- Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988; Bertagnolli et al., J. Immunol. 149:3778-3783, 1992.
Dendritic cell-dependent assays (which will identify, among others, proteins expressed by dendritic cells that activate naive T-cells) include, without limitation, those described in: Guery et al., J. Immunol. 134:536-544, 1995; Inaba et al., Journal of Experimental Medicine 173:549-559, 1991; Macatonia et al., Journal of Immunology 154:5071-5079, 1995; Porgador et al, Journal of Experimental Medicine 182:255-260, 1995; Nair et al, Journal of Virology 67:4062-4069, 1993; Huang et al., Science 264:961-965, 1994; Macatonia et al., Journal of Experimental Medicine 169:1255-1264, 1989; Bhardwaj et al., Journal of Clinical Investigation 94:797-807, 1994; and Inaba et al., Journal of Experimental Medicine 172:631-640, 1990.
Assays for lymphocyte survival /apoptosis (which will identify, among others, proteins that prevent apoptosis after superantigen induction and proteins that regulate lymphocyte homeostasis) include, without limitation, those described in: Darzynkiewicz et al., Cytometry 13:795-808, 1992; Gorczyca et al., Leukemia 7:659-670, 1993; Gorczyca et al., Cancer Research 53:1945-1951, 1993; Itoh et al, Cell 66:233-243, 1991; Zacharchuk, Journal of Immunology 145:4037-4045, 1990; Zamai et al, Cytometry 14:891-897, 1993; Gorczyca et al., International Journal of Oncology 1:639-648, 1992.
Assays for proteins that influence early steps of T-cell commitment and development include, without limitation, those described in: Antica et al., Blood
84:111-117, 1994; Fine et al., Cellular Immunology 155:111-122, 1994; Galy et al., Blood 85:2770-2778, 1995; Toki et al., Proc. Nat. Acad Sci. USA 88:7548-7551, 1991.
Hematopoiesis Regulating Activity A protein of the present invention may be useful in regulation of hematopoiesis and, consequently, in the treatment of myeloid or lymphoid cell deficiencies. Even marginal biological activity in support of colony forming cells or of factor-dependent cell lines indicates involvement in regulating hematopoiesis, e.g. in supporting the growth and proliferation of erythroid progenitor cells alone or in combination with other cytokines, thereby indicating utility, for example, in treating various anemias or for use in conjunction with irradiation /chemotherapy to stimulate the production of erythroid precursors and /or erythroid cells; in supporting the growth and proliferation of myeloid cells such as granulocytes and monocytes/macrophages (i.e., traditional CSF activity) useful, for example, in conjunction with chemotherapy to prevent or treat consequent myelo-suppression; in supporting the growth and proliferation of megakaryocytes and consequently of platelets thereby allowing prevention or treatment of various platelet disorders such as thrombocytopenia, and generally for use in place of or complimentary to platelet transfusions; and/or in supporting the growth and proliferation of hematopoietic stem cells which are capable of maturing to any and all of the above- mentioned hematopoietic cells and therefore find therapeutic utility in various stem cell disorders (such as those usually treated with transplantation, including, without limitation, aplastic anemia and paroxysmal nocturnal hemoglobinuria), as well as in repopulating the stem cell compartment post irradiation /chemotherapy, either in-vivo or ex-vivo (i.e., in conjunction with bone marrow transplantation or with peripheral progenitor cell transplantation (homologous or heterologous)) as normal cells or genetically manipulated for gene therapy.
The activity of a protein of the invention may, among other means, be measured by the following methods: Suitable assays for proliferation and differentiation of various hematopoietic lines are cited above.
Assays for embryonic stem cell differentiation (which will identify, among others, proteins that influence embryonic differentiation hematopoiesis) include, without limitation, those described in: Johansson et al. Cellular Biology 15:141-151, 1995; Keller et al., Molecular and Cellular Biology 13:473-486, 1993; McClanahan et al., Blood 81:2903-2915, 1993.
Assays for stem cell survival and differentiation (which will identify, among others, proteins that regulate lympho-hematopoiesis) include, without limitation, those described in: Methylcellulose colony forming assays, Freshney, M.G. In Culture of Hematopoietic Cells. R.I. Freshney, et al. eds. Vol pp. 265-268, Wiley-Liss, Inc., New York,
NY. 1994; Hirayama et al., Proc. Natl. Acad. Sci. USA 89:5907-5911, 1992; Primitive hematopoietic colony forming cells with high proliferative potential, McNiece, I.K. and Briddell, R.A. In Culture of Hematopoietic Cells. R.I. Freshney, et al. eds. Vol pp. 23-39, Wiley-Liss, Inc., New York, NY. 1994; Neben et al, Experimental Hematology 22:353-359, 1994; Cobblestone area forming cell assay, Ploemacher, R.E. In Culture of Hematopoietic
Cells. R.I. Freshney, et al. eds. Vol pp. 1-21, Wiley-Liss, Inc., New York, NY. 1994; Long term bone marrow cultures in the presence of stromal cells, Spooncer, E., Dexter, M. and Allen, T. In Culture of Hematopoietic Cells. R.I. Freshney, et al. eds. Vol pp. 163-179, Wiley-Liss, Inc., New York, NY. 1994; Long term culture initiating cell assay, Sutherland, H.J. In Culture of Hematopoietic Cells. R.I. Freshney, et al. eds. Vol pp. 139-162, Wiley-Liss, Inc., New York, NY. 1994.
Tissue Growth Activity A protein of the present invention also may have utility in compositions used for bone, cartilage, tendon, ligament and /or nerve tissue growth or regeneration, as well as for wound healing and tissue repair and replacement, and in the treatment of burns, incisions and ulcers.
A protein of the present invention, which induces cartilage and /or bone growth in circumstances where bone is not normally formed, has application in the healing of bone fractures and cartilage damage or defects in humans and other animals. Such a preparation employing a protein of the invention may have prophylactic use in closed as well as open fracture reduction and also in the improved fixation of artificial joints. De novo bone formation induced by an osteogenic agent contributes to the repair of congenital, trauma induced, or oncologic resection induced craniof acial defects, and also is useful in cosmetic plastic surgery.
A protein of this invention may also be used in the treatment of periodontal disease, and in other tooth repair processes. Such agents may provide an environment to attract bone-forming cells, stimulate growth of bone-forming cells or induce differentiation of progenitors of bone-forming cells. A protein of the invention may also be useful in the treatment of osteoporosis or osteoarthritis, such as through stimulation of bone and /or cartilage repair or by blocking inflammation or processes of tissue destruction (collagenase activity, osteoclast activity, etc.) mediated by inflammatory processes. Another category of tissue regeneration activity that may be attributable to the protein of the present invention is tendon /ligament formation. A protein of the present invention, which induces tendon/ligament-like tissue or other tissue formation in circumstances where such tissue is not normally formed, has application in the healing of tendon or ligament tears, deformities and other tendon or ligament defects in humans and other animals. Such a preparation employing a tendon/ligament-like tissue inducing protein may have prophylactic use in preventing damage to tendon or ligament tissue, as well as use in the improved fixation of tendon or ligament to bone or other tissues, and in repairing defects to tendon or ligament tissue. De novo tendon /ligament-like tissue formation induced by a composition of the present invention contributes to the repair of congenital, trauma induced, or other tendon or ligament defects of other origin, and is also useful in cosmetic plastic surgery for attachment or repair of tendons or ligaments. The compositions of the present invention may provide an environment to attract tendon- or ligament-forming cells, stimulate growth of tendon- or ligament-forming cells, induce differentiation of progenitors of tendon- or ligament-forming cells, or induce growth of tendon /ligament cells or progenitors ex vivo for return in vivo to effect tissue repair. The compositions of the invention may also be useful in the treatment of tendinitis, carpal tunnel syndrome and other tendon or ligament defects. The compositions may also include an appropriate matrix and /or sequestering agent as a carrier as is well known in the art.
The protein of the present invention may also be useful for proliferation of neural cells and for regeneration of nerve and brain tissue, i.e. for the treatment of central and peripheral nervous system diseases and neuropathies, as well as mechanical and traumatic disorders, which involve degeneration, death or trauma to neural cells or nerve tissue. More specifically, a protein may be used in the treatment of diseases of the peripheral nervous system, such as peripheral nerve injuries, peripheral neuropathy and localized neuropathies, and central nervous system diseases, such as Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome. Further conditions which may be treated in accordance with the present invention include mechanical and traumatic disorders, such as spinal cord disorders, head trauma and cerebrovascular diseases such as stroke. Peripheral neuropathies resulting from chemotherapy or other medical therapies may also be treatable using a protein of the invention.
Proteins of the invention may also be useful to promote better or faster closure of non-healing wounds, including without limitation pressure ulcers, ulcers associated with vascular insufficiency, surgical and traumatic wounds, and the like.
It is expected that a protein of the present invention may also exhibit activity for generation or regeneration of other tissues, such as organs (including, for example, pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac) and vascular (including vascular endothelium) tissue, or for promoting the growth of cells comprising such tissues. Part of the desired effects may be by inhibition or modulation of fibrotic scarring to allow normal tissue to regenerate. A protein of the invention may also exhibit angiogenic activity. A protein of the present invention may also be useful for gut protection or regeneration and treatment of lung or liver fibrosis, reperfusion injury in various tissues, and conditions resulting from systemic cytokine damage.
A protein of the present invention may also be useful for promoting or inhibiting differentiation of tissues described above from precursor tissues or cells; or for inhibiting the growth of tissues described above.
The activity of a protein of the invention may, among other means, be measured by the following methods:
Assays for tissue generation activity include, without limitation, those described in: International Patent Publication No. WO95/ 16035 (bone, cartilage, tendon); International Patent Publication No. WO95/05846 (nerve, neuronal); International Patent Publication No. WO91/07491 (skin, endothelium ).
Assays for wound healing activity include, without limitation, those described in: Winter, Epidermal Wound Healing, pps. 71-112 (Maibach, HI and Rovee, DT, eds.), Year Book Medical Publishers, Inc., Chicago, as modified by Eaglstein and Mertz, J. Invest. Dermatol 71:382-84 (1978).
Activin/Inhibin Activity
A protein of the present invention may also exhibit activin- or inhibin-related activities. Inhibins are characterized by their ability to inhibit the release of follicle stimulating hormone (FSH), while activins and are characterized by their ability to stimulate the release of follicle stimulating hormone (FSH). Thus, a protein of the present invention, alone or in heterodimers with a member of the inhibin family, may be useful as a contraceptive based on the ability of inhibins to decrease fertility in female mammals and decrease spermatogenesis in male mammals. Administration of sufficient amounts of other inhibins can induce infertility in these mammals. Alternatively, the protein of the invention, as a homodimer or as a heterodimer with other protein subunits of the inhibin- β group, may be useful as a fertility inducing therapeutic, based upon the ability of activin molecules in stimulating FSH release from cells of the anterior pituitary. See, for example, United States Patent 4,798,885. A protein of the invention may also be useful for advancement of the onset of fertility in sexually immature mammals, so as to increase the lifetime reproductive performance of domestic animals such as cows, sheep and pigs.
The activity of a protein of the invention may, among other means, be measured by the following methods: Assays for activin/inhibin activity include, without limitation, those described in: Vale et al., Endocrinology 91:562-572, 1972; Ling et al., Nature 321:779-782, 1986; Vale et al., Nature 321:776-779, 1986; Mason et al., Nature 318:659-663, 1985; Forage et al., Proc. Natl. Acad. Sci. USA 83:3091-3095, 1986.
Chemotactic/Chemokinetic Activity
A protein of the present invention may have chemotactic or chemokinetic activity (e.g., act as a chemokine) for mammalian cells, including, for example, monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and /or endothelial cells. Chemotactic and chemokinetic proteins can be used to mobilize or attract a desired cell population to a desired site of action. Chemotactic or chemokinetic proteins provide particular advantages in treatment of wounds and other trauma to tissues, as well as in treatment of localized infections. For example, attraction of lymphocytes, monocytes or neutrophils to tumors or sites of infection may result in improved immune responses against the tumor or infecting agent.
A protein or peptide has chemotactic activity for a particular cell population if it can stimulate, directly or indirectly, the directed orientation or movement of such cell population. Preferably, the protein or peptide has the ability to directly stimulate directed movement of cells. Whether a particular protein has chemotactic activity for a population of cells can be readily determined by employing such protein or peptide in any known assay for cell chemotaxis.
The activity of a protein of the invention may, among other means, be measured by the following methods:
Assays for chemotactic activity (which will identify proteins that induce or prevent chemotaxis) consist of assays that measure the ability of a protein to induce the migration of cells across a membrane as well as the ability of a protein to induce the adhesion of one cell population to another cell population. Suitable assays for movement and adhesion include, without limitation, those described in: Current Protocols in Immunology, Ed by J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W.Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 6.12, Measurement of alpha and beta Chemokines 6.12.1-6.12.28; Taub et al. J. Clin. Invest. 95:1370-1376, 1995; Lind et al. APMIS 103:140-146, 1995; Muller et al Eur. J. Immunol. 25: 1744-1748; Gruber et al. J. of Immunol. 152:5860-5867, 1994; Johnston et al. J. of Immunol. 153: 1762-1768, 1994. Hemostatic and Thrombolytic Activity
A protein of the invention may also exhibit hemostatic or thrombolytic activity. As a result, such a protein is expected to be useful in treatment of various coagulation disorders (including hereditary disorders, such as hemophilias) or to enhance coagulation and other hemostatic events in treating wounds resulting from trauma, surgery or other causes. A protein of the invention may also be useful for dissolving or inhibiting formation of thromboses and for treatment and prevention of conditions resulting therefrom (such as, for example, infarction of cardiac and central nervous system vessels (e.g., stroke). The activity of a protein of the invention may, among other means, be measured by the following methods:
Assay for hemostatic and thrombolytic activity include, without limitation, those described in: Linet et al., J. Clin. Pharmacol. 26:131-140, 1986; Burdick et al., Thrombosis Res.45:413-419, 1987; Humphrey et al., Fibrinolysis 5:71-79 (1991); Schaub, Prostaglandins 35:467-474, 1988.
Receptor/Ligand Activity
A protein of the present invention may also demonstrate activity as receptors, receptor ligands or inhibitors or agonists of receptor /ligand interactions. Examples of such receptors and ligands include, without limitation, cytokine receptors and their ligands, receptor kinases and their ligands, receptor phosphatases and their ligands, receptors involved in cell-cell interactions and their ligands (including without limitation, cellular adhesion molecules (such as selectins, integrins and their ligands) and receptor/ligand pairs involved in antigen presentation, antigen recognition and development of cellular and humoral immune responses). Receptors and ligands are also useful for screening of potential peptide or small molecule inhibitors of the relevant receptor/ligand interaction. A protein of the present invention (including, without limitation, fragments of receptors and ligands) may themselves be useful as inhibitors of receptor/ligand interactions. The activity of a protein of the invention may, among other means, be measured by the following methods:
Suitable assays for receptor-ligand activity include without limitation those described in:Current Protocols in Immunology, Ed by J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W.Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 7.28, Measurement of Cellular Adhesion under static conditions 7.28.1-7.28.22), Takai et al, Proc. Natl. Acad. Sci. USA 84:6864-6868, 1987; Bierer et al., J. Exp. Med. 168:1145-1156, 1988; Rosenstein et al., J. Exp. Med. 169:149-160 1989; Stoltenborg et al., J. Immunol. Methods 175:59-68, 1994; Stitt et al, Cell 80:661-670, 1995.
Anti-Inflammatory Activity
Proteins of the present invention may also exhibit anti-inflammatory activity. The anti-inflammatory activity may be achieved by providing a stimulus to cells involved in the inflammatory response, by inhibiting or promoting cell-cell interactions (such as, for example, cell adhesion), by inhibiting or promoting chemotaxis of cells involved in the inflammatory process, inhibiting or promoting cell extravasation, or by stimulating or suppressing production of other factors which more directly inhibit or promote an inflammatory response. Proteins exhibiting such activities can be used to treat inflammatory conditions including chronic or acute conditions), including without limitation inflammation associated with infection (such as septic shock, sepsis or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine-induced lung injury, inflammatory bowel disease, Crohn's disease or resulting from over production of cytokines such as TNF or IL-1. Proteins of the invention may also be useful to treat anaphylaxis and hypersensitivity to an antigenic substance or material.
Cadherin/ Tumor Invasion Suppressor Activity
Cadherins are calcium-dependent adhesion molecules that appear to play major roles during development, particularly in defining specific cell types. Loss or alteration of normal cadherin expression can lead to changes in cell adhesion properties linked to tumor growth and metastasis. Cadherin malfunction is also implicated in other human diseases, such as pemphigus vulgaris and pemphigus foliaceus (auto-immune blistering skin diseases), Crohn's disease, and some developmental abnormalities. The cadherin superfamily includes well over forty members, each with a distinct pattern of expression. All members of the superfamily have in common conserved extracellular repeats (cadherin domains), but structural differences are found in other parts of the molecule. The cadherin domains bind calcium to form their tertiary structure and thus calcium is required to mediate their adhesion. Only a few amino acids in the first cadherin domain provide the basis for homophilic adhesion; modification of this recognition site can change the specificity of a cadherin so that instead of recognizing only itself, the mutant molecule can now also bind to a different cadherin. In addition, some cadherins engage in heterophilic adhesion with other cadherins. E-cadherin, one member of the cadherin superfamily, is expressed in epithelial cell types. Pathologically, if E-cadherin expression is lost in a tumor, the malignant cells become invasive and the cancer metastasizes. Transfection of cancer cell lines with polynucleotides expressing E-cadherin has reversed cancer-associated changes by returning altered cell shapes to normal, restoring cells' adhesiveness to each other and to their substrate, decreasing the cell growth rate, and drastically reducing anchorage- independent cell growth. Thus, reintroducing E-cadherin expression reverts carcinomas to a less advanced stage. It is likely that other cadherins have the same invasion suppressor role in carcinomas derived from other tissue types. Therefore, proteins of the present invention with cadherin activity, and polynucleotides of the present invention encoding such proteins, can be used to treat cancer. Introducing such proteins or polynucleotides into cancer cells can reduce or eliminate the cancerous changes observed in these cells by providing normal cadherin expression.
Cancer cells have also been shown to express cadherins of a different tissue type than their origin, thus allowing these cells to invade and metastasize in a different tissue in the body. Proteins of the present invention with cadherin activity, and polynucleotides of the present invention encoding such proteins, can be substituted in these cells for the inappropriately expressed cadherins, restoring normal cell adhesive properties and reducing or eliminating the tendency of the cells to metastasize.
Additionally, proteins of the present invention with cadherin activity, and polynucleotides of the present invention encoding such proteins, can used to generate antibodies recognizing and binding to cadherins. Such antibodies can be used to block the adhesion of inappropriately expressed tumor-cell cadherins, preventing the cells from forming a tumor elsewhere. Such an anti-cadherin antibody can also be used as a marker for the grade, pathological type, and prognosis of a cancer, i.e. the more progressed the cancer, the less cadherin expression there will be, and this decrease in cadherin expression can be detected by the use of a cadherin-binding antibody.
Fragments of proteins of the present invention with cadherin activity, preferably a polypeptide comprising a decapeptide of the cadherin recognition site, and polynucleotides of the present invention encoding such protein fragments, can also be used to block cadherin function by binding to cadherins and preventing them from binding in ways that produce undesirable effects. Additionally, fragments of proteins of the present invention with cadherin activity, preferably truncated soluble cadherin fragments which have been found to be stable in the circulation of cancer patients, and polynucleotides encoding such protein fragments, can be used to disturb proper cell-cell adhesion.
Assays for cadherin adhesive and invasive suppressor activity include, without limitation, those described in: Hortsch et al. J Biol Chem 270 (32): 18809-18817, 1995; Miyaki et al. Oncogene 11: 2547-2552, 1995; Ozawa et al. Cell 63: 1033-1038, 1990.
Tumor Inhibition Activity
In addition to the activities described above for immunological treatment or prevention of tumors, a protein of the invention may exhibit other anti- tumor activities. A protein may inhibit tumor growth directly or indirectly (such as, for example, via ADCC). A protein may exhibit its tumor inhibitory activity by acting on tumor tissue or tumor precursor tissue, by inhibiting formation of tissues necessary to support tumor growth (such as, for example, by inhibiting angiogenesis), by causing production of other factors, agents or cell types which inhibit tumor growth, or by suppressing, eliminating or inhibiting factors, agents or cell types which promote tumor growth.
Other Activities
A protein of the invention may also exhibit one or more of the following additional activities or effects: inhibiting the growth, infection or function of, or killing, infectious agents, including, without limitation, bacteria, viruses, fungi and other parasites; effecting (suppressing or enhancing) bodily characteristics, including, without limitation, height, weight, hair color, eye color, skin, fat to lean ratio or other tissue pigmentation, or organ or body part size or shape (such as, for example, breast augmentation or diminution, change in bone form or shape); effecting biorhythms or caricadic cycles or rhythms; effecting the fertility of male or female subjects; effecting the metabolism, catabolism, anabolism, processing, utilization, storage or elimination of dietary fat, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional factors or component(s); effecting behavioral characteristics, including, without limitation, appetite, libido, stress, cognition (including cognitive disorders), depression (including depressive disorders) and violent behaviors; providing analgesic effects or other pain reducing effects; promoting differentiation and growth of embryonic stem cells in lineages other than hematopoietic lineages; hormonal or endocrine activity; in the case of enzymes, correcting deficiencies of the enzyme and treating deficiency-related diseases; treatment of hyperproliferative disorders (such as, for example, psoriasis); immunoglobulin-like activity (such as, for example, the ability to bind antigens or complement); and the ability to act as an antigen in a vaccine composition to raise an immune response against such protein or another material or entity which is cross-reactive with such protein.
ADMINISTRATION AND DOSING A protein of the present invention (from whatever source derived, including without limitation from recombinant and non-recombinant sources) may be used in a pharmaceutical composition when combined with a pharmaceutically acceptable carrier. Such a composition may also contain (in addition to protein and a carrier) diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials well known in the art. The term "pharmaceutically acceptable" means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredient(s). The characteristics of the carrier will depend on the route of administration. The pharmaceutical composition of the invention may also contain cytokines, lymphokines, or other hematopoietic factors such as M-CSF, GM-CSF, TNF, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IFN, TNFO, TNFl, TNF2, G-CSF, Meg-CSF, thrombopoietin, stem cell factor, and erythropoietin. The pharmaceutical composition may further contain other agents which either enhance the activity of the protein or compliment its activity or use in treatment. Such additional factors and /or agents may be included in the pharmaceutical composition to produce a synergistic effect with protein of the invention, or to minimize side effects. Conversely, protein of the present invention may be included in formulations of the particular cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent to minimize side effects of the cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent. A protein of the present invention may be active in multimers (e.g., heterodimers or homodimers) or complexes with itself or other proteins. As a result, pharmaceutical compositions of the invention may comprise a protein of the invention in such multimeric or complexed form. The pharmaceutical composition of the invention may be in the form of a complex of the protein(s) of present invention along with protein or peptide antigens. The protein and/or peptide antigen will deliver a stimulatory signal to both B and T lymphocytes. B lymphocytes will respond to antigen through their surface immunoglobulin receptor. T lymphocytes will respond to antigen through the T cell receptor (TCR) following presentation of the antigen by MHC proteins. MHC and structurally related proteins including those encoded by class I and class II MHC genes on host cells will serve to present the peptide antigen(s) to T lymphocytes. The antigen components could also be supplied as purified MHC-peptide complexes alone or with co-stimulatory molecules that can directly signal T cells. Alternatively antibodies able to bind surface immunolgobulin and other molecules on B cells as well as antibodies able to bind the TCR and other molecules on T cells can be combined with the pharmaceutical composition of the invention.
The pharmaceutical composition of the invention may be in the form of a liposome in which protein of the present invention is combined, in addition to other pharmaceutically acceptable carriers, with amphipathic agents such as lipids which exist in aggregated form as micelles, insoluble monolayers, liquid crystals, or lamellar layers in aqueous solution. Suitable lipids for liposomal formulation include, without limitation, monoglycerides, diglycerides, sulfatides, lysolecithin, phospholipids, saponin, bile acids, and the like. Preparation of such liposomal formulations is within the level of skill in the art, as disclosed, for example, in U.S. Patent No. 4,235,871; U.S. Patent No. 4,501,728; U.S. Patent No. 4,837,028; and U.S. Patent No. 4,737,323, all of which are incorporated herein by reference.
As used herein, the term "therapeutically effective amount" means the total amount of each active component of the pharmaceutical composition or method that is sufficient to show a meaningful patient benefit, i.e., treatment, healing, prevention or amelioration of the relevant medical condition, or an increase in rate of treatment, healing, prevention or amelioration of such conditions. When applied to an individual active ingredient, administered alone, the term refers to that ingredient alone. When applied to a combination, the term refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially or simultaneously.
In practicing the method of treatment or use of the present invention, a therapeutically effective amount of protein of the present invention is administered to a mammal having a condition to be treated. Protein of the present invention may be administered in accordance with the method of the invention either alone or in combination with other therapies such as treatments employing cytokines, lymphokines or other hematopoietic factors. When co-administered with one or more cytokines, lymphokines or other hematopoietic factors, protein of the present invention may be administered either simultaneously with the cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors, or sequentially. If administered sequentially, the attending physician will decide on the appropriate sequence of administering protein of the present invention in combination with cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors.
Administration of protein of the present invention used in the pharmaceutical composition or to practice the method of the present invention can be carried out in a variety of conventional ways, such as oral ingestion, inhalation, topical application or cutaneous, subcutaneous, intraperitoneal, parenteral or intravenous injection. Intravenous administration to the patient is preferred.
When a therapeutically effective amount of protein of the present invention is administered orally, protein of the present invention will be in the form of a tablet, capsule, powder, solution or elixir. When administered in tablet form, the pharmaceutical composition of the invention may additionally contain a solid carrier such as a gelatin or an adjuvant. The tablet, capsule, and powder contain from about 5 to 95% protein of the present invention, and preferably from about 25 to 90% protein of the present invention. When administered in liquid form, a liquid carrier such as water, petroleum, oils of animal or plant origin such as peanut oil, mineral oil, soybean oil, or sesame oil, or synthetic oils may be added. The liquid form of the pharmaceutical composition may further contain physiological saline solution, dextrose or other saccharide solution, or glycols such as ethylene glycol, propylene glycol or polyethylene glycol. When administered in liquid form, the pharmaceutical composition contains from about 0.5 to 90% by weight of protein of the present invention, and preferably from about 1 to 50% protein of the present invention. When a therapeutically effective amount of protein of the present invention is administered by intravenous, cutaneous or subcutaneous injection, protein of the present invention will be in the form of a pyrogen-free, parenterally acceptable aqueous solution. The preparation of such parenterally acceptable protein solutions, having due regard to pH, isotonicity, stability, and the like, is within the skill in the art. A preferred pharmaceutical composition for intravenous, cutaneous, or subcutaneous injection should contain, in addition to protein of the present invention, an isotonic vehicle such as Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, Lactated Ringer's Injection, or other vehicle as known in the art. The pharmaceutical composition of the present invention may also contain stabilizers, preservatives, buffers, antioxidants, or other additives known to those of skill in the art. The amount of protein of the present invention in the pharmaceutical composition of the present invention will depend upon the nature and severity of the condition being treated, and on the nature of prior treatments which the patient has undergone. Ultimately, the attending physician will decide the amount of protein of the present invention with which to treat each individual patient. Initially, the attending physician will administer low doses of protein of the present invention and observe the patient's response. Larger doses of protein of the present invention may be administered until the optimal therapeutic effect is obtained for the patient, and at that point the dosage is not increased further. It is contemplated that the various pharmaceutical compositions used to practice the method of the present invention should contain about 0.01 μg to about 100 mg (preferably about O.lng to about 10 mg, more preferably about 0.1 μg to about 1 mg) of protein of the present invention per kg body weight.
The duration of intravenous therapy using the pharmaceutical composition of the present invention will vary, depending on the severity of the disease being treated and the condition and potential idiosyncratic response of each individual patient. It is contemplated that the duration of each application of the protein of the present invention will be in the range of 12 to 24 hours of continuous intravenous administration. Ultimately the attending physician will decide on the appropriate duration of intravenous therapy using the pharmaceutical composition of the present invention.
Protein of the invention may also be used to immunize animals to obtain polyclonal and monoclonal antibodies which specifically react with the protein. Such antibodies may be obtained using either the entire protein or fragments thereof as an immunogen. The peptide immunogens additionally may contain a cysteine residue at the carboxyl terminus, and are conjugated to a hapten such as keyhole limpet hemocyanin
(KLH). Methods for synthesizing such peptides are known in the art, for example, as in R.P. Merrifield, J. Amer.Chem.Soc. 85, 2149-2154 (1963); J.L. Krstenansky, et al, FEBS Lett. 211, 10 (1987). Monoclonal antibodies binding to the protein of the invention may be useful diagnostic agents for the immunodetection of the protein. Neutralizing monoclonal antibodies binding to the protein may also be useful therapeutics for both conditions associated with the protein and also in the treatment of some forms of cancer where abnormal expression of the protein is involved. In the case of cancerous cells or leukemic cells, neutralizing monoclonal antibodies against the protein may be useful in detecting and preventing the metastatic spread of the cancerous cells, which may be mediated by the protein.
For compositions of the present invention which are useful for bone, cartilage, tendon or ligament regeneration, the therapeutic method includes administering the composition topically, systematically, or locally as an implant or device. When administered, the therapeutic composition for use in this invention is, of course, in a pyrogen-free, physiologically acceptable form. Further, the composition may desirably be encapsulated or injected in a viscous form for delivery to the site of bone, cartilage or tissue damage. Topical administration may be suitable for wound healing and tissue repair. Therapeutically useful agents other than a protein of the invention which may also optionally be included in the composition as described above, may alternatively or additionally, be administered simultaneously or sequentially with the composition in the methods of the invention. Preferably for bone and /or cartilage formation, the composition would include a matrix capable of delivering the protein-containing composition to the site of bone and /or cartilage damage, providing a structure for the developing bone and cartilage and optimally capable of being resorbed into the body. Such matrices may be formed of materials presently in use for other implanted medical applications.
The choice of matrix material is based on biocompatibility, biodegradability, mechanical properties, cosmetic appearance and interface properties. The particular application of the compositions will define the appropriate formulation. Potential matrices for the compositions may be biodegradable and chemically defined calcium sulfate, tricalciumphosphate, hydroxyapatite, polylactic acid, polyglycolic acid and polyanhydrides. Other potential materials are biodegradable and biologically well- defined, such as bone or dermal collagen. Further matrices are comprised of pure proteins or extracellular matrix components. Other potential matrices are nonbiodegradable and chemically defined, such as sintered hydroxapatite, bioglass, aluminates, or other ceramics. Matrices may be comprised of combinations of any of the above mentioned types of material, such as polylactic acid and hydroxyapatite or collagen and tricalciumphosphate. The bioceramics may be altered in composition, such as in calcium- aluminate-phosphate and processing to alter pore size, particle size, particle shape, and biodegradability.
Presently preferred is a 50:50 (mole weight) copolymer of lactic acid and glycolic acid in the form of porous particles having diameters ranging from 150 to 800 microns. In some applications, it will be useful to utilize a sequestering agent, such as carboxymethyl cellulose or autologous blood clot, to prevent the protein compositions from disassociating from the matrix.
A preferred family of sequestering agents is cellulosic materials such as alkylcelluloses (including hydroxyalkylcelluloses), including methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropyl- methylcellulose, and carboxymethylcellulose, the most preferred being cationic salts of carboxymethylcellulose (CMC). Other preferred sequestering agents include hyaluronic acid, sodium alginate, poly(ethylene glycol), polyoxyethylene oxide, carboxyvinyl polymer and poly(vinyl alcohol). The amount of sequestering agent useful herein is 0.5-20 wt%, preferably 1-10 wt% based on total formulation weight, which represents the amount necessary to prevent desorbtion of the protein from the polymer matrix and to provide appropriate handling of the composition, yet not so much that the progenitor cells are prevented from infiltrating the matrix, thereby providing the protein the opportunity to assist the osteogenic activity of the progenitor cells. In further compositions, proteins of the invention may be combined with other agents beneficial to the treatment of the bone and/or cartilage defect, wound, or tissue in question. These agents include various growth factors such as epidermal growth factor (EGF), platelet derived growth factor (PDGF), transforming growth factors (TGF-α and TGF-β), and insulin-like growth factor (IGF). The therapeutic compositions are also presently valuable for veterinary applications. Particularly domestic animals and thoroughbred horses, in addition to humans, are desired patients for such treatment with proteins of the present invention. The dosage regimen of a protein-containing pharmaceutical composition to be used in tissue regeneration will be determined by the attending physician considering various factors which modify the action of the proteins, e.g., amount of tissue weight desired to be formed, the site of damage, the condition of the damaged tissue, the size of a wound, type of damaged tissue (e.g., bone), the patient's age, sex, and diet, the severity of any infection, time of administration and other clinical factors. The dosage may vary with the type of matrix used in the reconstitution and with inclusion of other proteins in the pharmaceutical composition. For example, the addition of other known growth factors, such as IGF I (insulin like growth factor I), to the final composition, may also effect the dosage. Progress can be monitored by periodic assessment of tissue/bone growth and /or repair, for example, X-rays, histomorphometric determinations and tetracycline labeling.
Polynucleotides of the present invention can also be used for gene therapy. Such polynucleotides can be introduced either in vivo or ex vivo into cells for expression in a mammalian subject. Polynucleotides of the invention may also be administered by other known methods for introduction of nucleic acid into a cell or organism (including, without limitation, in the form of viral vectors or naked DNA).
Cells may also be cultured ex vivo in the presence of proteins of the present invention in order to proliferate or to produce a desired effect on or activity in such cells. Treated cells can then be introduced in vivo for therapeutic purposes.
Patent and literature references cited herein are incorporated by reference as if fully set forth.
SEQUENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLICANT: Jacobs, Kenneth McCoy, John M. LaVallie, Edward R. Racie, Lisa A. Merberg, David Treacy, Maurice Spaulding, Vikki Agostino, Michael J.
(ii) TITLE OF INVENTION: SECRETED PROTEINS AND POLYNUCLEOTIDES ENCODING THEM
(iii) NUMBER OF SEQUENCES: 34
(iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Genetics Institute, Inc.
(B) STREET: 87 CambridgePark Drive
(C) CITY: Cambridge
(D) STATE: MA
(E) COUNTRY: U.S.A.
(F) ZIP: 02140
(v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: Patentln Release #1.0, Version #1.30
(vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:
(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Sprunger, Suzanne A.
(B) REGISTRATION NUMBER: 41,323
(ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: (617) 498-8284
(B) TELEFAX: (617) 876-5851
(2) INFORMATION FOR SEQ ID NO : 1 :
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 349 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO : 1 :
ACTTCGCANC CCATCCCGGC TGGACGCGAC CGGGGAGTGC AGCAGCCCGT TCCCCTCCTC 60
GGTGCCGCCT CTGCCCAGCG TTTGCTTGGC TGGGCTACCA CCTGCGCTCG GACGGCGCTC 120
GGAGGGTCCT CGCCCCCGGC CTGCCTACCT GAAAACCANA ACTGATGGCT CTATTTGCAG 180
TCTTTCANAC AACATTCTTC TTAACATTGC TGTCCTTGAG GACTTACCAN ANTGAAGTCT 240
TGGCTGAACG TTTACCATTG ACTCCTGTTN TCACTTAAAG TTTCCACCAA TTCTACGCGT 300
CAGAGTTTGC ACTTACAATG GACTGTCCAC AACCTTCCTT ATCATCAGG 349 (2) INFORMATION FOR SEQ ID NO : 2 :
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 563 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO : 2 :
TCCATTCCAG CACCAGCCAA CAGCACAAAA TTAATCCTTG ACAGGTGTTC CTACCAAATT 60
TGNGTCATAG CCAACAACAG TGNGGGTGCT TCTCCTGCTT CTGTAATAGT CATTTNTGCA 120
GACCCCGAAA ACAAAGAGGT TGAGGAAGAA AGAATTGCAG GCACAGAGGG TGGATTNTTT 180
TTNTTTTGGA AACCCCAACC TGGAGATGTT ATAGGTTATG TTGTGGANTG GTGTGACCAN 240
ACCCAGGATG TGCCTCGGTG ATTTCCAGTG GAAGAATGTA GGTCCCAATA CCACAAGCAC 300
AGTCATTAGC ACAGATGCTT TTAGGCCAGG AGTTCGATAT GACTTCAGAA TTTATGGGTT 360
ATCTACAAAA AGGATTGCTT GTTTATTAGA GAAAAAAAAC AGGATACTCT CAGGAACTTG 420
CTCCTTCAGA CAACCCTCAC GTGCTGGTGG ATACATTGAC ATCCCACTCC TTCACTCTGA 480
GTTGGAAAGA TTACTCTACT GAATCTCAAC CTGGTTTTAT ACAAGGGTAC CATGTCTATC 540
TGAAATCCAA GGCGAGGCAG TGC 563 (2) INFORMATION FOR SEQ ID NO : 3 : (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 58 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO : 3 :
Arg Lys Lys Thr Gly Tyr Ser Gin Glu Leu Ala Pro Ser Asp Asn Pro 1 5 10 15
His Val Leu Val Asp Thr Leu Thr Ser His Ser Phe Thr Leu Ser Trp 20 25 30
Lys Asp Tyr Ser Thr Glu Ser Gin Pro Gly Phe lie Gin Gly Tyr His 35 40 45
Val Tyr Leu Lys Ser Lys Ala Arg Gin Cys 50 55
(2) INFORMATION FOR SEQ ID NO : 4 :
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 361 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO : 4 :
GAAAAGGCAG TTCTTTCAGA TGGTTCAGAA TGTTGCAAAT ACAAAATTGA CAACCCGGAA 60
GAAAAGGCAT TGATTGTGGA CAACCTAAAG CCAGAATCCT TNTANGAGTT TTTCATCACT 120
CCATTCACTA GTGCTGGTGA AGGCCCCAGT GCNACGTTCA CGAAGGTCAC GACTCCGGAT 180
GAACANTCCT NGATGCTGAT TCATATCCTA CTGCCCATGG TTTTCTGCGT CTTGCTCATC 240
ATGGTCATGT GNNACTTGAA AAGTCAGTGG ATCAAGGAGA CCTGTTATCC TGACATCCCT 300
GACCCTTACA AGAGCAGCAT CCTGTCATTA ATAAAATTCA AGGTAAAAAA AAAAAAAAAA 360
A 361 (2) INFORMATION FOR SEQ ID NO : 5 : (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 756 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO : 5 :
ATTGAATTCT AGACCTGCGG CCGCTGCTCC CTCAGANGCC CCTGATGTCT GGANAATTGT 60
GAGCTTGGAG CCAGGAAATC ATACTGTGAC CTTATTCTGG AAGCCATTAT CAAAACTGCA 120
TGCCAATGGA AAGATCCTGT TCTATAATGT AGTTGTAGAA AACCTAGACA AACCATCCAG 180
TTCAGAGCTC CATTCCATTC CAGCACCAGC CAACAGCACA AAACTAATCC TTGACAGGTG 240
TTCCTACCAA ATCTGCGTCA TAGCCAACAA CAGTGTGGGT GCTTCTCCTG CTTCTGTAAT 300
AGTCATYTCT GCAGACCCCG AAAACAAAGA GGTTGAGGAA GAAAGAATTG CAGGCACAGA 360
GGGTGGATTT TTTTTNTTTT GGAAACCCCA ACCTGGAGAT GTTATAGGTT ATGTTGTGGA 420
CTGGTGTGAC CANACCCAGG ATGTGCCTCG GTGATTTCCA GTGGAAGAAT GTAGGTCCCA 480
ATACCACAAG CACAGTCATT AGCACAGATG CTTTTAGGCC AGGAGTTCGA TATGACTTCA 540
GAATTTATGG GTTATCTACA AAAAGGATTG CTTGTTTATT AGAGAAAAAA AACAGGATAC 600
TCTCAGGAAC TTGCTCCTTC AGACAACCCT CACGTGCTGG TGGATACATT GACATCCCAC 660
TCCTTCACTC TGAGTTGGAA AGATTACTCT ACTGAATCTC AACCTGGTTT TATACAAGGG 720
TACCATGTCT ATCTGAAATC CAAGGCGAGG CAGTGC 756 (2) INFORMATION FOR SEQ ID NO : 6 :
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 58 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO : 6 : Arg Lys Lys Thr Gly Tyr Ser Gin Glu Leu Ala Pro Ser Asp Asn Pro 1 5 10 15
His Val Leu Val Asp Thr Leu Thr Ser His Ser Phe Thr Leu Ser Trp 20 25 30
Lys Asp Tyr Ser Thr Glu Ser Gin Pro Gly Phe lie Gin Gly Tyr His 35 40 45
Val Tyr Leu Lys Ser Lys Ala Arg Gin Cys 50 55
(2) INFORMATION FOR SEQ ID NO : 7 :
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 79 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO : 7 : TCATTAATAA AATTCAAGGT AAATGTTAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA 60 AAAAAAAAAA AAAAAAAAA 79
(2) INFORMATION FOR SEQ ID NO : 8 :
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1939 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO : 8 : ATTGGTTTTC AAATATTAAA CCAGCATTTT ATTTTAAAAT AAACCCCACT TAGTTATGAT 60
ATTTTATCTT TTTTATATAA TGTGGGATTT GATTTGCCGA TATTTTATTA AAGATTTTTG 120
CATCATGTTC TTTTTCTGAA ATTTTATTTT GTTCTAATGT CATAAAATAA GTTGGAAATT 180
ATCCTCTCTA TCTCTACTTT GTGAAAGAAT TTATATTACA TTGGTATTAT TTCTTCCTTG 240
AATGTTTGAT AGACTATACT AGTGAAAGCA TCTGGGCCTA GGGTTTTCTC TGTGGAAGAT 300 TTTCAGTTAC AAATTCAATT TTACTGAGTC AGGTTTGATA AGTTACATTT CTCAAGGAAT 360
TTATCTATTT AATCATTGAA TGTATTGAAC ATTCATTTGT TTATAATTTT GTTTTGTTAT 420
TGAAAATGTC TGTAAGATTT ATAGTGATGT TCCCTTTTCT ATTCCTGACA TTGTTAATTT 480
GTGTTCTCTC TCCCTCCATC CCTCTCTCAC TCTCTCTTGT CAGCTGGTCT GTGGGATTAT 540
CACCTTTATT AATCTTTTCA GAGAACCACT TTTTATTTCT TTGATTTCCT TTATTGTTTG 600
TTAACTTTTT AGTTTATTGA TTCCCTCTCT TAGCTTTATT ACTTCCTTCC TTCTACTTAG 660
TAAGAGTTTA ATTTGCCCTC ATTTTTTTAG CTTCTTAAGG TAGGAAATTT GATTATATTT 720
TAAACTTAAA AAAACTTAAA GCTATAAAAT TCCCTTTAAG CACTGTTTTA GCTGAATTCT 780
ACATATTTTG ATTGGGTATG TTTTCATCAT TCAATTAAAA ACATAGTTTC TAATTTTTTC 840
TTGCAATTTC TTCTTTAACC CATAGGTTAT TTGGCAGTTT GCTGCTGAAT TTCAAAGTGC 900
TTGGGAGGTT TTATAGCTAT CTTGTTAAAA ATTGATTTCT AATTTAATTT TGTCAGAGAA 960
CATACTTTGT ATGACTTAAA TCTTTTAAAA TACGTTCAGA CTGATTTAGG GTCCAGCATA 1020
TGGTACGTCT TAGTGAATGT AATATATGCC ATTGGAAATG ATGCACATTC TGCAATTGTT 1080
GGTTGTAATG TGCTATAAAT GTCAACCAGG TTAACTTGGT TGATAGTATT GTTGAATTCC 1140
TGTGTTCCAA ATGATATTTT TTGTCTGTTT ATTCTATCAA TTAATGAGAA AGGTTTATTA 1200
AAATCTCCAA CCATTGTTGT GCATTTATTT CTATTTCTTT AGTTCTGTTG ATTTTTGTTT 1260
TATATATTTT GAAGCTCTGA GTACATCTCC CTGATGAGTT GACCCTTTTA TCATTATGAA 1320
ATGTCATTCT TTCTCTGTAA TGCTTATCTT AAAATCTACT TTGTTTGATA TGAATGTAGC 1380
CACTTAAGCT TTCTTATGCA TACTGTTTGC AAAGTGTGTG TGTGTGTGTG TGTGTGTGTG 1440
TGTATCTATC TCAATCCTTT AGTTTCCGCC TATCTCTGTC TTTTTATTTA AAGTGTGTTT 1500
TTGCAGGTAG TGTATAACTT GGATCTTGTT TTTATATTCA GTCTGACAAT TTATGCTTCT 1560
TGATTATTGT GTTTAGTTTA TTTGCATAGT GTGTAGTCCA TTGACATTTG GCATAATATT 1620
GATAATTTGT GTTGGAGCGT ATTGTCTTCA TTTCTGATTG TCCCATCTGG TTTTGTTGCT 1680
GTTTTGTTGT TCCTCTGTTC CACACTTTTT GTCTTCTTTT GGGTTAATCA AATATTCTTT 1740
GGCTTTGCAT CTTATGTCTT CTGTTGGATT TTTATCTATA CCTTGTCGTA TTTTTCTTTA 1800
GTGGTTTCTC TAGGGGTTAC ACTATACATT ATTAATTAAT CATAGTCCAT TTAGAATTAA 1860
TATTGTACAC TTTACATAAA ATGTAAAACA TTTGTCACAG TATAAAGTCT ATTCCTTCCA 1920
AAAAAAAAAA AAAAAAAAA 1939 ( 2 ) INFORMATION FOR SEQ ID NO : 9 :
( i ) SEQUENCE CHARACTERI STICS :
(A ) LENGTH : 52 amino acids
( B ) TYPE : amino ac id
( C ) STRANDEDNESS :
( D) TOPOLOGY : linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO : 9 :
Met Ser Val Arg Phe lie Val Met Phe Pro Phe Leu Phe Leu Thr Leu 1 5 10 15
Leu lie Cys Val Leu Ser Pro Ser lie Pro Leu Ser Leu Ser Leu Val 20 25 30
Ser Trp Ser Val Gly Leu Ser Pro Leu Leu lie Phe Ser Glu Asn His 35 40 45
Phe Leu Phe Leu 50
(2) INFORMATION FOR SEQ ID NO: 10:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1252 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:
GTAGAAATCC CAAAAAGATT TGGACAGAGG CAGAGCCTAT GTCACTACAC CTTAAAGGAT 60
AACAAGGTTT ATATCAAGAC TCATGGTGAA CATGTAGGTT TTAGAATTTT CATGGATGCC 120
ATACTACTTT CTTTGACTAG AAAGGTGAAG ATGCCAGATG TGGAGCTCTT TGTTAATTTG 180
GGAGACTGGC CTTTGGAAAA AAAGAAATCC AATTCAAACA TCCATCCGAT CTTTTCCTGG 240
TGTGGCTCCA CAGATTCCAA GGATATCGTG ATGCCTACGT ACGATTTGAC TGATTCTGTT 300
CTGGAAACCA TGGGCCGGGT AAGTCTGGAT ATGATGTCCG TGCAAGCTAA CACGGGTCCT 360
CCCTGGGAAA GCAAAAATTC CACTGCCGTC TGGAGAGGGC GAGACAGCCG CAAAGAGAGA 420 CTCGAGCTGG TTAAACTCAG TAGAAAACAC CCAGAACTCA TAGACGCTGC TTTCACCAAC 480
TTTTTCTTCT TTAAACACGA TGAAAACCTG TATGGTCCCA TTGTGAAACA TATTTCATTT 540
TTTGATTTCT TCAAGCATAA GTATCAAATA AATATCGATG GCACTGTAGC AGCTTATCGC 600
CTGCCATATT TGCTAGTTGG TGACAGTGTT GTGCTGAAGC AGGATTCCAT CTACTATGAA 660
CATTTTTACA ATGAGCTGCA GCCCTGGAAA CACTACATTC CAGTTAAGAG CAACCTGAGC 720
GATCTGCTAG AAAAACTTAA ATGGGCGAAA GATCACGATG AAGAGGCCAA AAAGATAGCA 780
AAAGCAGGAC AAGAATTTGC AAGAAATAAT CTCATGGGCG ATGACATATT CTGTTATTAT 840
TTCAAACTTT TCCAGGAATA TGCCAATTTA CAAGTGAGTG AGCCCCAAAT CCGAGAGGGC 900
ATGAAAAGGG TAGAACCACA GACTGAGGAC GACCTCTTCC CTTGTACTTG CCATAGGAAA 960
AAGACCAAAG ATGAACTCTG A ATGCAAAA TAACTTCTAT TAGAATAATG GTGCTCTGAA 1020
GACTCTTCTT AACTAAAAAG AAGAATTTTT TTAAGTATTA ATTCCATGGA CAATATAAAA 1080
TCTGTGTGAT TGTTTGCAGT ATGAAGACAC ATTTCTACTT ATGCAGTATT CTCATGACTG 1140
TACTTTAAAG TACATTTTTA GAATTTTATA ATAAAACCAC CTTTATTTTA AAGGAAAAAA 1200
AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AA 1252 (2) INFORMATION FOR SEQ ID NO: 11:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 289 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:
Met Asp Ala lie Leu Leu Ser Leu Thr Arg Lys Val Lys Met Pro Asp 1 5 10 15
Val Glu Leu Phe Val Asn Leu Gly Asp Trp Pro Leu Glu Lys Lys Lys 20 25 30
Ser Asn Ser Asn lie His Pro lie Phe Ser Trp Cys Gly Ser Thr Asp 35 40 45
Ser Lys Asp lie Val Met Pro Thr Tyr Asp Leu Thr Asp Ser Val Leu 50 55 60 Glu Thr Met Gly Arg Val Ser Leu Asp Met Met Ser Val Gin Ala Asn 65 70 75 80
Thr Gly Pro Pro Trp Glu Ser Lys Asn Ser Thr Ala Val Trp Arg Gly 85 90 95
Arg Asp Ser Arg Lys Glu Arg Leu Glu Leu Val Lys Leu Ser Arg Lys 100 105 110
His Pro Glu Leu lie Asp Ala Ala Phe Thr Asn Phe Phe Phe Phe Lys 115 120 125
His Asp Glu Asn Leu Tyr Gly Pro lie Val Lys His lie Ser Phe Phe 130 135 140
Asp Phe Phe Lys His Lys Tyr Gin lie Asn lie Asp Gly Thr Val Ala 145 150 155 160
Ala Tyr Arg Leu Pro Tyr Leu Leu Val Gly Asp Ser Val Val Leu Lys 165 170 175
Gin Asp Ser lie Tyr Tyr Glu His Phe Tyr Asn Glu Leu Gin Pro Trp 180 185 190
Lys His Tyr lie Pro Val Lys Ser Asn Leu Ser Asp Leu Leu Glu Lys 195 200 205
Leu Lys Trp Ala Lys Asp His Asp Glu Glu Ala Lys Lys lie Ala Lys 210 215 220
Ala Gly Gin Glu Phe Ala Arg Asn Asn Leu Met Gly Asp Asp lie Phe 225 230 235 240
Cys Tyr Tyr Phe Lys Leu Phe Gin Glu Tyr Ala Asn Leu Gin Val Ser 245 250 255
Glu Pro Gin lie Arg Glu Gly Met Lys Arg Val Glu Pro Gin Thr Glu 260 265 270
Asp Asp Leu Phe Pro Cys Thr Cys His Arg Lys Lys Thr Lys Asp Glu 275 280 285
Leu
(2) INFORMATION FOR SEQ ID NO: 12:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 492 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:
CTAGGTTCTG GGAAGATGGC GAAGGTCTCA GAGCTTTACG ATGTCACTTG GGAAGAAATG 60
AGAGATAAAA TGAGAAAATG GAGAGAAGAA AACTCAAGAA A AGTGAGCA AATTGTGGAA 120
GTTGGAGAAG AATTAATTAA TGAATATGCT TCTAAGCTGG GAGATGATAT TTGGATCATA 180
TATGAACAGG TGATGATTGC AGCACTAGAC TATGGTCGGG ATGACTTGGC ATTGTTTTGT 240
CTTCAAGAGC TGAGAAGACA GTTCCCTGGC AGTCACAGAG TCAAGCGATT AACAGGCATG 300
AGATTTGAAG CCATGGAAAG ATATGATGAT GCTATACAGC TATATGATAG GATTTTACAA 360
GAAGATCCAA CTAACACTGC TGCAAGAAAG CGTAAGATTG CCATTCGAAA AGCCCAGGGG 420
AAAAATGTGG AGGCCATTCG GGAGCTGAAT GAGTATCTGG AACAATTTGT TGGAGACCAA 480
GAAGCCTGGC AT 492 (2) INFORMATION FOR SEQ ID NO : 13 :
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 159 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:
Met Ala Lys Val Ser Glu Leu Tyr Asp Val Thr Trp Glu Glu Met Arg 1 5 10 15
Asp Lys Met Arg Lys Trp Arg Glu Glu Asn Ser Arg Asn Ser Glu Gin
20 25 30 lie Val Glu Val Gly Glu Glu Leu lie Asn Glu Tyr Ala Ser Lys Leu 35 40 45
Gly Asp Asp lie Trp lie lie Tyr Glu Gin Val Met lie Ala Ala Leu 50 55 60
Asp Tyr Gly Arg Asp Asp Leu Ala Leu Phe Cys Leu Gin Glu Leu Arg 65 70 75 80
Arg Gin Phe Pro Gly Ser His Arg Val Lys Arg Leu Thr Gly Met Arg 85 90 95 Phe Glu Ala Met Glu Arg Tyr Asp Asp Ala lie Gin Leu Tyr Asp Arg
100 105 110 lie Leu Gin Glu Asp Pro Thr Asn Thr Ala Ala Arg Lys Arg Lys lie 115 120 125
Ala lie Arg Lys Ala Gin Gly Lys Asn Val Glu Ala lie Arg Glu Leu 130 135 140
Asn Glu Tyr Leu Glu Gin Phe Val Gly Asp Gin Glu Ala Trp His 145 150 155
(2) INFORMATION FOR SEQ ID NO: 14:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 85 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14: CCTTGTTAAA TAAACCATGN TGATTTNTTA AACTTGCCAA AAAAAAAAAA AAAAAAAAAA 60 AAAAAAAAAA AAAAAAAAAA AAAAA 85
(2) INFORMATION FOR SEQ ID NO: 15:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 313 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15: CCTTGGATTA TCTGAACTAA AAATTGGACA GATTGATCAG CTGGTAAAAA ATCTACTTCC 60
TGGATTTNGT AAAGGCAAAA ACATTTCTTC CCATTGGCAT ACATCCCNTG TCTCTGCACA 120
ATCCTTCTTT GAAAATNAAT ATGGTAACTT AAATATATTT AGTACATTAC GTTCCTCTTG 180
CTTGTATCGA CATCATTCAA AAGCTCTTCA AAGCATTTGT TCAAATCTTC AGTACTGGCC 240
AGTTTTCATA CAGTCTCGGG GTTTTAAAAC TTTGAAATCA AGGACACNAC GTCTCCAGTC 300 TACCTCCGAG AGA 313
(2) INFORMATION FOR SEQ ID NO: 16:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 964 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:
GCTTTTCCGG AGCAGAGTTG GAGAATCTTG TGAACCAGGC TGCATTAAAA GCAGCTGTTG 60
ATGGAAAAGA AATGGTTACC ATGAAGGAGC TGGAGTTTTC CAAAGACAAA ATTCTAATGG 120
GGCCTGAAAG AAGAAGTGTG GAAATTGATA ACAAAAACAA AACCATCACA GCATATCATG 180
AATCTGGTCA TGCCATTATT GCATATTACA CAAAAGATGC AATGCCTATC AACAAAGCTA 240
CAATCATGCC ACGGGGGCCA ACACTTGGAC ATGTGTCCCT GTTACCTGAG AATGACAGAT 300
GGAATGAAAC TAGAGCCCAG CTGCTTGCAC AAATGGATGT TAGTATGGGA GGAAGAGTGG 360
CAGAGGAGCT TATATTTGGA ACCGACCATA TTACNACAGG TGCTTCCAGT GATTTTGATA 420
ATGCCACTAA AATAGCAAAG CGGATRGYTA CCAAATTTGG AATGAGTGAA AAGCTTGGAG 480
TTATGACCTA CAGTGATACA GGGGAAACTA AGTCCAGAAA CCCAATCTGC CATCGAACAA 540
GAAATAAGAA TCCTTCTAAG GGACTCATAT GAACGAGCAA AACATATCTT GAAAACTCAT 600
GCAAAGGAGC ATAAGAATCT CGCAGAAGCT TTATTGACCT ATGAGACTTT GGATGCCAAA 660
GAGATTCAAA TTGTTCTKGA GGGGAAAAAG TTGGAAGTGA GATGATAACT CTCTKGATAT 720
GGATGCTTGC TGGTTTTATT GCAAGAATAT AAGTAGCATT GCAGTAGTCT ACTTTTACAA 780
CGCTTTCCCC TCATTCTTGA TGTGGTGTAA TTGAAGGGTG TGAAATGCTT TGTCAATCAT 840
TTGTCACATT TATCCAGTTT GGGTTATTCT CATTAGGACA CCTATTGCAA ATTAGCATCC 900
CATGGCAAAT ATATTTTGAA AAAATAAAGA ACTATCAGGA TTGAAAAAAA AAAAAAAAAA 960
AAAA 964
(2) INFORMATION FOR SEQ ID NO: 17:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 166 amino acids (B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:
Met Val Thr Met Lys Glu Leu Glu Phe Ser Lys Asp Lys He Leu Met 1 5 10 15
Gly Pro Glu Arg Arg Ser Val Glu He Asp Asn Lys Asn Lys Thr He 20 25 30
Thr Ala Tyr His Glu Ser Gly His Ala He He Ala Tyr Tyr Thr Lys 35 40 45
Asp Ala Met Pro He Asn Lys Ala Thr He Met Pro Arg Gly Pro Thr 50 55 60
Leu Gly His Val Ser Leu Leu Pro Glu Asn Asp Arg Trp Asn Glu Thr 65 70 75 80
Arg Ala Gin Leu Leu Ala Gin Met Asp Val Ser Met Gly Gly Arg Val 85 90 95
Ala Glu Glu Leu He Phe Gly Thr Asp His He Thr Thr Gly Ala Ser 100 105 110
Ser Asp Phe Asp Asn Ala Thr Lys He Ala Lys Arg Xaa Xaa Thr Lys 115 120 125
Phe Gly Met Ser Glu Lys Leu Gly Val Met Thr Tyr Ser Asp Thr Gly 130 135 140
Glu Thr Lys Ser Arg Asn Pro He Cys His Arg Thr Arg Asn Lys Asn 145 150 155 160
Pro Ser Lys Gly Leu He
165
(2) INFORMATION FOR SEQ ID NO: 18:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1362 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:
CTTTTCATAT CCTTTTATTT TCCCAATTCA TATAGGAAAG ATAAGTATTT TCCCTTTCAT 60
TTTCAAAATT GATTGGTACA CTAACCTCCT CCATAGTAAC TAATTTGTAT TTTTTTATTA 120
TGAACTCATG AATTTAAACA TTTGATGTTG TTTCAGTCCA TTGCAGTCAT TATCCTTATT 180
GATTCTCAAA GTGTTTTATT TTTGACAAAT AAGTTCTTCA AATTAGTTAG TTATTTTGAT 240
AGTGACCTTA ATAGTCTTTG CTAGCTTCCA TCCCTGTATG GCATAACAAA ACATTCCAGG 300
CCCCTTTAGT ACATTTCCTG TCCCAGACCT GGTATTAGTC ATCTAATCTG GAAGCCCTGC 360
TTTCTTTCTG TGGGAAACAT TATTTCAAGA CATTAGGGAT AAGAATGCCA GTTGCTACTG 420
AGTTGGTTAT TGTTTCAAGG ATTTATCAAT ACATAGAGCA AATAATTATG TTTTGCTTTG 480
TCTTATTTTT ATTTCTTTAC TTTAGAAACA GTACAGCTAC TTACAAATCA AGTTTAGAAC 540
TCTCAGGTTA TCTTAAATCT GAAGCTTCTA CCTTCCTAAG AACAAAACAC CGGAATGATG 600
AGATGTCATA TAAATATCCA TTTATTTTAT TTCACAATAC ATACATTGAC CTATTGTATG 660
TATGATTAGT ACAAATGGTT TAAATTGGCT TGTTGTGCTT TGTTTTGTTT TTGCAGTTTT 720
TTTTTGTCAT TAGATTTTAT CTCACTAGAA ATGTATAGTC AAATTTCTGT GTTCTAAAGT 780
CACTTGAAGT AGTTTTTCTG TTTGTAGTAA TGTTACCAGT TGGACACATT AGGTTCATTT 840
ATTTTTGGGA ATTGCTTTTG TTCCCATTTA AATTTTTATT TATCTTGCGT ATCTTGGATT 900
AACGGTAATA GACCATATAC AATTTTCTCT ACTTTTTTTC ATTKGAGAGT TTCCTCATTT 960
ATTTTGTTTT CGGATGCAAA GTATTTCATT GTATGAATTA CCAGTTTGTT CAATTAGTTT 1020
TCTTTGATAA CATTTGGGTT GCTTCTAGTC TTTTGTTATW ACAGAGTCTT GCAATGAATA 1080
GTCTTATGCT TATATGTTTT GTGGTTTCTG GCAAGGATTT CAACGTAATT TAAGGCTATC 1140
CTCTACTTAA GTTATGGCCA ATTAAGTGTC TGATTAAATG TCTGTAATAA TTTAAAAATA 1200
ACAATACTTA ATTTAAAAGA GCTTATAATA CATAATTATT CATTAGAGAG ATGCAGCAAA 1260
CCACCATGGC AAATGTATTC CTATGTAACA AACCTGCACG TTCAGCAAGT GTATCCCAGC 1320
ACTGAAAGTA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AA 1362 (2) INFORMATION FOR SEQ ID NO: 19:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 86 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS : (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:
Met Pro Val Ala Thr Glu Leu Val He Val Ser Arg He Tyr Gin Tyr 1 5 10 15
He Glu Gin He He Met Phe Cys Phe Val Leu Phe Leu Phe Leu Tyr 20 25 30
Phe Arg Asn Ser Thr Ala Thr Tyr Lys Ser Ser Leu Glu Leu Ser Gly 35 40 45
Tyr Leu Lys Ser Glu Ala Ser Thr Phe Leu Arg Thr Lys His Arg Asn 50 55 60
Asp Glu Met Ser Tyr Lys Tyr Pro Phe He Leu Phe His Asn Thr Tyr 65 70 75 80
He Asp Leu Leu Tyr Val 85
(2) INFORMATION FOR SEQ ID NO: 20:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 479 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:
CTGGCTTCTT CGGAGCTGTG TAKTCTTAAT TTGCTTTGCT GCTGGCTGGC TGACAGCTGA 60
TGGGGGACTC CTCAGGACGG ACTCCCTTCC AGATGCACCC ATCTCCATCC TTCTCAACTC 120
CCCAACCTTT GTCCTCCCCA CTCTTCGCTC GCGCGGCGGT CTGAGACCAC CAGGACCAGT 180
TTCAGGGGTT TCCTTCTCCA GCGAGACTTG GCAGAACAGG CTTTAAAAGC AAAGGAGGCA 240
GCGGAAGACT GTGAATTCCT TTGGACAATT GATGATATTT ATCATTGTGC CCAGTTTCTA 300
CAAATAAAAG ATGGGTGGAT TATTTTCTCG ATGGAGGACA AAACCTTCAA CTGTAGAAGT 360
TCTAGAAAGT ATAGATAAGG AAATTCAAGC ATTGGAAGAA TTTAGGGAAA AAAAAAAAAA 420 AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAA 479 (2) INFORMATION FOR SEQ ID NO: 21:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:
Met Gly Gly Leu Phe Ser Arg Trp Arg Thr Lys Pro Ser Thr Val Glu 1 5 10 15
Val Leu Glu Ser He Asp Lys Glu He Gin Ala Leu Glu Glu Phe Arg 20 25 30
Glu
(2) INFORMATION FOR SEQ ID NO: 22:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 333 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:
CTGACTTACT AATACTAAAG AAGTGGGGGG AGCTCGAGAG CCAGACGGCC AGACAGGCAG 60
ACCCCTCCAN AGGCCCGCCA GGTGGGCATG GTCCCCCATT TTCTTTAAGG CAGCACCTGG 120
AGTGGAGAGA GGCCACTCCC TCTCCAGCCC CCGATNTGGA CCCGGGGGAG GGGAGGCTGA 180
TGCNTTTGGC CCCGGCCTGG CCAAAANAGC CCATCCCCAG GGCAGTTTCA GGTGCCGGCT 240
GGGCCCTGAA TGTCAAGGAT AATATATAGC CCGCTCCTGG GTCCTGGAGC TGTGGCCCTT 300
TGTACTCNTG TTGTGTCCAT TGTGTGTGTG CGT 333 (2) INFORMATION FOR SEQ ID NO: 23: (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 611 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23: GTCCATTGTG TGTGTGCGTG GGGACAGAGG CCTGGAAATG CGGAGGACTA TACAGAGAAG 60
GNAGGTTTTG TGAAGGCCAG GCAGGGTTGG AGGCCGGGGG TGTGAGAGGA GAGGCCCATA 120
GGGCTGAGTG GGGTCGGGTG AGGCAGAGGT CAGAAACAGA AGAGCTGCAG TTGCTGGAGC 180
TGGGNTGAGA ANTGGGCTGC CTCCTGCCAT CCCCCCGTCT CCTCCCCTTC TCCCCTTGGT 240
GCCCCCCTNT GCTCAGAATC TGAAGTAGTT CCCTCCTCAG CAATTTCATN TCTTGAACAC 300
TGACTCACAC CTTTTAGGCA CCTACTGTGT GCATAGCATT CCACCAGGAC TCATCTCCCT 360
TCCTTCTCAG GGGGTCCCGA GCCCCGACTA GCTTTGCCCT AACTCCTTCA TCAAAAGACC 420
CCCCGCCAGC TTCCCACACC TCATACGCAG CCACATCTGC CCTATTCTCC ATGCTTTCCA 480
GCTTGCCTGC CCTTCCTCAT CTCTCCCTGC CTGTGCAGAC CTCCACCCTT CTTTCCTCCA 540
CCCCTCCATC CCCCAATGCT TGTAGACCTT CCATTCATTC CGTCTCATCG TGCGTGGTCT 600
CTGATCGTCC A 611 (2) INFORMATION FOR SEQ ID NO: 24:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 47 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:
Met Leu Ser Ser Leu Pro Ala Leu Pro His Leu Ser Leu Pro Val Gin 1 5 10 15
Thr Ser Thr Leu Leu Ser Ser Thr Pro Pro Ser Pro Asn Ala Cys Arg 20 25 30 Pro Ser He His Ser Val Ser Ser Cys Val Val Ser Asp Arg Pro 35 40 45
(2) INFORMATION FOR SEQ ID NO: 25:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 274 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:
ATCCAGGGCG TGGGGAGACC ATTGGCATTT GGGAACCATT TTCCTTCGAA CGGCTTCCCC 60
TTGAGCTGAG CATTCTGCTT GCTGCAGTAG ACGGGTCGCC TTTTGCCCAT ACCGAAATTT 120
TCTGAAATTA AATCGCACAC CCCCACCATT TCCTCTCCCC TGGGATCTGG AGGAACATCA 180
TACATAGTAG GTGAATCGTT TTGTAGAGTG AAGAATGCTA ATGTAAAGCA AATAGTCACC 240
CACGTTCCCT TGTAAATCCA AAAAAAAAAA AAAA 274 (2) INFORMATION FOR SEQ ID NO: 26:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "oligonucleotide"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26: ANGGAGCAAGT TCCTGAGAGT ATCCTGTT 29
(2) INFORMATION FOR SEQ ID NO: 27:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "oligonucleotide"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27: ANGGAGCAAGT TCCTGAGAGT ATCCTGTT 29
(2) INFORMATION FOR SEQ ID NO: 28:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "oligonucleotide"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28: GNATGGAGGGA GAGAGAACAC AAATTAAC 29
(2) INFORMATION FOR SEQ ID NO: 29:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "oligonucleotide"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29: GNGACAGTGTT GTGCTGAAGC AGGATTCC 29
(2) INFORMATION FOR SEQ ID NO: 30:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "oligonucleotide" (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30: CNTCTCCAACT TCCACAATTT GCTCACTA 29
(2) INFORMATION FOR SEQ ID NO: 31:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "oligonucleotide"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31: TNGGAGGAAGA GTGGCAGAGG AGCTTATA 29
(2) INFORMATION FOR SEQ ID NO: 32:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "oligonucleotide"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32: CNGTGTTTTGT TCTTAGGAAG GTAGAAGC 29
(2) INFORMATION FOR SEQ ID NO: 33:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "oligonucleotide" (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 33: CNGCCAGCCAG CAGCAAAGCA AATTAAGA 29
(2) INFORMATION FOR SEQ ID NO: 34:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "oligonucleotide"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34: TNGAGGAAAGA AGGGTGGAGG TCTGCACA 29

Claims

What is claimed is:
1. A composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:2;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:2 from nucleotide 390 to nucleotide 563;
(c) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone BD441_1 deposited under accession number ATCC 98264;
(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BD441_1 deposited under accession number ATCC 98264;
(e) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone BD441_1 deposited under accession number ATCC 98264;
(f) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone BD441_1 deposited under accession number ATCC 98264;
(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:3;
(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:3 having biological activity;
(i) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(f) above;
(j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ; and
(k) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h).
2. A composition of claim 1 wherein said polynucleotide is operably linked to at least one expression control sequence.
3. A host cell transformed with a composition of claim 2.
4. The host cell of claim 3, wherein said cell is a mammalian cell.
5. A process for producing a protein encoded by a composition of claim 2, which process comprises:
(a) growing a culture of the host cell of claim 3 in a suitable culture medium; and
(b) purifying said protein from the culture.
6. A protein produced according to the process of claim 5.
7. The protein of claim 6 comprising a mature protein.
8. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:3;
(b) fragments of the amino acid sequence of SEQ ID NO:3; and
(c) the amino acid sequence encoded by the cDNA insert of clone BD441_1 deposited under accession number ATCC 98264; the protein being substantially free from other mammalian proteins.
9. The composition of claim 8, wherein said protein comprises the amino acid sequence of SEQ ID NO:3.
10. The composition of claim 8, further comprising a pharmaceutically acceptable carrier.
11. A method for preventing, treating or ameliorating a medical condition which comprises administering to a mammalian subject a therapeutically effective amount of a composition of claim 10.
12. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:2, SEQ ID NO:l or SEQ ID NO:4 .
13. A composition comprising an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5 from nucleotide 583 to nucleotide 756;
(c) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone BD441_2 deposited under accession number ATCC 98264;
(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BD441_2 deposited under accession number ATCC 98264;
(e) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone BD441_2 deposited under accession number ATCC 98264;
(f) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone BD441_2 deposited under accession number ATCC 98264;
(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:6;
(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity;
(i) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(f) above;
(j ) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ; and
(k) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h).
14. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:6;
(b) fragments of the amino acid sequence of SEQ ID NO:6; and
(c) the amino acid sequence encoded by the cDNA insert of clone BD441_2 deposited under accession number ATCC 98264; the protein being substantially free from other mammalian proteins.
15. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:5 or SEQ ID NO:7.
16. A composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:8;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:8 from nucleotide 426 to nucleotide 581;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:8 from nucleotide 495 to nucleotide 581;
(d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:8 from nucleotide 354 to nucleotide 503;
(e) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone BG102_3 deposited under accession number ATCC 98264;
(f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BG102_3 deposited under accession number ATCC 98264;
(g) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone BG102_3 deposited under accession number ATCC 98264;
(h) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone BG102_3 deposited under accession number ATCC 98264;
(i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:9;
(j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:9 having biological activity;
(k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;
(1) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ; and
(m) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(j).
17. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:9;
(b) the amino acid sequence of SEQ ID NO:9 from amino acid 1 to amino acid 26;
(c) fragments of the amino acid sequence of SEQ ID NO:9; and
(d) the amino acid sequence encoded by the cDNA insert of clone BG102_3 deposited under accession number ATCC 98264; the protein being substantially free from other mammalian proteins.
18. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:8.
19. A composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:10;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:10 from nucleotide 112 to nucleotide 978;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:10 from nucleotide 436 to nucleotide 1048;
(d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone BK158_1 deposited under accession number ATCC 98264;
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BK158_1 deposited under accession number ATCC 98264;
(f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone BK158_1 deposited under accession number ATCC 98264;
(g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone BK158_1 deposited under accession number ATCC 98264;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:ll;
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:ll having biological activity; (j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and
(1) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).
20. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:ll;
(b) fragments of the amino acid sequence of SEQ ID NO:ll; and
(c) the amino acid sequence encoded by the cDNA insert of clone BK158_1 deposited under accession number ATCC 98264; the protein being substantially free from other mammalian proteins.
21. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:10.
22. A composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:12;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 12 from nucleotide 16 to nucleotide 492;
(c) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone BP163_1 deposited under accession number ATCC 98264;
(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BP163_1 deposited under accession number ATCC 98264;
(e) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone BP163_1 deposited under accession number ATCC 98264;
(f) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone BP163_1 deposited under accession number ATCC 98264; (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:13;
(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:13 having biological activity;
(i) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(f) above;
(j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ; and
(k) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h).
23. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:13;
(b) fragments of the amino acid sequence of SEQ ID NO:13; and
(c) the amino acid sequence encoded by the cDNA insert of clone BP163_1 deposited under accession number ATCC 98264; the protein being substantially free from other mammalian proteins.
24. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:12 or SEQ ID NO:14.
25. A composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:16;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:16 from nucleotide 72 to nucleotide 569;
(c) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone BZ16_3 deposited under accession number ATCC 98264;
(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BZ16_3 deposited under accession number ATCC 98264; (e) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone BZ16_3 deposited under accession number ATCC 98264;
(f) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone BZ16_3 deposited under accession number ATCC 98264;
(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:17;
(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:17 having biological activity;
(i) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(f) above;
(j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ; and
(k) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h).
26. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO: 17;
(b) the amino acid sequence of SEQ ID NO:17 from amino acid 1 to amino acid 124;
(c) fragments of the amino acid sequence of SEQ ID NO: 17; and
(d) the amino acid sequence encoded by the cDNA insert of clone BZ16_3 deposited under accession number ATCC 98264; the protein being substantially free from other mammalian proteins.
27. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:16 or SEQ ID NO:15.
28. A composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:18; (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:18 from nucleotide 405 to nucleotide 662;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 18 from nucleotide 519 to nucleotide 662;
(d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:18 from nucleotide 1 to nucleotide 584;
(e) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone CC182_1 deposited under accession number ATCC 98264;
(f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CC182_1 deposited under accession number ATCC 98264;
(g) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone CC182_1 deposited under accession number ATCC 98264;
(h) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone CC182_1 deposited under accession number ATCC 98264;
(i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:19;
(j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 19 having biological activity;
(k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;
(1) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ; and
(m) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(j).
29. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO: 19;
(b) the amino acid sequence of SEQ ID NO:19 from amino acid 1 to amino acid 60;
(c) fragments of the amino acid sequence of SEQ ID NO: 19; and (d) the amino acid sequence encoded by the cDNA insert of clone CC182_1 deposited under accession number ATCC 98264; the protein being substantially free from other mammalian proteins.
30. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:18.
31. A composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:20;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:20 from nucleotide 311 to nucleotide 409;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:20 from nucleotide 24 to nucleotide 414;
(d) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone CG109_1 deposited under accession number ATCC 98264;
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CG109_1 deposited under accession number ATCC 98264;
(f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone CG109_1 deposited under accession number ATCC 98264;
(g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone CG109_1 deposited under accession number ATCC 98264;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:21;
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:21 having biological activity;
(j) a polynucleotide which is an allelic variant of a polynucleotide of
(a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and
(1) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).
32. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:21;
(b) fragments of the amino acid sequence of SEQ ID NO:21; and
(c) the amino acid sequence encoded by the cDNA insert of clone CG109_1 deposited under accession number ATCC 98264; the protein being substantially free from other mammalian proteins.
33. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:20.
34. A composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:23;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:23 from nucleotide 471 to nucleotide 611;
(c) a polynucleotide comprising the nucleotide sequence of the full- length protein coding sequence of clone CJ397_1 deposited under accession number ATCC 98264;
(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CJ397_1 deposited under accession number ATCC 98264;
(e) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone CJ397_1 deposited under accession number ATCC 98264;
(f) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone CJ397_1 deposited under accession number ATCC 98264;
(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:24;
(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:24 having biological activity;
(i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
(j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ; and (k) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h).
35. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:24;
(b) fragments of the amino acid sequence of SEQ ID NO:24; and
(c) the amino acid sequence encoded by the cDNA insert of clone CJ397_1 deposited under accession number ATCC 98264; the protein being substantially free from other mammalian proteins.
36. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:23, SEQ ID NO:22 or SEQ ID NO:25 .
PCT/US1997/021123 1996-11-20 1997-11-19 Secreted proteins and polynucleotides encoding them WO1998022501A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP52383798A JP2001505053A (en) 1996-11-20 1997-11-19 Secreted proteins and polynucleotides encoding them
EP97946948A EP0941242A2 (en) 1996-11-20 1997-11-19 Secreted proteins and polynucleotides encoding them
AU52024/98A AU5202498A (en) 1996-11-20 1997-11-19 Secreted proteins and polynucleotides encoding them
CA002272050A CA2272050A1 (en) 1996-11-20 1997-11-19 Secreted proteins and polynucleotides encoding them

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US75291296A 1996-11-20 1996-11-20
US08/752,912 1996-11-20
US80082697A 1997-02-14 1997-02-14
US08/800,826 1997-02-14
US97178697A 1997-11-17 1997-11-17
US08/971,786 1997-11-17

Publications (2)

Publication Number Publication Date
WO1998022501A2 true WO1998022501A2 (en) 1998-05-28
WO1998022501A3 WO1998022501A3 (en) 1998-08-13

Family

ID=27419437

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/021123 WO1998022501A2 (en) 1996-11-20 1997-11-19 Secreted proteins and polynucleotides encoding them

Country Status (5)

Country Link
EP (1) EP0941242A2 (en)
JP (1) JP2001505053A (en)
AU (1) AU5202498A (en)
CA (1) CA2272050A1 (en)
WO (1) WO1998022501A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000044783A1 (en) * 1999-01-29 2000-08-03 Kurokawa, Kiyoshi Meg-4 protein

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995033059A2 (en) * 1994-05-26 1995-12-07 Immunex Corporation Receptor for oncostatin m
US5536637A (en) * 1993-04-07 1996-07-16 Genetics Institute, Inc. Method of screening for cDNA encoding novel secreted mammalian proteins in yeast

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5536637A (en) * 1993-04-07 1996-07-16 Genetics Institute, Inc. Method of screening for cDNA encoding novel secreted mammalian proteins in yeast
WO1995033059A2 (en) * 1994-05-26 1995-12-07 Immunex Corporation Receptor for oncostatin m

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JACOBS K ET AL: "A NOVEL METHOD FOR ISOLATING EUKARYOTIC CDNA CLONES ENCODING SECRETED PROTEINS" JOURNAL OF CELLULAR BIOCHEMISTRY - SUPPLEMENT 10, vol. 21A, 10 March 1995, page 19 XP002027246 *
MOSLEY, B. ET AL.: "Dual Oncostatin M (OSM) Receptors" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 50, 20 December 1996, pages 32635-32643, XP002057901 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000044783A1 (en) * 1999-01-29 2000-08-03 Kurokawa, Kiyoshi Meg-4 protein
US6680370B1 (en) 1999-01-29 2004-01-20 Toshio Miyata Meg-4 protein
AU773638B2 (en) * 1999-01-29 2004-05-27 Kurokawa, Kiyoshi MEG-4 protein

Also Published As

Publication number Publication date
AU5202498A (en) 1998-06-10
WO1998022501A3 (en) 1998-08-13
JP2001505053A (en) 2001-04-17
CA2272050A1 (en) 1998-05-28
EP0941242A2 (en) 1999-09-15

Similar Documents

Publication Publication Date Title
CA2269755A1 (en) Secreted proteins and polynucleotides encoding them
WO1999020644A1 (en) Secreted proteins and polynucleotides encoding them
EP1032593A1 (en) Secreted proteins and polynucleotides encoding them
WO1997046682A2 (en) Polynucleotides from human adult pbmc encoding secreted proteins
EP0971954A2 (en) Secreted proteins and polynucleotides encoding them
WO1998020130A2 (en) Secreted proteins and polynucleotides encoding them
CA2273845A1 (en) Secreted proteins and polynucleotides encoding them
WO1998030582A2 (en) Secreted proteins and polynucleotides encoding them
CA2281015A1 (en) Secreted proteins and polynucleotides encoding them
WO1998030696A2 (en) Secreted proteins and polynucleotides encoding them
WO1999026973A1 (en) Secreted proteins and polynucleotides encoding them
WO1999053045A1 (en) Secreted proteins and polynucleotides encoding them
WO1999027079A1 (en) Secreted proteins and polynucleotides encoding them
WO1999047555A1 (en) Secreted proteins and polynucleotides encoding them
EP0941242A2 (en) Secreted proteins and polynucleotides encoding them
WO1998014576A2 (en) Secreted proteins and polynucleotides encoding them
CA2295212A1 (en) Secreted proteins and polynucleotides encoding them
WO1998030584A2 (en) Secreted proteins and polynucleotides encoding them
EP1002072A1 (en) Human semaphorin e and polynucleotides encoding it
EP1032589A1 (en) Secreted proteins and polynucleotides encoding them
EP0915971A2 (en) Polynucleotides from human adult pbmc endocing secreted proteins
AU5159998A (en) Secreted proteins and polynucleotides encoding them
EP0944646A1 (en) Secreted proteins and polynucleotides encoding them
CA2267121A1 (en) Secreted proteins and polynucleotides encoding them
EP1177440A1 (en) Secreted proteins and polynucleotides encoding them

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase in:

Ref document number: 2272050

Country of ref document: CA

ENP Entry into the national phase in:

Ref country code: JP

Ref document number: 1998 523837

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1997946948

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1997946948

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1997946948

Country of ref document: EP